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Resumo  
 
A SIDA continua a ser uma prioridade em saúde pública com o número de pessoas 
infetadas com o HIV-1 a aumentar. Apesar dos progressos feitos na área da prevenção, o 
controlo da infeção por HIV-1 dependerá do desenvolvimento e aplicação de uma vacina 
segura e eficaz contra este vírus. Os anticorpos neutralizantes de largo espetro (bNAbs) 
são considerados um elemento crucial numa vacina preventiva para o HIV sendo capazes 
de se ligar ao vírus bloqueando a sua entrada na célula hospedeira. Assim, o 
desenvolvimento de imunogénios que induzam a produção de bNAbs contra as diversas 
estirpes de HIV-1 constitui a maior prioridade na área das vacinas. A maior parte dos 
regimes vacinais usados atualmente para a indução de bNAbs consiste na administração 
combinada e sequencial de diferentes imunogénios. O uso de vetores virais recombinantes 
como primeira imunização (designada “priming”) seguido de reforços (“boosts”) com 
proteínas do invólucro do HIV constitui uma das abordagens mais usadas uma vez que 
induzem no hospedeiro um largo espetro de respostas imunes incluindo anticorpos e 
células T. Baseado numa estratégia semelhante, o ensaio clínico RV144 foi até à data o 
único em que se observou algum grau de proteção, embora modesto, contra a infeção por 
HIV reforçando a ideia de que o desenvolvimento de uma vacina preventiva contra o 
HIV-1 é uma tarefa concretizável. Contudo, com a exceção dos recentes resultados 
observados em vacas imunizadas com o trímero BG505 SOSIP, nenhum candidato a 
vacina foi capaz de induzir de forma consistente bNAbs contra vírus tier 2 heterólogos 
de diferentes subtipos [1]. 
Num estudo recente, a imunização de ratinhos BALB/c com vírus da vacina recombinante 
a expressar a glicoproteína de superfície do invólucro juntamente com um reforço com 
polipéptidos recombinantes constituídos pela loop V3 e pelas regiões circundantes C2 e 
C3 do invólucro de um isolado HIV-2 com tropismo R5 induziu a produção de bNAbs 
contra diversos isolados de HIV-2 com tropismo R5 [2]. Este trabalho demonstrou pela 
primeira vez que, com uma estratégia de vacinação relativamente simples e os antigénios 
adequados, é possível obter uma resposta neutralizante de largo espetro. Assim, o 
principal objetivo deste trabalho foi investigar se uma estratégia vacinal semelhante 
induzia a produção de bNAbs contra o HIV-1 em ratinhos BALB/c e em coelhos. Para 
aumentar as hipóteses de sucesso no contexto da enorme diversidade do HIV-1, decidiu-
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se utilizar glicoproteínas do invólucro representativas dos genótipos mais comuns a nível 
mundial e provenientes de vírus característicos de uma epidemia antiga e estável como é 
o caso de Angola. Neste contexto, o primeiro objetivo específico desta tese foi 
caracterizar a nível genómico diferentes isolados de HIV-1 provenientes de Angola. 
Outros objetivos específicos foram expressar genes env dos isolados virais em vírus da 
vacina, produzir gp120 solúvel e polipéptidos recombinantes contendo as regiões C2, V3 
e C3 dos diferentes isolados, caracterizar a antigenicidade e imunogenicidade, em 
particular a resposta em anticorpos neutralizantes, dos novos antigénios em ratinhos 
BALB/c e coelhos com diferentes estratégias vacinais e, finalmente, caracterizar as 
respostas celulares envolvidas na neutralização, nomeadamente, células T foliculares 
auxiliares (Tfh) e reguladoras (Tfr).  
Angola tem uma epidemia antiga de HIV-1 que data da primeira metade do século 20 e 
terá desempenhado um papel crucial na disseminação inicial do HIV-1 a nível regional e 
mundial. Para melhor compreender a origem e dinâmica de transmissão dos subtipos e 
formas recombinantes do HIV-1 presentes neste país, sequenciou-se e analisou-se 
filogeneticamente os genomas completos de três vírus isolados em 1993 provenientes de 
três indivíduos originários de Cabinda (capítulo 2). Descobriu-se que um dos isolados era 
do subtipo J, outro era maioritariamente do subtipo J mas tinha uma pequena região de 
classificação incerta no local gag/pol e o último era um recombinante H/U/CRF02_AG 
nunca anteriormente descrito. Os resultados sugeriram ainda que o subtipo J de Angola 
poderá estar na origem mundial do subtipo J. Estes resultados confirmam que a epidemia 
de HIV-1 é antiga em Angola e contribuem para a expansão das bases de dados mundiais 
de sequências do HIV-1 dos subtipos mais raros (H e J).  
O objetivo do capítulo 3 foi o de investigar no modelo murino se a estratégia semelhante 
à usada previamente contra o HIV-2 induzia a produção de anticorpos neutralizantes 
contra o HIV-1. Um imunogénio vacinal ideal contra o HIV-1 deverá induzir no 
hospedeiro uma resposta em anticorpos neutralizantes de largo espetro, ou seja, 
anticorpos que neutralizem vírus contemporâneos de todos os genótipos. A estratégia 
adotada para gerar uma vacina que fosse de largo espetro foi recorrer aos vírus em 
circulação nas epidemias Angolana (vírus não-B) e Portuguesa (subtipo B) entre 1993 e 
2008. A hipótese que se colocou foi a de que os invólucros dos vírus ancestrais presentes 
nestas duas epidemias exporiam epítopos conformacionais conservados ao longo da 
evolução devido a restrições de natureza funcional e induziriam de forma eficaz a 
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produção de anticorpos capazes de neutralizar todo o tipo de vírus contemporâneos. 
Assim, os genes env de isolados dos genótipos B, C, CRF02_AG, G, H e J foram 
amplificados, sequenciados e clonados em vetores de expressão do vírus da vacina. Todos 
os isolados possuíam tropismo para o co-receptor CCR5 indicando que seriam aptos para 
vacinação uma vez que a maioria dos vírus transmitidos usa este co-receptor. Foram 
produzidos com sucesso vírus da vacina recombinantes a expressar glicoproteínas gp120 
dos subtipos B, C, CRF02_AG e J. Adicionalmente produziram-se polipéptidos 
recombinantes contendo as regiões C2V3C3 e a proteína gp120 solúvel de cada um dos 
subtipos. Todas as novas proteínas reagiram positivamente em ELISA e Western Blot 
com anticorpos presentes no soro de indivíduos infetados com HIV-1 indicando que 
apresentavam uma conformação apropriada. Por outro lado, o anticorpo monoclonal 
humano 447-52D, direcionado contra o motivo GPGR da região V3, reagiu fortemente 
em ELISA e Western Blot com a proteína gp120 do subtipo CRF02_AG, enquanto o 
anticorpo monoclonal HJ16, específico para a região de ligação ao CD4, reagiu contra 
todas as proteínas embora apenas em ELISA. Estes resultados demonstram que os novos 
imunogénios apresentam adequadamente o epítopo neutralizante presente no loop da V3 
e, ainda, algum grau de exposição dos epítopos presentes no local de ligação ao CD4.  
Ratos BALB/c foram imunizados com três combinações vacinais incluindo vírus da 
vacina a expressar as glicoproteínas gp120 dos subtipos B, C, CRF02_AG e J, 
polipéptidos recombinantes contendo as regiões C2V3C3 e a proteína gp120 solúvel de 
cada um dos subtipos. Em geral todos os ratos imunizados desenvolveram anticorpos de 
ligação contra as proteínas gp120 autólogas e heterólogas sendo que apenas alguns 
desenvolveram anticorpos de ligação contra a C2V3C3. Os animais inoculados com 
imunogénios derivados do genótipo CRF02_AG produziram uma boa resposta 
neutralizante (>50%)  contra seis pseudovírus heterólogos de tier 2 e três isolados 
primários de diferentes subtipos de HIV-1. A produção de bNAbs foi observada apenas 
nos grupos de animais infetados inicialmente com vírus da vacina recombinantes 
suportando, por um lado, a importância do uso de vetores vacinais replicativos como 
componente de uma vacina para o HIV-1 e, por outro, o potencial do uso de monómeros 
da gp120 quando usados em regimes de combinação.  
O alvo dos anticorpos neutralizantes não foi identificado formalmente. No entanto, uma 
vez que a gp120 do isolado vacinal CRF02_AG se ligou a um anticorpo monoclonal 
neutralizante que têm por alvo a região V3, juntamente com o facto do isolado 
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neutralizado por todos os grupos imunizados com este imunogénio ter o motivo GPGR 
na V3 (PX2278) e os não neutralizados terem um motivo diferente (GPGQ), sugere que 
os anticorpos neutralizantes induzidos nos ratos têm sobretudo por alvo o motivo GPGR 
da região V3. No entanto, a ligação, embora fraca, do anticorpo monoclonal HJ16 a todos 
os imunogénios gp120 em ELISA juntamente com a indução de bNAbs contra 
pseudovírus e isolados primários de subtipos B e não B (que não possuem o motivo 
(GPGR) indica que outros epítopos possam estar envolvidos. Assim, embora os novos 
imunogénios utilizados neste estudo não pareçam originar epítopos conformacionais, os 
resultados demonstraram que as respostas induzidas contra os epítopos na V3 foram 
suficientes para neutralizar vários isolados tier 2 de HIV-1 suportando a importância da 
inclusão da região V3 numa vacina contra o HIV-1. 
Ao contrário do que tinha sido observado previamente para o HIV-2, verificou-se que os 
polipéptidos recombinantes C2V3C3 não induzem uma resposta neutralizante contra o 
HIV-1 provavelmente porque os epítopos neutralizantes da V3 não são apresentados de 
forma correta por estes polipéptidos. Nos ratos imunizados com vírus da Vacina 
recombinante a expressar gp120 truncada dos subtipos C, CRF02_AG e J seguidos de um 
reforço com polipéptidos recombinantes C2V3C3 e a proteína gp120 solúvel dos mesmos 
isolados (ensaio piloto) o número de células Tfh correlacionou-se de forma positiva com 
o número e níveis de anticorpos de ligação contra os imunogénios gp120 e a frequência 
de células Tfr correlacionou-se negativamente com as respostas neutralizantes. Estes 
resultados constituem um suporte adicional para o uso de vírus da vacina replicativos 
como componente de uma vacina para o HIV uma vez que estes são capazes de induzir 
respostas celulares específicas envolvidas na indução de anticorpos anti-HIV.  
No capítulo 4 efetuou-se um novo estudo vacinal em coelhos com o objetivo de investigar 
se o nosso protótipo de vacina baseado em imunogénios de genótipo CRF02_AG, 
também induzia bNAbs num modelo animal distinto e mais próximo dos primatas. Os 
coelhos foram imunizados com vírus da vacina recombinante a expressar a proteína 
gp120 truncada derivada do subtipo CRF02_AG seguido de reforço com a proteína gp120 
truncada do mesmo isolado. Todos os coelhos imunizados desenvolveram elevados 
títulos de anticorpos de ligação contra proteínas do invólucro autólogas e heterólogas 
tendo um dos animais neutralizado a mais de 50% a maioria (13/16) dos vírus testados. 
Estes resultados confirmaram os observados previamente em ratos (capítulo 3), 
reforçando o potencial desta estratégia vacinal. 
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Em conclusão, o trabalho desenvolvido nesta tese demonstrou que uma estratégia vacinal 
baseada no uso de um vetor viral replicativo a expressar uma proteína do invólucro 
derivada de um isolado ancestral de subtipo não-B juntamente com um reforço com a 
proteína gp120 autóloga induziu a produção de bNAbs contra diversos subtipos de HIV-
1 em dois modelos animais distintos sendo este o tipo de resposta pretendido com uma 
vacina preventiva contra este vírus.  
  
Palavras-chave: diversidade genética do HIV, vacinas contra HIV/SIDA, imunogénios 
do invólucro, anticorpos neutralizantes, células T foliculares 
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Abstract 
 
New immunogens that elicit the production of broadly neutralizing antibodies (bNAbs) 
are needed to prevent and control HIV-1 epidemic. However, their induction by 
vaccination is still a difficult task. Prime-boost immunization strategies combining 
poxvirus with envelope glycoproteins constitutes a promising approach for an HIV-1 
preventive vaccine as they provide strong immune responses. Recently, bNAbs against 
HIV-2 were elicited in mice using a Vaccinia vector-prime C2V3C3 polypeptide boost 
vaccination strategy. Thus, the main goal of this thesis was to determine if a similar 
strategy would elicit the production of bNAbs against HIV-1. The general aims of this 
thesis were: obtain and examine HIV-1 samples derived from Angolan isolates as a 
paradigm of the ancestral viruses we intended to use in a new type of vaccine, express 
envelope genes from Angolan and Portuguese isolates in Vaccinia virus and produce the 
autologous C2V3C3 recombinant polypeptides, investigate the immunogenicity of these 
immunogens in mice and rabbits using different regimens and quantify the respective 
cellular immune responses. In chapter 2, three full-length genomes from Angolan patients 
were sequenced and analyzed in order to better understand the origin and dynamics of 
HIV-1 in Angola. A pure subtype J, a subtype J with a small uncertain region and the first 
H/U/CRF02_AG recombinant were identified. Overall, these results supported the 
extraordinary genetic diversity of HIV-1 and confirm the ancestral presence of this 
subtypes in Angola. In chapters 3, gp120 glycoproteins expressed in Vaccinia virus, 
soluble gp120 and C2V3C3 polypeptides derived from several HIV-1 isolates from 
Angola and Portugal (clades B, C, CRF02_AG and J) were produced and used as 
immunogens in mice and rabbits (chapter 4). CRF02_AG based immunogens were able 
to elicit bNAbs against several heterologous HIV-1 tier 2 viruses and V3 region was 
found to be one of the main target of this immunogen. Antibody responses were 
associated with adequate Tfh and Tfr responses indicating that this strategy targeted the 
cellular subsets required for the induction of an effective NAb response.    In conclusion, 
the results obtained suggest that the novel CRF02_AG based immunogens and prime-
boost immunization strategy may be able to induce the type of response intended in a 
preventive HIV-1 vaccine. 
Keywords: HIV genetic diversity, HIV/AIDS vaccines, Envelope based immunogens, 
neutralizing antibodies, follicular T cells
xix 
 
Abbreviations  
 
Ab  Antibody 
Ad   Adenovirus 
ADCC  Antibody-dependent cell-mediated cytotoxicity 
ADCVI   Antibody-dependent cell-mediated virus inhibition  
aLRT   Approximate likelihood-ratio test 
AIDS     Acquired Immunodeficiency Syndrome 
APC   Antigen presenting cells 
ART   Antiretroviral therapy 
BI   Branching index 
BCG   Bacille Calmette-Guerin 
BSA       Bovine serum albumin 
BSL-2  Biosafety level 2 
bNAb    Broadly neutralizing antibody 
CA       Conic shaped viral capsid 
CD4        Cluster of differentiation 
CD4bs     CD4 binding site 
CCR5      C-C chemokine receptor type 5 
CDC   Center for disease control and prevention 
CDR H3 Third heavy chain complementary determining regions 
CLR      C-type lectin receptors 
CMV   Cytomegalovirus 
CO2       Carbon dioxide 
CRF   Circulating recombinant form 
 xx 
 
CTL  T cytotoxic lymphocytes 
DC  Dendritic cell 
DMEM Dulbecco´s minimal essential medium 
DNA   Deoxyribonucleic acid 
dsDNA Double stranded DNA 
DRC   Democratic Republic of Congo 
ELISA Enzyme-Linked Immunosorbent Assay 
Fab   Antigen-binding fragment 
FBS  Fetal bovine serum 
Fc  Fragment crystallizable region 
FcRs  Fc receptors 
FP   Fusion peptide 
GALT  Gut associated lymphoid tissue 
GC  Germinal Centers 
GPCR  G-protein-coupled receptor 
HIV-1  Human immunodeficiency virus type 1 
HIV-2  Human immunodeficiency virus type 2 
HLA  Human leukocyte antigen 
HR1   Heptad Region 1 
HR2             Heptad region 2 
HTLV  Human T-cell leukaemia viruses 
Hu-BLT Humanized mice 
HuMAbs Human Monoclonal antibodies 
ICOS  Inducible T cell co-stimulator 
IDUs  Injecting Drug users 
 xxi 
 
IFN   Type I interferon  
IgG                 Immunoglobulin 
IN   Integrase 
IQR  Interquartile range 
jpHMM  Jumping profile Hidden Markov Model 
KIR  Killer immunoglobulin receptor  
LCMV Lymphocytic choriomeningitis virus 
LTR  Long terminal repeat 
MA   Matrix protein 
MALT Mucosa-associated lymphoid tissue 
mDC   Myeloid dendritic cell 
ML     Maximum likelihood 
MPER Membrane proximal external region 
mRNA Messenger RNA 
MRCA Most recent common ancestor  
MSM   Men who have sex with men 
MVA  Modified Vaccinia virus Ankara 
NAb             Neutralizing antibody 
NC             Nucleocapsid protein 
NHPs  Non-human primates 
NK                  Natural killer cells 
NYVAC         Vaccinia virus derived from the Copenhagen Vaccinia strain 
OD              Optical density 
PAMPs Pathogen-associated molecular patterns  
PBMC  Peripheral blood mononuclear cell 
 xxii 
 
PBS   Phosphate buffered saline 
PCR   Polymerase chain reaction 
pDC  Plasmacytoid dendritic cell 
PEP  Post-exposure prophylaxis 
PIC  Pre-integration complex 
PNGS  N-linked glycosylation sites 
PrEP   Pre-exposure prophylaxis 
PRRs   Pathogen-recognition receptors  
PR   Protease 
RC   Republic of Congo 
RIP   Recombinant Identification Program 
RLU  Relative light units 
RNA   Ribonucleic acid 
RRE   Rev Response element 
RT   Reverse transcriptase 
RTC   Reverse transcriptase complexes 
SD   Standard deviation 
Sgp120           Supernatant containing gp120 protein 
SHM  Somatic Hypermutation 
SHIV  Simian-Human Immunodeficiency Virus 
SIV  Simian immunodeficiency virus 
SLPC  Short-lived plasma cells 
SPF  Specific pathogen free 
SU   Surface glycoprotein 
TAR   Trans-acting response 
 xxiii 
 
TB  Tuberculosis 
TD   Transmembrane domain 
Tfh  T Follicular helper cells 
Tfr  T Follicular regulatory cells 
TI   Thymus-independent antigens 
TLR    Toll-like receptor  
TM   Transmembrane glycoprotein 
TNF- α Tumor necrosis factor α  
URF   Unique recombinant form 
USA   United States of America 
VACV   Vaccinia virus 
VLPs  Virus-like particles             
VSV   Vesicular stomatitis virus 
VV  Vaccinia virus 
VVWR   Western Reserve strain of Vaccinia virus 
WHO   World Health Organization 
 
Units 
ºC          Celsius degrees 
kb  Kilobase 
kDa   kilodalton 
ml  milliliter 
nm   nanometers 
µg   micrograms 
µl             microliter
xxv 
 
Table of contents 
  
Acknowledgements ........................................................................................................................ i 
Preface ........................................................................................................................................... v 
Resumo ......................................................................................................................................... xi 
Abstract ..................................................................................................................................... xvii 
Abbreviations ............................................................................................................................. xix 
Chapter 1...................................................................................................................................... 1 
1. General introduction ........................................................................................................... 3 
1.1. Discovery of HIV ........................................................................................................... 3 
1.2 Origin and Genetic diversity of HIV-1 ............................................................................ 3 
1.3 HIV-1 Genome and structure .......................................................................................... 6 
1.4 HIV-1 life cycle ............................................................................................................... 7 
1.5 HIV-1 transmission ......................................................................................................... 9 
1.6 HIV-1 prevention .......................................................................................................... 11 
1.7 HIV-1 pathogenesis ....................................................................................................... 12 
2. HIV-1 envelope .................................................................................................................. 15 
2.1 Molecular and structural organization ........................................................................... 15 
2.2 HIV-1 entry and Interaction between the Env protein and the cell ............................... 17 
3. Immune responses against HIV-1 .................................................................................... 18 
3.1 Innate immune responses .............................................................................................. 19 
3.2 Adaptive immune responses .......................................................................................... 22 
3.2.1 Cellular responses ...................................................................................................... 22 
3.2.2 Humoral responses ..................................................................................................... 27 
3.2.2.1 B cells ...................................................................................................................... 28 
3.2.2.3 Neutralizing antibodies ........................................................................................... 33 
3.2.2.4 Neutralizing epitopes in Env ................................................................................... 36 
3.3 Search for an HIV-1 vaccine ......................................................................................... 42 
3.3.1 Primer of vaccinology ................................................................................................ 42 
3.3.2 Recombinant vaccines ................................................................................................ 45 
3.3.2.1 Recombinant protein vaccines................................................................................. 47 
3.3.2.2 Live recombinant bacterial or viral vector vaccines................................................ 47 
3.3.2.3 Recombinant DNA vaccine vectors ........................................................................ 52 
3.3.2.4 Prime-boost strategies ............................................................................................. 52 
3.3.3 HIV-1 completed efficacy trials ................................................................................. 53 
 xxvi 
 
3.3.4 Vaccination strategies to induce bNAbs .................................................................... 56 
Aims and work plan .................................................................................................................. 59 
Chapter 2                                                                                                                                                     
Rare HIV-1 subtype J genomes and a new H/U/CRF02_AG recombinant genome suggests an 
ancient origin of HIV-1 in Angola .............................................................................................. 63 
Chapter 3                                                                                                                                                       
A prime-boost immunization strategy with Vaccinia virus expressing novel envelope gp120 
glycoproteins from non-B subtypes induces cross-clade tier 2 HIV-1 neutralizing antibodies in 
mice ............................................................................................................................................. 77 
Chapter 4                                                                                                                                                   
Induction of tier 2 cross-clade neutralizing antibodies in rabbits by a prime-boost immunization 
strategy with Vaccinia virus expressing novel HIV gp120 glycoproteins from clade CRF02_AG
 ................................................................................................................................................... 121 
Chapter 5                                                                                                                                                   
General Discussion and Conclusions ........................................................................................ 143 
References ................................................................................................................................ 153 
 
 
 
  
  
 
 
 
 
 
Chapter 1 
 
Introduction 
 
 
 
 
 
 
 
 
 
Chapter 1 - General Introduction 
 
3 
 
1. General introduction  
1.1. Discovery of HIV 
 
The discovery of the Human Immunodeficiency virus type 1 (HIV-1) as the causative 
agent of the Acquired Immunodeficiency Syndrome (AIDS) constitutes one of the major 
scientific discoveries in recent history. AIDS was first described in 1981, when several 
cases of Pneumocystis carinii pneumonia and Kaposi´s Sarcoma were observed in healthy 
men who have sex with men (MSM) in Los Angeles, New York and California[3, 4]. 
After one year, there were 593 reported cases of AIDS of which 243 resulted in death 
(41%)[5]. Between 1982 and 1983 the disease was also reported in patients from Haiti, 
Africa and Europe [6-11] and in other risk groups like injection drug users, hemophiliacs, 
heterosexual women and infants (vertical transmission) [5, 12-14]. In 1983, Luc 
Montaigner and Françoise Barré-Sinoussi from the Pasteur Institute in France isolated a 
new retrovirus from an AIDS patient belonging to the family of the human T-cell 
leukemia viruses (HTLV) that could be the causative agent of AIDS[15]. In 1984, a group 
of American investigators announced the discovery of a similar retrovirus (HTVL-III) 
which later in 1986 was officially called HIV and considered to be the causative agent of 
AIDS [16-20].  Soon after this discovery, a new retrovirus distinct from HIV-1 that caused 
clinical symptoms similar to AIDS was isolated in patients from Guinea-Bissau and Cape 
Verde Islands that were admitted in a hospital in Lisbon, Portugal. Later, this new virus 
was classified as Human Immunodeficiency virus type 2 (HIV-2) [21, 22]. 
 
1.2 Origin and Genetic diversity of HIV-1  
 
HIV-1 and HIV-2 are of zoonotic origin and result from multiple transmission events 
from SIVs (Simian immunodeficiency virus) of non-human primates (NHPs) to 
humans[23]. Although it is not known how humans acquired the virus it is believed that 
transmission must have occurred as a result of the frequent contact with primates in many 
parts of Africa due to primate hunting and meat consumption[24, 25]. SIV infection have 
been documented in more than 40 different primate species from Africa with a 
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seroprevalence that can be close to 50% in some species[26]. The great majority of 
primate species harbor a single strain of SIV[27].   
HIV-1 was originated from SIVcpz that infects West Central African chimpanzees (Pan 
troglodytes troglodytes) and from SIVgor that infects Western lowland gorillas (Gorilla 
gorilla gorilla) [28-30] whereas HIV-2 descend from SIVsmm which is found in sooty 
mangabey monkeys (Cercocebus atys)[31-34]. The four groups (M, N, O, P) that 
constitutes HIV-1 are the result of four independent cross-species transmissions from 
chimpanzees and gorillas. HIV-1 groups M and N descend from SIVcpzPtt that was 
transmitted from chimpanzees to humans in southern Cameroon whereas HIV-1 groups 
O and P descend from SIVs (SIVgor) infecting western lowland gorillas [29, 35-38]. 
Phylogenetic analysis of divergent HIV-2 strains demonstrated that at least nine cross-
species transmissions have been described, resulting in nine HIV-2 groups (A-I)[39].  
Transmission from simians to humans is estimated to have occurred between the end of 
the 19th century in Kinshasa (now Democratic Republic of Congo, DRC) and the 
beginning of the 20th century [40-46]. In fact, HIV-1 strains were identified in a blood 
sample from DRC and in a biopsy in 1960 and they already presented a high genetic 
diversity [40, 42]. Molecular epidemiological studies demonstrated that HIV-1 group M 
started to spread in humans around 1908 (1884-1924) and that the epicenter was the 
western part of the DRC where ancestors have been identified [37, 46-49]. For HIV-1 
group O radiation is estimated to be around 1920 (1890-1940) [43, 45, 50] and for group 
P the estimated date is between 1845 and 1989[51]. Group N presents the lower 
intragroup genetic diversity suggesting a more recent introduction in human population 
(1948-1977)[45].  
The extreme genetic diversity of HIV-1 is the result of several mechanisms as the lack of 
proofreading activity of the reverse transcriptase, host immune pressure and high 
recombination rate [35, 52-54]. HIV-1 group M is responsible for the pandemic being the 
only HIV-1 group that has spread across Africa and all the globe [35, 49, 55-57]. The 
remaining groups are restricted to West Africa and are much less prevalent [58-61]. HIV-
1 M group is divided in nine different subtypes or clades (A, B, C, D, F, G, H, J, K) which 
have arisen from just one cross-species transmission event[34]. Subtypes E and I have 
been described but further analysis revealed that they have a mosaic structure [62, 63]. 
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 Within group M the intersubtype genetic variability is 15% for the gag gene and 25% for 
the env gene[64]. Within a subtype it is still possible to identify several subsubtypes which 
are phylogenetically more related to each other than to other subtypes. For instance, 
clades A and F can be separated in subsubtypes A1-A5 and F1-F2, respectively[63].  
HIV-1 group M also includes more than 70 circulating recombinant forms (CRFs) and 
many unique recombinant forms (URFs)[62, 65, 66]. Of note, a recombinant form is 
named CRF if it is documented in at least three individuals that are not epidemiological 
related and URF if it is restricted to a limited number of individuals. When three or more 
subtypes are involved the term cpx is used to refer a complex mosaic structure. CRFs can 
recombine and in that case the viruses are called second or even third generation 
CRFs[35]. On a global perspective, the most prevalent subtypes are C (50%), A (12%), 
B (11%), followed by CRF02_AG (8%), G (5%), CRF01_AE (5%) and D (2%). The 
remaining subtypes and recombinant strains represent less than 1% of all HIV-1 
infections (Figure 1)[35]. In fact, there are less than nine full-length genomes of subtypes 
J and H available in the Los Alamos sequence database[65].  Geographic distribution of 
HIV-1 subtypes is illustrated in figure 1.  
 
 
 
 
 
 
 
 
Figure 1-  Global distribution and prevalence of HIV-1 (adapted from[64]) .  
Because HIV-1 pandemic originated in West Central Africa, the highest genetic diversity 
is observed in DRC and surrounding countries. For instance, in Angola, a country 
surrounded by Namibia, Zambia, DRC and Republic of Congo (RC) all subtypes except 
B and many CRFs and URFs have been detected[66-68]. In Portugal, the most prevalent 
subtypes are B, G and CRF14_BG [69-71]. 
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1.3 HIV-1 Genome and structure 
 
HIV-1 and HIV-2 belong to the Retroviridae family, Orthoretrovirinae subfamily and 
Lentivirus genus[72]. HIV is a spherical enveloped retrovirus with 120nm in 
diameter[73]. HIV particles are surrounded by an envelope that is composed of a lipid 
bilayer where a transmembrane glycoprotein (TM) with approximately 41kDa is inserted.  
 
 
 
 
 
 
Figure 2- Schematic structure of HIV-1 particle (adapted from[74] ). 
Anchored to the TM there is an outer surface glycoprotein (SU) with approximately 
120kDa[75]. In the mature virion, glycoproteins TM and SU are associated as trimers in 
the cell surface by non-covalent interactions [76]. The envelope is surrounded internally 
by matrix proteins (MA) and within the matrix there is a conical shape viral capsid (CA) 
which includes two identical copies of a positive sense single stranded ribonucleic acid 
(RNA) associated with nucleocapsid proteins (NC)[75]. HIV-1 capsid is formed by 
approximately 1500 CA subunits and provides structural stability to the virion[77]. Inside 
the particle there are the viral enzymes reverse transcriptase (RT), integrase (IN), protease 
(PR) and the accessory proteins Nef, Vif, Vpr and Vpu[75].  
Each RNA molecule that constitutes HIV-1 genome consists of approximately 9800 
nucleotides long and is flanked by long terminal repeats (LTR) at both ends (5´-3´) 
(Figure 3). HIV genome contains nine genes that encode major structural, regulatory and 
accessory proteins in the mature virion[75]. Structural proteins and viral enzymes are 
essential components for the retroviral particle whereas regulatory proteins modulate 
transcriptional and posttranscriptional steps of gene expression being also essential for 
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virus propagation. Although  not necessary for viral propagation in tissue culture, 
accessory proteins play an important role in vivo[78].  
 
 
 
 
 
Figure 3- Genomic organization of HIV-1. MA- matrix proteins); CA- capsid; NC-nucleocapsid proteins; 
PR-protease; RT- reverse transcriptase; IN-integrase; SU- surface glycoprotein; TM-transmembrane 
glycoprotein (adapted from https://www.hiv.lanl.gov/content/sequence/HIV/MAP/landmark.html). 
 
Genes gag, pol and env encode for structural or enzymatic proteins, tat and rev for 
regulatory proteins and finally nef, vif, vpr and vpu for accessory proteins[75, 79, 80]. 
The gag encodes the polyprotein precursor P55Gag that is posteriorly cleaved by the viral 
protease into the MA (p17), CA (p24), NC (p7), p6 proteins and two additionally spacer 
peptides (p1 and p2)[75]. The pol gene encodes the viral enzymes PR (p15), IN (p31) and 
RT (p66 and p51 subunits). These enzymes are produced as a Gag-Pol precursor 
polyprotein (Pr160GagPol) that is processed by PR. The env gene encodes for a polyprotein 
precursor Pr160Env which is processed by furin into the SU (gp120) and TM (gp41) 
glycoproteins [75, 81].  
 
1.4 HIV-1 life cycle 
 
The initial step of the HIV life cycle consists of viral entry into the host cells in order to 
initiate infection. Host cells (e.g. T-helper cells, monocytes, macrophages and dendritic 
cells) which expresses the CD4 (cluster of differentiation 4) glycoprotein receptor on its 
surface are the main target of HIV[78]. Binding of HIV Env (SU, gp120) to CD4 receptor 
present in the host cell surface induces conformational changes in the SU and a second 
receptor (co-receptor) belonging to the chemokine receptor family, CXCR4 and CCR5 
becomes exposed [82, 83]. Binding of gp120 both to CD4 and co-receptor triggers new 
MA   CA      NC 
PR          RT                      IN 
SU                                     TM                      
Chapter 1 - General Introduction 
 
8 
 
conformational changes in TM glycoprotein that result in the insertion of gp41 fusion 
peptide into the host cellular membrane leading to the fusion of viral and cellular 
membranes and the release of the viral core into the cytoplasm[75, 84]. After uncoating 
of the virus in the cytoplasm, the viral RNA is reverse transcribed by the viral RT enzyme 
generating a linear double-stranded DNA molecule (dsDNA)[84]. Uncoating of the viral 
core leads to the establishment of the reverse transcriptase complexes (RTCs) and pre-
integration complexes (PICs)[75, 78, 84]. PIC, which includes dsDNA, MA, NC, IN, RT 
and Vpr, is then conducted to the nucleus using the cytoplasmatic microtubules network 
and this process is mediated by IN and Vpr [75, 78]. Still outside the nucleus, IN binds to 
each end of the newly formed cDNA and removes 2 nucleotides at each 3´end of both 
DNA strands originating two recessive ends[75, 78]. Later in the nucleus, PIC-dsDNA is 
inserted into an open region of the host chromosomal genome. Finally, the unpaired 
regions between HIV and host dsDNA are repaired through cellular cofactors and a 
provirus is generated[78]. In productively infected cells, integrated provirus serves as a 
template for the transcription of both viral mRNA and genomic RNA. Transcription of 
proviral DNA is mediated by the promotor region within the 5´LTR. However, when 
5´LTR is defective, 3´LTR activation can occur [85]. Successful transcription leads to the 
generation of HIV viral transcripts which are derived from a single full-length transcript 
by alternative splicing, generating messenger RNA (mRNA) with common 5´and 3´ends 
[86]. HIV-1 transcripts can further be grouped into three different classes: completely 
spliced mRNA or early transcripts (encoding early regulatory proteins as Tat, Nef and 
Rev), incompletely spliced mRNA or late transcripts (encoding Env, Vif, Vpr and Vpu) 
and unspliced and complete mRNA that encode for the polyprotein precursors Gag and 
Gag-Pol[75, 86]. Unspliced mRNAs are later incorporated in the viral particles as 
genomic RNA. To complete the expression of the later transcripts proteins from the early 
transcripts (Tat and Rev) are necessary. Tat binds to a secondary structure located in the 
R region of the 5’ LTR, named the trans-acting response (TAR) element resulting in an 
increased processivity of RNA polymerase. Rev is responsible for the transport of 
unspliced and incompletely spliced mRNA outside the nucleus to the cytoplasm to be 
translated. This process is mediated by the binding of Rev to the Rev response element 
(RRE), a 240 base region of complex RNA secondary structure [75, 87]. 
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Figure 4- Life cycle of HIV-1 (adapted from www.niaid.nih.gov and [88]) 
The Env precursor polyproteins are glycosylated in the Golgi apparatus before they 
oligomerize in trimers. Then, polyproteins are cleaved into the SU and TM glycoproteins 
and conducted to the cytoplasmatic membrane in order to initiate assembly process. The 
assembling virion includes all of the components necessary for infectivity, i.e., two copies 
of viral RNA, cellular tRNA, molecules to prime cDNA synthesis, Env, Gag, PR, RT and 
IN. HIV-1 Gag and Gag-Pol precursor polyproteins mediate the virion assembly 
including the generation of spherical particles and genomic RNA packaging[80].  
Immature viral particles bud from the cell by gemulation of the cytoplasmatic membrane 
and acquire the lipid envelope containing the TM/SU trimers. The last step of HIV-1 life 
cycle consists in the release of new  HIV mature particles and cleavage of the Gag and 
Gag-Pol precursors into the functional proteins by PR [75, 80]. 
 
1.5 HIV-1 transmission 
 
In 2015, about 2.1 million (1.8 million-2.4 million) new HIV cases were reported 
resulting in a total of 70 million infected people since the beginning of the HIV epidemic 
[89]. Although this represent a reduction in new infections (2.6 million new infections in 
2009), the reduction has not been uniform across different regions and group risks. Thus, 
HIV infection continues to be a major global public health issue [90, 91]. 
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HIV-1 transmission mainly results from sexual contact across mucosal surfaces, 
maternal-infant exposure (during pregnancy, delivery and breastfeeding) and 
percutaneous inoculation (through contaminated blood or blood products)[92] . Once a 
person is infected, HIV is present in semen, vaginal fluids, breast milk, blood and rectal 
secretions. Sexual contact with an infected person constitutes the most frequent mode of 
transmission of HIV and the majority of HIV transmissions worldwide occur through 
heterosexual contacts [93]. The risk of transmission of HIV-1 depends largely on the 
susceptibility of the uninfected host but also on the viral features. HIV viral load (i.e. 
amount of HIV in a body fluid) in the transmitting partner seems to affect the efficiency 
of the infection and varies according to the stage of disease [94]. In fact, HIV-1 
transmission is likely to occur with more probability during the acute stage of HIV 
infection (earliest days) and in the latest stage of the disease (AIDS) where intense viral 
replication is observed [90, 94-96]. Moreover, taking antiretroviral therapy (ART) can 
reduce the risk of an HIV-infected person transmitting the infection to another by as much 
as 96%[97] . HIV transmission is also influenced by the presence of co-infection with 
other STDs (Sexual Transmitted Diseases) such as syphilis and herpes simplex-2 (HSV-
2) [90, 98, 99]. Also, genital ulcers and inflammation can contribute to enhance HIV-1 
sexual transmission with ulcerative STDs presenting an additional entry point for HIV 
[90, 99].  
Despite the high diversity of HIV variants observed in infected patients, HIV transmission 
involves a limited number of variants (bottleneck effect)  that are not necessarily the 
dominant variant in the donor [90, 100].  Thus, while chronically infected patients present 
a set of viral quasispecies that are genetically diverse, acutely infected patients frequently 
present a more “homogenous” set of viral variants that result from the transmission of 
one or few closely related viruses [90, 100, 101]. This is observed both in sexual and 
percutaneous routes of infection albeit at different levels [100, 101]. Transmission of 
multiple and more heterogeneous variants can be observed in injecting drug users (IDUs) 
probably due to the lack of a mucosal barrier and the associated protective cells (e.g. 
Langerhans cells) and innate immune response (e.g. production of IFNɣ by local 
macrophages) that play an important  role in reducing HIV-1 transmission [101, 102]. 
Because the majority of HIV variants that are transmitted present a strong preference for 
CCR5 co-receptor, the capacity of HIV to establish an efficient infection also depends on 
the availability of target CD4 cells expressing CCR5 co-receptors [101, 103].   In fact, 
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the defective expression of CCR5 in humans (Δ32 mutation) is known to confer 
protection from HIV infection[104].  
 
1.6 HIV-1 prevention 
 
In the absence of a cure, the control of HIV/AIDS epidemic requires the implementation 
of several prevention measures. There are several options to reduce the risk of acquisition 
and transmission of HIV. This includes behavioral interventions (e.g. counseling and sex 
education of susceptible populations, use of condoms, needle and syringe programs) and 
biomedical interventions (e.g. male circumcision, HIV testing, antiretroviral drugs, pre 
and post-exposure prophylaxis[105].  
Because globally only 54% of individuals infected with HIV-1 are aware of their status, 
HIV testing should be considered one of the first prevention methods. Awareness of HIV 
status is crucial to identify HIV infected individuals in order to establish the appropriate 
measures to get HIV treatment and also to prevent HIV transmission to others [92]. In 
fact, the WHO established with the 90-90-90 objectives that by 2020, 90% of all people 
living with HIV will know their status, 90% of all people with diagnosed HIV infection 
will receive sustained antiretroviral therapy and 90% of all people receiving ART will 
have viral suppression[106].  
Besides their role in the improvement of health quality and survival rate in HIV-1 infected 
individuals, antiretroviral therapy is also crucial in preventing HIV transmission and 
infection. In fact, ART contributes crucially to lower viral load to undetectable levels in 
blood and genital secretions in HIV-1 infected individuals thereby reducing HIV 
transmission to negligible levels (< 1%) and can also be used to prevent infection very 
efficiently in uninfected (PreP, Pre-Exposure Prophylaxis) or recently infected 
individuals (PEP, Post-Exposure Prophylaxis) [97, 107-110]. Currently, oral PrEP 
consists of a combination of tenofovir disoproxil fumarate and emtricitabine and is able 
to reduce the risk of getting HIV by more than 90% if taken consistently everyday [111-
114]. More recently, topical microbicides have been proposed to prevent HIV sexual 
transmission by directly inactivate or prevent HIV entry or replication in susceptible 
target cells present in the vagina and/or rectum. Topical microbicides can be delivered 
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over a prolonged period of time (e.g. intravaginal ring) or applied on a daily basis (e.g. 
gel)[115].  Recent results from the ASPIRE study conducted in Malawi, South Africa, 
Uganda and Zimbabwe demonstrated that the use of a vaginal ring continuously releasing 
dapivirine provided a modest degree of protection against HIV particularly in subgroups 
with evidence of increased adherence[116]. Currently, there is still no safe and effective 
microbicide available to the public. 
Despite the important role of ART and PrEP in lowering and prevent HIV infection, in 
2015 less than 50% of HIV infected adults and children were accessing treatment and 2.1 
million people became newly infected with HIV[117]. Therefore, control and ultimately 
eradication of HIV will depend on the development of a safe and effective HIV vaccine 
accessible to all. Despite several years of investigation and important advances in vaccine 
field there is still no effective vaccine available for HIV.  Currently, vaccine trial HVTN 
702, based in the optimization of the RV144 trial[118], is being conducted among South 
African adults in order to test if an experimental vaccine regimen safely prevents HIV 
infection[119]. Vaccination including HIV vaccines will be explained in more detail in 
chapter 3.  
Other biological interventions like male circumcision also contributes to lower HIV 
infection. In fact, this method reduces the risk of infection up to 60% by eliminating many 
cellular targets of HIV (e.g.Langerhans' cells) that are present in the penile foreskin [120, 
121].  Nonetheless, behavioral interventions (e.g. sexual abstinence, reduced number of 
sexual partners, use of condoms, implementation of needle and syringe cleaning practices 
among IDUs) and better access to healthcare services are also important strategies to 
reduce the risk of HIV infection[105, 122]. Because no single intervention measure has 
been found to be completely effective it is believed that the combination of different 
prevention approaches that integrate behavioral and biomedical strategies will lead to an 
important reduction in new HIV infections [123].  
 
1.7 HIV-1 pathogenesis  
 
The first stage of HIV infection (acute phase or primary infection) is characterized by an 
intense viral replication that, in the absence of antiretroviral therapy, declines after three 
to four weeks after initial exposure (Figure 5) [103]. The first symptoms occur two to 
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four weeks after transmission and includes flu-like clinical manifestations, fatigue, 
myalgia, fever and lymphadenopathy[124]. During several months plasma viremia 
continues to gradually decline before reaching a steady state (viral set point)[103]. Viral 
set point constitute an important determinant on the rate of disease progression because 
it points out the beginning of the chronic stage of HIV infection[103]. 
 CD4 T cells are the first targets of the virus. Along with the high replication of HIV in 
the mucosa, submucosa and draining lymphoreticular tissues there is a dramatic loss of 
CD4+T cells in the peripheral blood that is associated with the depletion of CCR5+ 
memory CD4+ T cells in the gut associated lymphoid tissue (GALT)[103, 125]. In fact, 
GALT harbors the majority of lymphoid tissue being an important site for viral replication  
and interactions with the host immune system during HIV infection[126]. This condition 
is followed by the dissemination of the virus to peripheral lymphoid tissue, particularly 
lymph nodes, and the establishment of persistent lymphoid tissue viral reservoirs[103]. 
The decline of CD4+ T cells is closely related with the direct effect of the viral infection 
of these cells together with the host cellular responses (e.g.  host cytotoxic responses and 
natural killer cells)[127].  
Seroconversion, with detection of HIV specific antibodies, occurs normally after three to 
12 weeks after HIV exposure [103, 128]. The first antibodies detected are those directed 
against p24 antigen followed by antibodies directed to gp120 and gp41 (envelope)[128]. 
Approximately 12 weeks after transmission neutralizing antibodies (NAbs) start to arise 
and evolve but this response seems not to be enough to clear the virus. The first NAbs are 
directed against the autologous virus and are not able to neutralize more divergent virus 
(heterologous viruses) [128-132].   
The chronic stage of HIV-1 infection (second stage) is asymptomatic (or latent) and lasts 
between eight to ten years (Figure 5). It is characterized by low but persistent levels of 
viral replication in the lymph nodes and constant antigen stimulation by the host immune 
system [103, 127, 133]. During this period, the immune system becomes activated by 
several factors that include viral proteins, microbial products that are translocated from 
the GALT and host responses. As cells are activated, they produce a set of 
proinflammatory cytokines which in addition with viral replication will ultimately lead to 
chronic immune activation[103]. This persistent immune activation is seen by an 
increased T cells turnover, monocytes and natural killer cells (NK), high levels of CD4 
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and CD8 T cell apoptosis and polyclonal B cell activation that can lead to 
hypergammaglobulinemia [103, 127, 134-136]. 
Figure 5- Natural course of untreated HIV-1 infection. Representation of the relation between HIV viral 
load (red) and CD4 counts (blue) during the course of HIV infection (adapted from [137] and [138].  
 
Together, these changes within each cell population greatly affect the overall 
immunologic competence leading to the exhaustion of the immune system. Moreover, in 
the absence of ART the majority of HIV infected patients become susceptible to the 
occurrence or reactivation of opportunistic infections (e.g. candidiasis, pneumonia, 
tuberculosis) as well as the development of virus induced tumors (e.g. Epstein-Barr virus 
related lymphomas, Kaposi´s sarcoma and cervical cancer caused by Human 
Papillomavirus [103, 134]). These symptoms define the early symptomatic stage of HIV 
chronic phase. In untreated patients, the progressive loss of CD4+ T cells can lead to an  
increased state of immunodeficiency that mark the onset of the last stage of HIV-1 
infection:  AIDS.  According to Center for disease control and prevention (CDC), CD4 
counts less than 200 cells/ul associated with opportunistic infections is a criterion that 
defines the AIDS stage [139]. Most untreated HIV-1 infected patients develop AIDS and 
eventually die [140]. A small minority (<5%) of individuals termed long-term 
nonprogressors remains healthy for several years in the absence of treatment [140, 141]. 
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2. HIV-1 envelope 
2.1 Molecular and structural organization 
 
HIV-1 entry to host cells is mediated by interactions between the virus envelope (SU and 
TM glycoproteins) and the host cell receptors. The HIV-1 envelope glycoprotein (Env) is 
a trimer composed of three copies of non-covalently associated heterodimers of gp120 
(SU) and gp41 (TM) that represent several spikes in the viral surface. These glycoproteins 
result from a gp160 precursor glycoprotein that is cleaved by cellular proteases and 
remain non-covalently associated on the cell or viral surface [142, 143]. Whereas gp120 
interacts with cellular receptors and co-receptors, gp41 mediates fusion between viral and 
cellular membranes [142]. In this context, the main exposed surface of HIV-1 envelope 
is composed of gp120 while gp41 is mostly shielded. HIV-1 gp120 envelope include five 
conserved regions (C1-C5) and five variable regions (V1-V5) (Figure 6)[144].  Whereas 
the five conserved regions compose the structural core of gp120, the five variable regions 
are highly glycosylated and protect the core from neutralizing antibodies [143, 145]. Four 
of these hypervariable regions (V1-V4) tend to form loops through disulfide bonds that 
are exposed on the outer surface of the viral Env [146, 147]. 
The V1/V2 loop is involved in Tat binding and Tat-mediated viral entry, a previously 
unknown mechanism[148], whereas V3 loop plays an essencial role in coreceptor binding 
and viral entry[83]. In addition, both regions represent a target for antibodies, including 
neutralizing antibodies, when accessible on the surface of the virion [149, 150].  
 
Figure 6- S linear representation of the surface   and transmembrane envelope glycoproteins. Surface 
glycoprotein (SU, gp120) includes five conserved (C1-C5) and five variable regions (V1-V5). 
Transmembrane glycoprotein (TM, gp41) contains the fusion peptide (FP), two heptad regions (HR1 and 
HR2), the membrane proximal external region (MPER), one transmembrane domain (TD) and a 
cytoplasmatic domain (adapted from [75] and [151]).  
 
In its native trimeric conformation, SU has one inner and outer domain (Figure 7). The 
outer domain is highly glycosylated and is involved in the interaction between SU and 
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the cellular receptors and co-receptors. The outer domain is the region more exposed to 
the host immune responses and has most of the antigenic determinants in Env including, 
for example, the  potent neutralizing antibody epitopes in V1/V2 and V3 loop [150, 152-
155]. The inner domain is hydrophobic and essential for the association between SU and 
TM. Between the inner and outer domain there is another domain named bridging sheet 
(Figure 7). This bridging sheet is formed between V1/V2 stem and β sheets 20 and 21 of 
C4 as the result of conformational changes that occur after gp120-CD4 binding [75, 146, 
156, 157]. After binding of the viral receptor and co-receptor by gp120 the fusion 
machinery in the gp41 subunit is readily activated.   
HIV gp41 glycoprotein is divided in three major domains: one extracellular domain or 
ectodomain (512-683 in HXB2), one transmembrane domain (TD) that inserts in the host 
membrane cell (683-707 in HXB2) and one cytoplasmatic domain (708-856 in HXB2).  
 
 
 
 
 
 
 
 
 
Figure 7- HIV-1 gp120 structure (adapted from [158, 159]). Monomeric (A) and trimeric (B) gp120 
core with inner (black) and outer domain (red) and the bridging sheet (violet). Secondary structure of gp120 
(C); 
 
The extracellular domain, which mediates the major functions of TM, can be subdivided 
in five functional regions: a fusion peptide (FP, 512-534 in HXB2) followed by two α-
helices containing leucine-zipper motifs designated heptad repeat 1 (HR1, 542-591 in 
HXB2) and heptad repeat 2 (HR2, 623-661 in HXB2), the loop region (593-622 in HXB2) 
that separate the HR1 and HR2 and finally the membrane proximal external region 
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(MPER, 662-683 in HXB2)[160]. Both fusion peptide and HR1/HR2 have a crucial role 
on the fusion of the virus to the host cell. The cytoplasmatic domain of TM binds to the 
matrix protein during the assembly of new viral particles [75, 160, 161].  
 
2.2 HIV-1 entry and interaction between the Env protein and the cell 
 
HIV-1 entry into host cells represents the first step in the viral infection cycle and is 
mediated by the Env glycoprotein. This process involves three major steps: 1) adhesion 
of the virus to the host cell and binding of the SU glycoprotein to the CD4 receptor, 2) 
binding of the SU glycoprotein to the cell co-receptor (CCR5 and/or CXCR4) and 3) 
fusion of the viral envelope with the cell membrane (Figure 8) [83]. 
Adhesion of the virus to the host cell brings Env glycoprotein into close proximity with 
the CD4 receptor. CD4 is a 60 kDa membrane glycoprotein belonging to the 
immunoglobulin superfamily and is expressed in functionally mature T cells, 
macrophages, dendritic cells, and monocytes [83, 162]. After binding to CD4 in the host 
cell, SU suffers major conformational changes that include rearrangements and exposure 
of V1/V2, V3 and C4 regions and formation of a bridging sheet as described previously. 
These conformational changes result in the approximation between the viral envelope and 
the cellular membranes which consequently leads to the interaction of the SU (namely 
V3 region) with the host cell co-receptors [83]. CCR5 and CXCR4 are considered the 
major HIV-1 co-receptors in vivo [75, 83, 163]. The chemokine receptor CCR5 is 
predominantly expressed on memory CD4+ T lymphocytes, activated T lymphocytes 
(mainly Th1 CD4+T cells) and macrophages whereas CXCR4 is mainly found on CD4+ 
and CD8+ T lymphocytes, monocytes, dendritic cells and B lymphocytes[104, 164, 165].   
Viruses that infect preferentially macrophages typically use the CCR5 coreceptor (R5 
viruses) mainly during the initial and asymptomatic stage of infection while viruses that 
infect mainly lymphocytic cell lines use the CXCR4 coreceptor (X4 viruses) 
preferentially later in the infection (AIDS stage)[104, 166].There are also viruses (the 
R5/X4 viruses) that are able to use indifferently the both co-receptors producing an 
effective infection [104, 165, 167, 168]. Moreover, R5 viruses seems to replicate more 
efficiently in CD4+ T cells compared with X4 viruses contributing to the R5 viral 
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dominance[169, 170]. As described above, the interaction of gp120 with CD4 results in 
the exposure of V3 loop of gp120 that subsequently binds to the co-receptors (Figure 8). 
V3 loop is the major determinant of cellular tropism and co-receptor specificity being 
responsible for the molecular recognition of the chemokine co-receptor in the cell 
membrane[171].  Specifically, the V3 tip and V3 base are the main regions involved in 
the co-receptor binding [172-174].  
 
Figure 8- HIV entry mechanism. HIV-1 Env (gp120 and gp41) attaches to the host cell and binds to CD4 
receptor. This leads to conformational changes in SU (gp120) and to the interaction of V3 loop of Env with 
the cell co-receptor. Finally, membrane fusion begins with the insertion of the fusion peptide of gp41 (TM) 
in the target membrane (adapted from [83]). 
Coreceptor binding causes the exposure of the gp41 fusion peptide which is inserted into 
the cytoplasmatic host membrane creating a prehairpin intermediate configuration of TM 
(Figure 8). After this, HR1 and HR2 fold in an antiparallel form originating a six-helix 
bundle which brings the viral envelope and the cellular membrane in close association 
resulting in the formation of the fusion pore and consequently in the entry of the viral 
capsid into the cell[83, 175]. 
 
3. Immune responses against HIV-1 
 
The immune system protects the host from a large range of pathogens (e.g. viruses, 
bacteria) and toxic or allergenic substances by controlling and/or eliminating them. Any 
immune response involves the recognition of a pathogen or other organism plus a reaction 
to eliminate it. In a general way, the immune response can be classified as innate or 
adaptive. Innate immune response constitutes the first line of defense against pathogens 
and is characterized for being non-specific and fast allowing a rapid response to invasion. 
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In contrast, the adaptive immune response is highly specific against a certain pathogen or 
substance and normally starts after an innate response. While the innate response remains 
unchanged after pathogen exposition, adaptive response can generate immunological 
memory that allows a more specific and efficient response in each subsequent exposition 
to the same pathogen. Although innate and adaptive responses behave in a totally different 
way they work together in order to achieve the same goal:  an effective immune response 
capable of protecting the body from “invaders” [176, 177].  
In HIV infection, both innate and adaptive immune responses are raised but they are 
inefficient to eliminate the virus. 
 
3.1 Innate immune responses  
 
The innate immune system includes external barriers as the skin, mucous membranes, 
cilia, secretions and tissue fluids containing antimicrobial agents. Soluble proteins and 
small molecules present in biological fluids (e.g. complement proteins, defensins and 
ficolins) or released from cells  (e.g. cytokines, chemokines, lipid mediators of 
inflammation, reactive free radical species and enzymes) are also part of the innate 
response as well as membrane receptors and cytoplasmatic proteins that bind to molecular 
patterns expressed in the pathogen surface [176]. Innate immune system is composed of 
an array of cell subsets derived from the bone marrow that include phagocytes 
(monocytes, macrophages, neutrophils), cytolytic cells (natural killer cells and 
neutrophils) and professional antigen-presenting cells (dendritic cells)[177-179]. 
Phagocytes, a particular group of cells that engulf pathogens via phagocytosis, bind to the 
foreign pathogen using receptors that recognize Pathogen-associated molecular patterns 
(PAMPs) which includes microbial nucleic acids (e.g. DNA and RNA), lipoproteins, 
surface glycoproteins and membrane components (e.g. peptidoglycans and 
lipopolysaccharide) [180, 181]. PAMPs are normally present in the pathogen surface and 
are recognized by innate immune receptors on certain leucocytes providing exogenous 
signals that alert the immune system to the presence of the pathogen [176, 177, 182]. This 
process can lead to the phagocytosis of the pathogen highlighting the interaction between 
the innate and adaptive immune responses.  
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Recognition of PAMPs is performed by pathogen-recognition receptors (PRRs) 
expressed by cells of the innate immune system. An example of PRR is the Toll-like 
receptor (TLR). Human TLRs can be expressed on the cell plasma membrane (e.g. TLRs 
1,2, 4, 5 and 6) or in endosomes (e.g. TLRs 3,7,8 and 9)[183]. TLRs are expressed at 
mucosal surfaces in several cell types including neutrophils, macrophages, DCs, T cells 
and epithelial cells [184, 185]. TLR function in epithelial tissues is particularly important 
since these are the main sites for microorganism exposure[186]. Besides the activation of 
phagocytes, killing pathogens and release of pro-inflammatory cytokines and anti-
microbial peptides, the activation of DCs by TLRs lead to the stimulation of the adaptive 
immune responses[182, 187].  
HIV-1 can be recognized by the innate immune system through PAMPs present in the 
viral particle or generated during different stages of HIV life cycle. For instance, the viral 
envelope glycoproteins may be recognized by TLRs and CLRs (C-type lectin receptors) 
as described for other retroviruses[188]. Also, genomic RNA, mRNA and viral structural 
and regulatory proteins may represent potential ligands for PRRs. For instance, HIV 
(ssRNA) is recognized by TLR7 and TLR8, which are present  in DCs and monocytes, 
leading to the potent activation of these cells and the release of type I interferons (IFNs) 
and tumor necrosis factor α (TNF- α)[189]. This contributes to the inhibition of viral 
replication (antiviral activity) in infected cells and activation of the immune response by 
recruiting other immune cells to the sites of infection [190, 191]. Interestingly, TRL7/8 
expression is reduced  in male and female lower genital tract [192, 193] and absent in the 
gut[186], two major sites for HIV exposure. However, several studies have shown that 
TLRs 7-9 are constitutively expressed in the upper female reproductive tract (reviewed 
in [194]. In addition, responsiveness to TLR9 is defective in HIV-1 infection. Direct 
interaction of gp120 with pDCs seems to inhibit TLR9-mediated IFN-α secretion leading 
to a reduced capacity to induce cytotoxic activity of NK cells and therefore to a decreased 
ability to initiate host immune responses [195, 196]. 
Among the innate immune cells involved in the early control of HIV-1 infection, NK cells 
play a major role. These cells are a subset of granular lymphocytes that do not express an 
antigen-specific receptor but instead, express a set of inhibitory and activating receptors 
on their surface [178, 191, 197]. NK cells recognize and kill virus-infected cells and are 
regulated by the balance between incoming inhibitory and activating signals with the 
inhibitory signals (received from Human leukocyte antigen class I molecules) being 
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usually predominant maintaining NK cells in a resting state [179, 198]. NK activation can 
be achieved when the magnitude of the activating signal overwhelms the dominant 
inhibitory signal (reviewed in [179]). In acute HIV-1 infection, NK cells expand rapidly 
specially in the seronegative window [191]. Co-expression of NK-cell receptors (named 
KIR-Killer immunoglobulin receptor) in association with their ligands is related with a 
slower HIV disease progression and early control of viremia supporting an important role 
for these cells in the first stage of the infection [199, 200]. Despite the important role of 
NK cells in controlling early infection, HIV-1 can impair NK cells and escape from 
recognition by several mechanisms, including the expression of counteracting proteins 
(e.g. Nef), leading ultimately to persistent infection[179]. Nef is able to down-regulate 
HLA class I molecules on the surface of the infected cells by decreasing HLA-A and 
HLA-B and maintaining HLA-C and HLA-E unchanged. This selective HLA-I 
downregulation protects HIV-1 infected cells from lysis mediated by NK cells expressing 
inhibitory receptors that are specific for HLA-C or HLA-E (reviewed in [198]).  
Finally, DCs, one of the earliest targets of HIV, are the main antigen-presenting cells and 
induce a primary immune response in resting naïve T cells[201]. Immature DCs develop 
into mature effector DCs upon activation by microorganisms or inflammatory signals and 
migrate to the draining lymph nodes where they stimulate naïve Th cells. Specifically, 
HIV-1 is captured by DCs in the mucosa and is delivered to the lymph node where it 
replicates [202]. Based on differences in function and expression of surface markers, DCs 
are divided in myeloid DCs (mDCs) and plasmacytoid DC (pDCs). mDCs include 
Langerhans cells, dermal DCs and interstitial DCs and are found in the blood, skin and 
mucosal tissues and act by capturing  antigens, processing them and presenting them on 
the cell surface linking the innate and adaptive systems. pDCs are located in blood and 
secondary lymphoid organs (but they can be recruited to inflammation sites) and play an 
important role in innate immune responses through the production of type I IFN, as 
described above. In HIV-1 infected individuals the number of mDCs and pDCs are 
substantially reduced. Interestingly, while mDCs can enhance HIV infection through 
capture and subsequent transmission of the virus, pDCs are capable to inhibit HIV 
replication due to the antiviral activity of IFN-α[202]. 
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3.2 Adaptive immune responses 
 
Adaptive immune response is characterized by the ability to recognize a wide range of 
antigens, for its high specificity and for a long immunological memory. There are two 
types of adaptive immune responses: cellular responses, mediated by T lymphocytes (or 
T cells) and humoral responses, mediated by antibodies produced by B lymphocytes (or 
B cells). 
 
3.2.1 Cellular responses  
 
There are several types of T lymphocytes according to its function, namely, helper T cells 
(CD4+), cytotoxic T cells (CD8+) and regulatory T cells (CD4+FOXP3+). Helper T cells 
include several main subsets of cells: Th1, Th2, Th9, Th17 and more recently, T follicular 
helper cells (Tfh). Th1 cells, which produce IFN-γ and IL-2, are involved in an efficient 
antiviral response and in the pathogenesis of autoimmunity, whereas Th2 cells, which 
secrete IL-4, IL-5, IL-10 and IL-13 cytokines, are involved in allergic responses and 
clearance of extracellular pathogens[203-205]. Th17 cells are one of the predominant 
proinflammatory cell types and through IL-17 production attract other innate immune 
cells such as macrophages and neutrophils to further aggravate chronic inflammation. 
Th17 are predominantly present in the gut to maintain homeostasis and are depleted to 
some degree in HIV infected individuals contributing to the pathogenesis of HIV 
infection [205, 206]. T-cytotoxic lymphocytes (CTL), which have cytotoxic activity, are 
responsible for the recognition and destruction of host cells infected by pathogens [177, 
207]. Follicular T cells will be described in detail further below. 
After infection, naïve T cells circulating through the lymphoid organs encounter specific 
antigens presented at the surface of antigen presenting cells (e.g. DCs). Due to this 
interaction, the antigen-specific T cell undergoes a process of extensive division and 
differentiation and becomes an activated effector T cell that migrates to tissues in order 
to fight the infection. This will lead to the production of a pool of memory T cells that are 
responsible for the rapid response to subsequent encounters with the same pathogen. By 
the end of puberty, memory T cells are predominantly present in lymphoid tissues, 
mucosal sites and skin and persist throughout adult life representing the most abundant 
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lymphocyte population in the body[208].  Although both CD4+ and CD8+ T cells 
differentiate simultaneously, CD8+ T cells divide sooner and more rapidly and therefore 
develop into effector cells quicker than CD4+ T cells. CD4+ T cells are important for 
optimal generation of memory CD8+ T cells following acute infections and for sustained 
CD8+ T cell responses during chronic infections[207, 209, 210]. 
Most cellular responses against HIV are mediated by CD8+ T cells. These cells have the 
capacity to kill HIV-1 infected cells and secrete IFN-γ being detected early in infection 
shortly before the peak of viremia, declining after 1-2 weeks when viremia also 
declines[211]. The rapid decline of CD8+ T cells responses observed during early HIV-1 
infection can be explained by several mechanisms that include a decrease in antigen load 
as viremia is brought under control, T cell exhaustion (due to persistent antigen exposure) 
and subsequent deletion of the early responding T cell populations and  selection of viral 
escape mutations that interfere with CD8+ T cells recognition [211-214].   
CD8+ T cells have an important antiviral activity against HIV-1 as they are associated 
with a rapid and drastic decline of the initial viral replication and also with the 
establishment and maintenance of the viral set point and thus the rate of disease 
progression [215, 216]. The antiviral effect of CD8+ T cells is particularly evident in HIV 
controllers, i.e. HIV-1 positive individuals who maintain plasma viral loads below the 
limit of detection without antiretroviral therapy. In contrast with HIV progressors, in HIV 
controllers there are  persistent and  highly strong and specific CD8+ T cells which are 
associated with the control of viral replication[217].   
In contrast with CD8+ T cells, which recognize viral determinants at the surface of 
infected cells through antigen presentation by HLA class I inducing apoptosis, CD4+ T 
cells recognize viral determinants through antigen presentation by HLA class II and act 
by proliferating and releasing cytokines[177, 218, 219]. IL-2 is a cytokine that regulates 
the proliferation, differentiation and survival of T cells [220-222]. It is secreted by 
activated CD4+T cells and its expression is regulated by a complex network involving 
transcription factors, chromatin remodeling and CD28 costimulation signaling [223].  
CD4+ T cells help in maturation of B cells and antibody class switching and also in the 
generation of cytotoxic CD8+ T cell responses and memory development [224, 225]. 
CD4+ T cells are particularly susceptible to HIV infection representing the main target of 
HIV-1[103, 226]. HIV infection is characterized by an acute stage of intense viral 
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replication and a decrease in CD4+ T cell counts, followed by a partial control of viremia 
and entry in a chronic state of infection (figure 5). Through the course of infection CD4+ 
T cells are progressively depleted and functionally impaired leading eventually to AIDS 
and death in untreated individuals [133, 140, 211, 227].  
In early HIV-1 infection, memory CD4+T cells are depleted from the lymphoid system, 
mainly in the gut. This depletion is observed in all memory CD4+T cells populations 
although those specific for HIV are preferentially infected and destroyed. However, only 
a few percent of these cells are infected suggesting that the majority of HIV-specific 
CD4+T cells escape [228].  The causes of CD4+ T cell depletion in the course of HIV 
infection have not been fully elucidated. However, apoptosis caused by a variety of HIV 
proteins (e.g. gp120, Tat, nef, Vpr) and the chronically activated and hyper inflammatory 
immune status characteristic of HIV infection have been associated to HIV-1 induced 
CD4+ T cell death  [229-231].  DNA-dependent protein kinase during viral integration is 
also associated with cell death during HIV infection [232]. More recently, CD4+ T cell 
death during HIV infection has been linked to a mechanism of caspase-1-mediated 
pyroptosis triggered by abortive viral infection[233]. In addition, HIV-1 infection of 
CD4+ T cells leads to an abnormal expression of the IL-2 gene disturbing the anti-viral 
immune responses mediated by IL-2 secretion (reviewed in [224]). This gradual loss of 
IL-2 secretion and proliferation  during the course of infection is strongly associated with 
T cell exhaustion[225]. Despite CD4+ T cell responses to HIV proteins are still unclear, 
HIV-1 Gag protein seems to constitute an important epitope for these cells in chronically 
infected patients. Streeck and colleagues have demonstrated that lower levels of viremia 
associated with an effective immune control were correlated with a high frequency and 
magnitude of Gag responses and low proportion of Env responses. Specifically, targeting 
of Gag was exhibited by elite controllers while Env was targeted by HIV 
progressors[234]. 
The recently characterized T follicular helper cells, which reside in follicles of secondary 
lymphoid organs assisting  B cells in the generation of antibodies are a key component of 
the adaptive immune system (Figure 9) [218, 235-238].  Tfh cell differentiation process 
starts at initial dendritic cell priming of a naïve CD4+ that subsequently undergoes cell 
division. If a CXCR5 chemokine receptor is expressed, the early Tfh cell migrate to the 
border of the B cell follicle leading to further Tfh cell differentiation. In contrast, if the 
cell receives Th1, Th2 or Th17 cell signals, CD4+ T cell will follow a Th1, Th2 or Th17 
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cell differentiation program that includes the upregulation of chemokine receptors for 
inflammatory chemokines which in turn will drive the effector cell to the site of infection 
or inflammation [239]. These cells are primarily found in germinal centers (GCs) and 
play a significant role supporting B cell activation, somatic hypermutation (SHM) and 
antibody class switching, following natural infection or vaccination [235, 240-242]. 
 
 
 
 
 
 
Figure 9- T follicular helper cell and B cell interaction in the lymph node (extracted from [243]). 
Activated Tfh (red) upregulate CXCR5 and migrate toward B cell follicles to form GC. Tfh in GC interact 
with antigen-specific B cells (green) through several molecules as ICOS-ICOSL, PD-1-PDL-1, CD40-
CD40L and IL-21R-IL-21 leading to memory B cells and plasma cells production. Plasma cells secrete 
long-lived antibodies in order to combat infectious agents. Tfr (purple) can regulate Tfh and GC responses 
to limit autoantibody production.  
 
Tfh cells are defined by the expression of CXCR5 chemokine receptor, program death-1 
(PD-1), ICOS (Inducible T cell co-stimulator), and secretion of IL-21 and their 
differentiation is regulated by B-cell lymphoma 6 (Bcl6) [235, 244, 245]. IL-21, primarily 
produced by CD4 T cells, is a key cytokine involved in the promotion of GC formation 
and maintenance, Tfh and B cell proliferation, and memory B cells/plasma cells 
differentiation. It is also critical to the generation of antigen-specific IgG antibodies and 
expansion of class-switched B cells and plasma cells in vivo, an important process during 
the production of NAbs[242, 246, 247].  
The interplay between HIV infection and Tfh is still not fully understood. Because Tfh 
cells have a central memory phenotype and express CCR5 coreceptor they are potentially 
susceptible to HIV infection[248]. In fact, Perreau et al., have demonstrated that Tfh cells 
are a major reservoir for HIV infection, replication and production [249]. In the earlier 
stages of the disease, Tfh levels are increased promoting HIV replication and disease 
progression [133, 236]. In fact, because Tfh are primarily found in follicles and GCs of 
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secondary lymphoid organs they are more susceptible to be infected compared to a CD4 
T cell outside the follicle[249, 250].  Despite being highly permissive to HIV, Tfh cells 
expand in early and chronic stage of the disease and part of this expansion is driven by 
antigen stimulation[251]. 
Increased evidences have linked many of HIV-infection-induced immune deficits (e.g. B 
cell dysfunction, decreased GC B cell and plasma cell numbers, 
hypergammaglobulinemia, loss of T-dependent responses) to impaired Tfh function [237, 
249, 252]. Recently, Haddak and colleagues [253] have demonstrated that, despite Tfh 
expansion during HIV infection, these cells were functionally impaired being unable to 
provide adequate B cell help. This was due to an increased PD-L1 expression by B cells 
from the GC leading to PD-1 triggering on Tfh cells which in turn affected Tfh cell 
proliferation, activation, ICOS expression and IL-21 secretion. Impairments in Tfh 
contribute to the ability of HIV to persist and evade humoral immunity interfering with 
the effective production of NAbs[237]. It was recently demonstrated that impairments in 
the capacity of Tfh to stimulate HIV specific antibody production by B cells occur soon 
after infection. In addition, Tfh from lymph nodes of untreated and treated HIV infected 
patients seems to be much more sensitive to Gag than to Env probably caused by the 
increased presence of Gag antigen compared to Env antigen in the lymph nodes of HIV 
infected individuals and also by the persistence of p24 antigen in lymph nodes after long-
term ART. Thus, this lack of specificity of Tfh to the HIV envelope may be one of the 
factors  contributing to the slow development (and failure) of bNAbs generated after 
several years of infection (reviewed in [237]).  
Besides the unclear role of  Tfh cells in bNAb development there are some evidences 
demonstrating that  these cells may contribute to HIV neutralization as showed by the 
positive correlation between the frequency (and quality) of Tfh subsets and effective 
humoral responses against HIV, measured by the development of bNAbs [240, 254-256]. 
Recently, Tfh cells from elite controllers were found to have a stronger ex vivo capacity 
of inducing B cell maturation and antibody switch compared with normal HIV 
progressors suggesting that the immune responses in this small subset of individuals are 
mediated by better helper activity compared with progressors[257]. Thus, due to the 
crucial interactions between Tfh cells and B cells, Tfh should be considered a potential 
target for vaccine strategies aiming to induce neutralizing antibodies. 
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Within follicular cells, a subset of cells with regulatory functions- T follicular regulatory 
cells (Tfr) - seems to moderate the role of Tfh cells in driving antibody production by B 
cells (Figure 9) [258-260]. These cells are also a crucial component of the GC response 
as they are able to inhibit GC expansion and regulate Tfh and GC responses to limit 
autoantibody production [259-261]. Similar to Tfh, Tfr express high levels of CXCR5, 
ICOS and PD-1, but they also express FOXP3 which contributes for its regulatory 
functions [259-261]. Tfr develop independently of Tfh from natural Treg precursors but 
they share similar signals with Tfh, such as CD28 and ICOS, in order to differentiate 
[260]. The role of immune tolerance has also been implicated in the development of 
bNAbs, with evidences of a negative correlation between Tfr and the presence of bNAbs 
in HIV-1-infected individuals compared with HIV-1 infected individuals without 
bNAbs[262]. Several studies reported that higher quality Env-specific (gp120) antibodies 
in SIV-infected rhesus macaques were correlated with a lower frequency of Tfrs [263]. 
Also neutralizing antibodies to HIV were negatively correlated to FOXP3+ Env-specific 
follicular T cells in SHIVA28 (Simian-Human immunodeficiency virus) infected rhesus 
macaques [256]. Together these data suggest that Tfrs increase during chronic HIV 
infection and may contribute for Tfh dysfunction resulting in disruption of proper B cell 
differentiation and SHM. In mice, circulating Tfrs were shown to be expanded after viral 
infection with influenza or lymphocytic choriomeningitis virus (LCMV) and could 
potently suppress Tfh function without requiring specific antigens[264]. As Tfrs 
frequency has been found to negatively correlate with bNAb generation it is important to 
consider this subset when developing new vaccine strategies [256, 263]. Moreover, recent 
studies have shown that the function of Tfr and/or a skew in the balance of Tfh/Tfr 
frequency can lead to impaired humoral immunity [264, 265]). Increased understanding 
of the biology of Tfh and Tfr cells may lead to improved vaccination strategies against 
HIV. 
 
3.2.2 Humoral responses  
 
The humoral immune response is characterized by the production of antibodies by B 
lymphocytes and their progeny, plasma cells [266].  
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3.2.2.1 B cells   
 
B cells development includes a first stage of antigen independency followed by a stage 
dependent of antigen presence. The first stage occurs in the bone marrow, where precursor 
B cells develop from hematopoietic cells into the immature B cell stage with the help of 
stromal cells. [267] 
Maturation of the B cells starts when the stem cell differentiates into the progenitor B cell 
(pro-B cell) (Figure 10). These cells proliferate and differentiate into precursor B cells 
(pre-B cells). Interactions between pre-B cells and stromal cells, which provide growth 
factors that stimulate lymphocyte differentiation and proliferation, are necessary to the 
development of immature B cells[267, 268]. Immature B cells undergo selection for self-
tolerance and ability to survive in the peripheral lymphoid tissues where they 
continuously circulate among all lymphoid tissues (including lymph and blood) becoming 
mature B cells (naïve B cells)[267].  
Effector cells (mature and fully functional B cells) migrate from the bone marrow to the 
peripheral lymphoid organs where they can find an antigen (antigen-dependent process). 
When a B cell with a specific receptor encounters a specific antigen it activates and starts 
to proliferate and differentiate into plasma and memory B cells (Figure 10). Plasma cells 
are non-dividing, terminally differentiated and immobile antibody-secreting cells of the 
B cell lineage. Plasma cells localized in the spleen and lymph nodes are mainly short-
lived plasma cells (SLPCs) and produce antibodies during a short period (e.g. few weeks). 
In contrast, long-lived plasma cells (LLPC) migrate to the bone marrow, where they 
produce antibodies for extended periods (e.g. years). Moreover, plasmablasts are plasma 
cells precursors that produce functional antibodies but, in contrast to plasma cells, are 
able to divide[177]. These cells can develop from any type of activated B cells (e.g. naïve, 
follicular, memory)[267]. Finally, memory B cells are generated in GC reactions in the 
course of T cell-dependent immune responses and are distinguished from naive B cells 
by an increased lifespan, faster and stronger response to stimulation and expression of 
somatically mutated and affinity matured immunoglobulin (Ig) genes [267, 269]. 
Activation of B cell can be achieved with or without T cell help.  Thymus-independent 
(TI) antigens can activate B cells and induce antibody production in the absence of helper 
T cells. B cells activated by TI antigens proliferate outside the lymphoid follicles in the 
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secondary lymphoid organs (without GCs formation) [267, 270]. In contrast, Thymus-
dependent antigens need T cell help to successfully activate B cells resulting in the 
production of both high-affinity memory B cells and LLPC [218, 267].  
Differentiation of B cells into memory cells and their affinity maturation and 
differentiation into long-lived plasma cells both take place in germinal centers of 
secondary lymphoid follicles [267, 271].  
During an acute viral infection, naïve B cells remain in the marginal zone and differentiate 
into SLPCs producing low-affinity antibodies which provide the first wave of defense 
against pathogens or, alternatively, with CD4 T cell help in B cell follicles, initiate 
germinal center reactions which produce both high-affinity memory B cells and LLPCs 
secreting high-affinity antibodies. These high-affinity antibodies are necessary to 
efficiently neutralize pathogens and toxins and for a persistent protection [271]. LLPCs 
migrate to the bone marrow where they can reside for extended periods maintaining these 
high affinity antibody levels in the serum and mucosa (reviewed in [272]).  
CD4 T cells play an essential role in helping B cells mediated immune responses. Tfh has 
been shown to specialize in providing B cell help (Figure 9). Tfh, by expressing the 
CXCR5 chemokine receptor, relocate into B cell follicles and provide cognate help to B 
cells in GCs. These cells are initially activated by antigen presented on dendritic cells 
outside the follicle. Then, B cells migrate into the B cell follicles to form GCs, where they 
proliferate and undergo somatic hypermutation and affinity maturation [235, 240, 242, 
273]. Of note, germinal centers develop after the activation of follicular B cells by TD 
antigens and consists of a specialized site within secondary lymphoid organs where  
antibody diversification and affinity maturation occur during an immune response to an 
infection[273].  
In contrast with T cells, B cells can circulate in the blood but also can reside in tissues as 
specialized lymphoid tissues (e.g. spleen, lymph nodes, tonsils and bone marrow). 
Moreover, B cells are present in the mucosa-associated lymphoid tissue (MALT) in the 
genitourinary and gastrointestinal tracts where they may play a critical role in host defense 
from pathogens [274-276].  
B cell dysfunctions have been associated with HIV-1 infection and they may occur at 
several different stages of B cell development resulting from HIV-induced immune 
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activation,  HIV-induced lymphopenia (i.e. abnormal low level of lymphocytes in the 
blood) or other factors [277, 278]. As humoral responses become compromised by defects 
in B cell function, opportunistic infections may arise [278, 279]. 
 
 
 
 
 
 
 
Figure10-Generation of plasma cells and memory B cells. Mature B cells become activated in secondary 
lymphoid tissue after interaction with antigen leading to the generation of plasma cells and long-lived 
memory cells. Antigen-specific naïve B cells can differentiate within secondary lymphoid tissue into short-
lived low-affinity antibody secreting plasma cells or undergo GC reaction. B cells that survived the GC 
reaction proceeds to form either memory B cells or high-affinity antibody secreting plasma cells. Memory 
B cells are re-activated by specific antigen proliferating and differentiating into the long-lived high affinity 
antibody producing plasma cells. CSR, antibody class switch recombination; IL-7, interleukin 7 
(hematopoietic growth factor); IL-7R, receptor pre IL-7; pre-B, precursor B cell; pro-B, progenitor B cell; 
SHM, somatic hypermutation; VCAM, vascular cell adhesion molecule; VLA-4, very late antigen 4 
 
Features of B-cell dysregulation associated with HIV-1 infection include 
hypergammaglobulinemia, extensive expansion of B-cell areas in lymphoid tissues, 
increased expression of activation, proliferation and terminal differentiation markers on 
circulating B cell, decrease in memory B cell frequencies and expansion of aberrant B 
cell populations and B cell exhaustion [135, 136, 280-282]. Despite 
hypergammaglobulinemia (i.e. high levels of gamma globulin) described in HIV-1 
infected patients, the frequency of HIV-specific B cells is quite low (<1.5%)[135, 136]. 
This is justified by the fact that plasmablasts, the terminally differentiating B cells 
responsible for the hypergammaglobulinemia condition, are maintained at abnormally 
high levels in HIV infection but the majority of these cells are not HIV specific[136]. 
Moreover, these unspecific plasmablasts are thought to arise early in the infection which 
may be associated with the inefficient antibody response in HIV-1 infection [136].Also, 
the delay in neutralizing antibody production following HIV-1 transmission may be 
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explained by HIV-1 associated damage in lymphoid tissues in gastrointestinal tract and 
the loss of CD4+ T help in those sites. This is because the gastrointestinal tract CD4+T 
cells are the main site for HIV-1 replication and the depletion of those cells occurs in the 
early stages of the disease [275, 276, 283].  
 
3.2.2.2 Antibodies  
 
Antibodies, also known as immunoglobulins, are large glycoproteins molecules found in 
the blood and tissue fluids[177]. They are presented on the surface of B cells acting like 
antigen receptors or can be secreted into the extracellular space where they can bind their 
antigen targets [266]. An antigen is the first element that drives all adaptive immune 
responses aiming to eliminate it. Antibodies bind to a restricted part of an antigen called 
epitope[177]. Antibody and cellular responses are generally directed against different 
determinants on the antigen.  
 An antibody consists of four protein chains, two heavy chains and two light chains that 
are bound by disulfide bounds (Figure 11). The antigen-binding fragment (Fab) is 
composed of one variable domain from each heavy and light chain and is involved in 
antigen binding. The constant domains of the heavy chains are less variable and are 
brought together and form the crystallizable fragment (Fc) which is responsible for the 
effector functions of the antibody through binding to Fc receptors (FcRs)[177, 266].The 
two heavy chains and the two light chains of an immunoglobulin molecule are identical 
and for that reason an antibody has two identical antigen binding sites being able to bind 
simultaneously to two identical structures[284]. Based in their Fc region, antibodies can 
be classified in five isotypes that are distinguished according to the C-terminus regions 
of heavy chain which do not participate in antigen binding: IgM, IgD, IgG, IgA, and IgE. 
IgG antibodies, the most abundant isotype in plasma and with longer lifetime, are 
subdivided in four isotypes: IgG1, IgG2, IgG3 and IgG4 [266]. Antigen specificity is 
determined by the antigen binding domain whereas effector functions are determined by 
antibody isotype and binding affinities of activating and inhibitory FcR on immune cells. 
Effector functions include: 1) neutralization of their targets (e.g. virus), 2) activation of 
macrophages and other immune cells by binding to Fc receptors that recognize the Fc 
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region of specific antibody isotypes (e.g. IgG1 and IgE ) and 3) activation of the 
complement system (e.g. IgM and IgG3) [266, 285]. 
. 
 
 
 
 
 
 
 
Figure 11- General structure of an immunoglobulin G1 (IgG1).The Fab portion comprise the antigen-
binding region and include the light chain and part of the heavy chain. Fc consists in two identical CH2 and 
CH3 fragments derived from the constant domains of the heavy chains. Fc fragments do not recognize the 
corresponding antigen and instead bind to cell receptors and complement proteins. All antibodies have in 
the Fc region an N-glycosilation site N297 (adapted from [255]. 
 
Naïve B cells, i.e. before antigen exposure, express IgM and IgD on their surface. After 
antigen contact, CD4+T cells induce B cells maturation causing isotype switch to IgG, 
IgA or IgE. Somatic hypermutation and subsequent clonal selection in the GCs under Tfh 
influence lead B cells to express high-affinity antibodies optimizing antibody-antigen 
affinity and selectivity. When isotypes switch random mutations are inserted in the 
antigen-binding coding sequences of the IgG and the higher affinity mutants to the antigen 
are selected [177, 218].  
During acute and chronic stages of HIV-1 disease, antibodies against Env are mainly from 
type IgG1 with higher titers of these antibodies being associated with better control of 
viral replication [286, 287].  IgG3 is also detected in HIV-1 infected patients, namely in 
HIV-1 controllers, although to a lesser extent compared with IgG1 [286]. IgA is 
predominant in mucosal surfaces being associated with protection against HIV-1 
infection in individuals who are highly sexually exposed to HIV-1 but remain uninfected 
[288, 289].  
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3.2.2.3 Neutralizing antibodies 
 
The initial antibody response to HIV-1 can be detected as early as 1 week after infection 
and is directed to non-neutralizing epitopes in Env. The first antibodies are against gp41 
region followed by the appearance of anti-gp120 antibodies a few weeks later and 
targeting the V3 loop [274, 290]. These binding antibodies mainly form immune 
complexes and don´t seem to have impact in viral replication suggesting that they are not 
responsible for the initial decline in plasma viral load [290].  However, although the first 
antibodies are not able to neutralize the virus, they may play a protective role in HIV-1 
infection. For instance, a study in macaques has shown that Tat and Env binding 
antibodies confer some degree of protection against SHIV challenge despite the lack of 
neutralizing antibodies [291]. Moreover, the modest protection observed in RV144 
(31.2%) trial may be in part due to binding antibodies that mediated antibody-dependent 
cell-mediated cytotoxicity (ADCC) and/or other non-neutralizing humoral effector 
functions [118, 131, 292]. Recently, a study performed in humanized mice using a 
replication-competent HIV-1 reporter virus expressing a heterologous HA-tag on the 
surface of infected cells and virions demonstrated that non-neutralizing antibodies can 
actually alter the course of HIV-1 infection, apply immune pressure on the infecting virus 
and also achieve modest levels of protection by a Fc receptor mediated mechanism. In 
this particular study, non-neutralizing antibodies were found to clear HIV-1 infected cells 
in vivo [293].  
Neutralizing antibodies act by binding cell-free virus preventing the virion to infect the 
host cell [130]. However, it is still not clear (due to the variability in the experimental 
approaches) the relative activity of NAbs in cell-to-cell transmission,  a major mechanism 
of HIV infection where HIV replicates more efficiently and rapidly through direct contact 
between cells[294, 295]. Overall, several studies have consistently demonstrated that 
NAbs are able to block HIV-1 infection at synapses, supporting the notion that cell-to-
cell infection occurs through the direct transfer of virions accessible to the external 
environment. However, higher concentrations of specific NAbs (e.g. b12 and VRC01 
against the CD4bs) are needed to inhibit cell-to-cell infection[296]. In addition, 
neutralizing polyclonal sera, which represent better the nature of the antibody response 
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during natural infection, is less effective in inhibiting cell-to-cell infection compared with 
cell-free infection, although it varies significantly according to the sera[294, 297].  
The first NAbs, targeting the variable regions of the HIV-1 envelope, arise several months 
post-infection and, although often potent, are directed to the infecting strain (i.e. 
autologous virus) being unable to neutralize more divergent viruses (i.e. heterologous 
virus) [130, 132, 298-300].  Despite the high specificity of autologous NAbs, they exert 
a selective pressure on the virus that rapidly evolves to escape neutralization [130, 300]. 
Thus, it seems that NAbs appears sequentially and demonstrate temporal fluctuations 
consisting with the emerging of new escape variants [128, 300, 301]. An evidence that 
supports neutralization escape driven by autologous NAbs is the fact that 
contemporaneous viruses are less sensitive to autologous neutralization in comparison 
with earlier viruses[128]. Viral escape to avoid recognition is mediated by several features 
of Env that limit or block the access of antibodies to conserved neutralizing epitopes 
(Figure 12). Such features include carbohydrate shielding and shifting, conformation 
masking, steric occlusion, temporary epitope exposure (e.g. pre-fusion state form of 
gp41) and non-functional envelope spikes which are not expressed by mature functional 
spikes (e.g. gp120-gp41 monomers, gp41 stumps or uncleaved gp160 precursors) and 
may deviate the immune response from functional targets (reviewed in [298]). In fact, 
gp120 carries about 18 to 32 N-linked glycans  which constitutes about 50% of the total 
molecular weight and function as a  glycan armor avoiding antibody recognition[147, 
302]. Also, the very limited number of gp160 glycoproteins per virion (between 21-42 
SU molecules or 7-14 trimers per particle) likely reduce the ability of antibodies to bind 
simultaneously to two Env molecules (bivalent antibody binding) [303, 304]. Single 
amino acid substitutions, insertions and deletions in Env also contribute to viral escape 
[130, 300]. 
Despite of all these features some individuals are able to develop bNAbs targeting 
conserved functional sites on gp120 and gp41.  In fact, during the course of infection, 
between 10-50% of HIV-1 infected individuals (depending on the definition of breadth 
and potency) develop broadly neutralizing antibody responses against diverse 
heterologous HIV-1 variants [305, 306].  Among them, few individuals (1%) called elite 
neutralizers develop highly potent and broad neutralizing responses. 
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Figure 12- Envelope features defense mechanism against antibody recognition (adapted from [298]). 
According to Simek et al, this elite activity is defined by the ability to neutralize, on 
average, more than one pseudovirus at an IC50 titer of 300 within a clade group and 
across at least four clade groups [307]. bNAbs  generally arise only 2-4 years after 
seroconversion (in the chronic stage) and are absent in newly infected individuals 
suggesting that persistent infection and antigen exposure are required for their 
development [262, 308]. However, in rare cases bNAbs can arise 1 year following 
infection [309]. Development of bNAbs in HIV-1 infection is associated with the duration 
of infection, high viral load, low CD4+ counts and a higher frequency of T cell help (Tfh) 
in the periphery [254, 305]. Also, the early preservation of both Tfh and B cells is 
associated with the later development of breadth of neutralizing antibody responses in 
chronic HIV-1 infection [310]. All of these factors are consistent with the requirement of 
high levels of antigenic stimulation of B cells and the T cell help in the maturation of 
breadth through the infection. Nonetheless, individuals with low viral loads can also 
develop bNAbs suggesting that high viral load alone is not a determinant of breadth [311, 
312].  In addition, viral genetic subtype may also be a contributing factor as exemplified 
by the more potent and broad humoral responses observed in subtype C chronically 
infected individuals compared with subtype B infected individuals [313, 314]. 
Interestingly, infants who acquired HIV-1 in utero, during delivery, or via breastfeeding 
can also mount bNAb responses as early as 20 months after infection suggesting that the 
development of bNAbs is not an inherent trait of adults and that even in early life there is 
an adequate B cell-functionality able to develop bNAbs against HIV-1. However, in this 
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study, bNAbs epitopes were unclear with only a modest response observed in one infant 
against MPER in gp41[315].   
Despite their protective role in vitro, bNAbs are unable to suppress viral replication in 
infected individuals due to viral escape [130, 300]. Demonstration that elicitation of 
bNAbs can be sufficient to prevent HIV-1 infection is now well documented based on 
passive immunization studies performed in animal models with human monoclonal 
antibodies (HuMAbs) with broadly neutralizing activity.  In nonhuman primates 
protection was observed against viral challenge via intravenous, rectal and vaginal routes 
after passive immunization with broadly neutralizing monoclonal antibodies (e.g. F105, 
2G12, 2F5, VRC01, PGT121, PGT126, b12, VRC07) [316-324]. Another study in 
macaques showed that the administration of PGT121 conferred sterilizing immunity 
against vaginal SHIV challenge at low concentrations [319].   Li and colleagues recently 
demonstrated that VRC01 was able to protect against HIV-1Ada vaginal and rectal 
challenge in hu-BLT mice (humanized mice) [318].  Also in humanized mice, passive 
administration of b12 and PGT126 provided sterilizing protection against repeated 
intravaginal HIV challenge [324].  
 
3.2.2.4 Neutralizing epitopes in Env 
 
Using novel antibody cloning techniques several potent and broadly neutralizing 
antibodies have been isolated from HIV-1 infected individuals in recent years. Mapping 
and structural definition of bNAb epitopes have allowed the identification of several sites 
of vulnerability on the HIV-1 envelope spike that are shared between subtypes and 
isolates. These conserved epitopes include: CD4 binding site (CD4bs), N-glycan-
associated epitopes in the V1/V2 loops and V3 loop (N-glycans and tip of the loop), 
gp120/gp41 interface, the MPER regions and the fusion peptide in the N terminus of the 
Env-gp41 subunit [298, 325-337].  
Recognition of neutralizing epitopes by multiple bNAbs is illustrated in figure 13.  
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Figure 13- Representation of bNAbs epitopes on HIV-1 trimer. A-Env structure obtained by electron 
microscopy, structure EMD-5782; CD4 binding site epitope (red), N-glycans V1/V2 loops (green), N-glycans V3 
loops (blue), gp120/gp41 interface (yellow, cyan and pink), MPER (grey); N-linked glycans regions are shown as 
grey sticks. For each epitope there is a set of representative bNAbs. B- Structure of the BG505 SOSIP.664-
VRC34.01 complex representation the fusion peptide site (salmon); Heavy chains are colored in green and light 
chains in yellow. CD4bs-CD4 binding site; MPER- membrane proximal external region (adapted from [298, 337, 
338].  
 
V1/V2 region constitutes an important target for autologous NAbs and can serve both as 
a direct antibody target but also as a shield for other vulnerable sites due to its location 
and extensive glycosylation (Figure 14)[339-341]. Sequence conserved regions of the 
V1/V2 domain and V3 loop form the V2 site at the apex of HIV-1 trimer which is 
protected by densely packed glycans. Multiple bNAbs recognize epitopes that are only 
present in the trimeric envelope (located within the V2 domain at the trimer apex) 
meaning that these epitopes are conformation-dependent [342]. bNAbs recognizing these 
epitopes include PG9, PG16, PGT145, CAP256-VRC26 and PGDM1400.  PG9 and 
PG16, which were isolated from a clade A chronically infected individual with 
exceptional plasma neutralization breadth, are quite frequent in sera from individuals who 
develop bNAbs[128, 153]. In fact, Burton and colleagues demonstrated that bNAbs 
present in the sera of 19 donors who exhibits a potent cross-clade neutralizing activity 
were directed against an epitope defined by PG9 and PG16 bNAbs[343]. With the 
exception of the CAP256-VRC26, all known bNAbs targeting the V1/V2 region interact 
with N156 and N160 glycans[150]. Moreover, these antibodies through its long CDR H3 
(third heavy chain complementary determining regions) loop have the ability to penetrate 
the glycan shield and recognize a conserved β-strand in V2 [344, 345].  PGDM1400 is 
MPER 
4E10, 2F5, 10E8, Z13, 
m66.6 
A                                                                                                                       B 
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one of the most potent bNAbs that has been isolated so far with cross-clade neutralization 
coverage of 83% [346]. 
V3 is a highly immunogenic region and anti-V3 antibodies have been found to neutralize 
up to 50% of the viruses in various multi-clade panels, including the broad and potent 
bNAb 447-52D [325, 326, 329, 330, 347, 348].  The cross-clade neutralizing activity of 
this particular bNAb is determined by the highly conserved motif GPGR (residues 312-
315 in the HXB2) at the tip of the V3 loop. In fact, this antibody was able to neutralize 
92% of 38 primary isolates carrying the motif GPGR from clades A, B, F or H. In contrast, 
none of the viruses with a GPGQ or other non-GPGR/Q motif was neutralized by this 
antibody[330]. More recently, maternal plasma antibodies targeting amino acid residues 
in the C-terminal region of the V3 loop crown were also associated with reduced 
peripartum HIV transmission risk in U.S. Woman and Infant Transmission Study (WITS) 
cohort suggesting the importance of this particular region in vaccine design [349, 350]. 
The target of the largest and most diverse group of bNAbs that recognize N-linked glycan 
containing epitopes is the region adjacent to the highly conserved N-linked glycosylation 
site at N332 which includes the V3 loop base and nearby glycans[351]. These bNAbs, in 
contrast with others, are able to approach the region centered on N332 from several 
different angles and include 2G12, PGT128, PGT121/10-1074 and PGT135[335, 352-
354]. Whereas 2G12 recognize a cluster of high-mannose glycans attached to N332, N295 
and N339, PGT128 recognize N-glycans attached to N332 and N301 in association with 
amino acid residues at the end of the V3 loop[351]. PGT121, PGT122 and 10-1074 are 
the most potent among the N332-dependent antibodies and target the glycan attached to 
N332 in combination with amino acid residues at the base of V3 loop and a glycan in 
V1/V2 regions[354]. Thus, despite the fact that the HIV-1 Env glycan shield blocks 
antibody access to potential epitopes it´s evident that some bNAbs overcame this obstacle 
by including the glycans as part of their target. 
Because CD4bs is a highly conserved site present in all HIV-1 clades needed for the initial 
host-CD4 receptor interaction it represents one of the most attractive targets for vaccines 
that aim to induce neutralizing responses. NAbs against this conserved site act by 
blocking HIV-1 trimer binding to the CD4 receptor. In contrast with bNAbs described 
above, CD4bs antibodies don´t interact much with glycans. Although CD4bs is highly 
conserved it´s not an easy target due to the CD4-binding pocket size limitation[355]. 
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Nevertheless, there are two distinct ways to produce antibodies that can reach this site. 
The first way is based on the mimetization of CD4 by positioning the antibody domain 
VH to bind gp120 by using the CDRH2 loop and framework residues and engaging the 
CD4 binding loop on gp120 with backbone atoms in the C strand of VH. Because the VH 
domain occupies the same location as the terminal immunoglobulin-like domain of CD4 
and both use the C strand these antibodies are CD4 mimetics. 
 
Figure 14- Site-specific glycosylation of the BG505 SOSIP.664 trimer. Trimer is shown as a grey surface 
and the glycans are shown as colored spheres according to the proportion (%) of oligomannose content 
(represented by green, yellow and blue colors) (adapted from [356]).  
 
Within the groups that mimic CD4, bNAbs can derive from the IgH VH1-2 germline gene 
segment (e.g. VRC01) or from VH1-46 gene segment that have unusually short CDRL3 
loops to avoid interactions with N276 glycan in the D loop of gp120 (e.g. 8ANC131) 
[357-360].  VRC01 is capable of neutralizing 91% of HIV-1 isolates and is also protective 
when used in a topical gel, protecting vaginally challenged humanized mice against HIV-
1 infection [358, 361]. In the second way, the mode of recognition does not mimic CD4 
75-100% 
25-75% 
<25% 
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but instead uses the CDR H3 loop region to reach CD4-binding loop (e.g. HJ16 and 
CH103) [325, 351, 362]. CH103 binds to the outer domain of gp120 by using a CDR H3 
dominated mode of interaction and is able to bind its donor autologous transmitted-
founder Env with high affinity (Figure 15) [362]. 
 
 
Figure 15- Structure of antibody CH103 in complex with the outer domain of gp120 demonstrating 
the non-mimetic mode of recognition of the CD4bs. A- overall structure of complex with gp120 
polypeptide depicted in red ribbon and CH103 as a molecular surface (heavy chain in green and light chain 
in blue). CH103 bind to loop D (orange), CD4bs (yellow) and loop V5 (purple). B- Superposition of outer 
domain bound by CH103 (red) and core gp120 bound by VRC01 (gray). C- CH103 epitope in green on the 
outer domain (red) with the initial CD4bs superposed (yellow lines); (adapted from [362]).  
 
gp120-gp41 interface was recently identified  as a target for bNAbs that interact with both 
gp120 and gp41 subunits as well as glycans being for that reason trimer specific [363]. 
These antibodies probably neutralize the virus by stabilizing the pre-fusion state and/or 
by interfering with the conformational modifications necessary for fusion [364]. 
Examples of this class of bNAbs are PGT151-158, 35O22 and 8ANC195 [336, 364]. Of 
note, PGT151 and PGT152 don´t recognize uncleaved Env trimers being specific only 
for cleaved Envs which is in contrast with 8ANC195 that bind both to gp120 monomers 
and gp140 trimers [359, 364, 365]. PGT151 was able to neutralize 66% of 117 cross-
clade isolates whereas 8ANC195, isolated from an HIV-1 elite controller, neutralized 
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57% of 118 isolates of different HIV-1 clades and 2/5 of VRC01-resistant isolates[359, 
366].  
Linear epitopes in the MPER of gp41, the region closer to the viral membrane, are also a 
target for several bNAbs like 4E10, 2F5, Z13, 10E8 and m66.6 [153, 325, 333, 334, 351]. 
This region contains conserved residues which have a critical role in the fusion process. 
Moreover, several factors like transient exposition, steric elements, hydrophobicity and 
host mimicry interfere negatively with the induction of bNAbs against this region [351]. 
Because 2F5 and 4E10 bNAbs recognize self-antigens, most autoreactive B cells are 
depleted which may justify the low frequency of this antibodies in infected patients and 
vaccines [367]. However, 4E10 possesses a potent and broad neutralizing activity with 
neutralization of more than 90% of different viral clades [153, 154, 325]. 2F5 also has 
neutralization activity although less potent and broad compared with 4E10 [153, 334].  
Finally, the HIV-1 fusion peptide, comprising 15 to 20 hydrophobic residues at the N 
terminus of the Env-gp41 subunit, is a target for some bNAbs like N123-VRC34.01-07 
and ACS202 [337, 368, 369]. VRC34.01 recognizes a unique trimer-specific cleavage-
dependent epitope in the gp120-gp41 interface that consists of the gp41 fusion peptide 
and glycan N88. VRC34.01 was able to neutralize 16/25 pseudoviruses and 49% of 208 
HIV-1 strains [337]. In addition, ACS202 was able to neutralize about 45% (34/75) of the 
viruses from all subtypes [368]. 
 Because not all the bNAbs activities and specificities have been studied new important 
neutralizing epitopes on HIV-1 Env are yet to be discovered. Moreover, it’s not 
completely understood if neutralization breadth is the result of a single or multiple 
specificities of bNAbs. Wu et al., have demonstrated that individual antibodies targeting 
the CD4bs were sufficient to induce broad HIV-1 neutralization [358]. In contrast, 
another study has shown that B-cell memory response in a selected group of patients with 
broad serum neutralizing activity is comprised of multiple clonal responses against 
several epitopes on gp120 [370]. More recently, Moore et al. demonstrated that the potent 
and broad neutralizing response from sera of one participant in CAPRISA Acute infection 
cohort was due to the sequential and transient appearance of three distinct broadly 
neutralizing specificities in different Env epitopes during the first 4.5 years of 
infection[301]. Another interesting issue is whether escape from bNAbs occurs as fast as 
seen in autologous NAbs. Although this question remains undefined, it´s clear that the 
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generation of multiple bNAbs in response to a constantly evolving viral population that 
escape from earlier NAbs contribute to the exposition of new neutralizing targets[301].  
bNAbs have acquired specific features through multiple rounds of affinity maturation  
that allowed them to overcome the Env defenses against antibody recognition: extensive  
hypermutation, long and hydrophobic CDR H3 loops, heavy chain domain-swapping, 
sulphated tyrosines and polireactivity (i.e. the ability to bind to a variety of structurally 
dissimilar antigens with moderate affinity) [128, 153, 371, 372]. Regarding 
hypermutation, HIV-1 bNAbs carry more than 40% amino acid substitutions in their 
heavy chains and nucleotide insertions and/or deletions in heavy and light chains[373]. 
In addition, the unusually long CDR H3 loops that characterize bNAbs are necessary to 
achieve a cryptic region of their epitope by penetrating the glycan shield or by extracting 
it from the membrane [351, 374]. All these features explain the difficulty in inducing 
bNAbs by immunization. 
 
3.3 Search for an HIV-1 vaccine 
  
3.3.1 Primer of vaccinology   
 
Immunization is the process in which a person is made immune or resistant to an 
infectious disease, typically by the administration of a vaccine. Currently, vaccines are 
one of the most effective methods of controlling infectious disease. The benefits of 
successful vaccination strategies are clear, providing not only direct protective effects but 
also indirect effects among unvaccinated individuals who cannot be vaccinated[177, 375].  
Immunization can be either passive or active. Passive immunity occurs with the transfer 
of antibodies to an unimmunized individual and can be classified as naturally or 
artificially acquired. Natural passive immunization is exemplified by the passage of 
maternal antibodies through the placenta to the fetus or through the colostrum or milk  to 
the infant[376, 377]. Artificial passive immunization includes the administration of 
immunoglobulin preparations to susceptible individuals. Immunoglobulins currently 
approved for use in infectious disease prophylaxis and immunotherapy include Human 
Tetanus Immunoglobulin and Human Hepatitis B immunoglobulin [378-380]. Passive 
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immunization provides protection only for a short-period of time because the immune 
system is unable to develop memory [378].  
Active immunization consists in the (natural or artificial) administration of an antigen in 
order to stimulate the host immune system to develop adaptive immunity against a certain 
pathogen and is based in two important features: specificity and memory[177]. Unlike 
passive immunity, active immunity usually lasts for many years or even for the whole 
life. Natural active immunization occurs with the exposure of an unimmunized individual 
to a pathogenic agent [377, 381]. In this case, the exposure to the pathogen  induces clonal 
expansion of specific T and B cells and leaves a population of memory B cells that enable 
the induction of a rapid and effective secondary response upon further encounter with the 
same antigen[382]. Another way to produce active immunity is through antigen 
vaccination which produces an immune response similar to that produced by the natural 
infection but without the disease and related complications. Moreover, the majority of 
vaccines are able to produce immunological memory similar to that acquired from natural 
disease[377]. Immune response to vaccination may be influenced by several factors like 
maternal antibodies, nature and dose of antigen (more antigens lead to better response), 
route of administration and the presence of an adjuvant. Also, host factors as age, genetics 
and immunological status may affect the response to vaccination[383]. In addition, 
vaccine antigens must be safe, induce the right subset of immune responses and must be 
accessible by the target population. For many diseases this has been achieved with success 
but, for others like AIDS, there is still no effective vaccine available[384]. In this 
particular case, an ideal vaccine immunogen should be able to deal with the remarkably 
high diversity of the HIV-1 envelope and induce in the host immune system the capacity 
to cross-react with contemporaneous heterologous viruses. 
Vaccines can be divided into two major types: live attenuated and killed/inactivated 
vaccines (Table I). Live attenuated vaccines contain usually attenuated viruses (whole 
virus) that are unable to cause disease when administered[385]. Attenuation may be 
achieved via the continuous passage of the virus through a series of cell cultures or animal 
embryos. The resulting attenuated virus loses its capacity to replicate in humans but is 
still recognized by the human immune system[386]. Vaccinia virus, the live replicative 
virus used for smallpox vaccination in humans, was naturally attenuated through its 
repeated passages in cows and other large animals (it causes Cowpox)[387].  Due to the 
high error rate of RNA viruses and selective pressures of the host environment, there is 
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some safety concerns regarding the fact that attenuated viruses can eventually revert back 
to wild-type virulence[388, 389]. However, this is very unlikely as the vaccine virus´s 
ability to replicate is limited. Killed or inactivated vaccines consist in the inactivation 
(destruction) of a pathogen (whole bacteria/virus or subunits) using heat or chemicals like 
formaldehyde or formalin[390]. Examples and the main characteristics of inactivated and 
live attenuated vaccines are described in table I.  
 
 Table I- Characteristics of inactivated and live attenuated vaccines 
BCG- Bacille Calmette-Guérin 
Apart from the antigen, all vaccines may contain preservatives (e.g. thimerosal), 
stabilizers (e.g. gelatin, human serum albumin), residual substances derived from 
production processes (e.g. antibiotics, acidity regulators) and adjuvants[396]. Thimerosal 
Vaccines 
 
 
 
 
 
 
 
 
 
Innactivated vacines  Live Attenuated vacines 
Type Examples Type     Examples 
1.Whole organism 
 
  Polio and hepatitis A[377] 
 
 Whole organism[377] 
 
1.Viral 
 
 
 
 
2.Bacterial 
 
 
 
 
 
 
 
 
measles, mumps, 
rubella, Vaccinia, 
varicella, 
zoster, yellow 
fever, rotavirus, 
intranasal 
influenza, oral 
Polio  
 
 
BCG, oral typhoid 
 
 
 
 
 
2.Fractional 
 
-protein-based[391, 392] 
-toxoid 
              - subunit 
 
-polysaccharide based 
[378, 391] 
-pure        
-conjugated 
 
 
 
 
 
 
 
 
 
Toxoid 
diphteria and tetanus 
 
Subunit 
hepatitis B, influenza and 
human papilloma virus 
 
Pure polysaccharide 
 pneumococcal disease, 
meningococcal disease and 
Salmonella Typhi 
 
Conjugated polysaccharide[393, 
394] 
pneumococcal and 
meningococcal disease  
Doses [378] Multiple doses One dose required 
Stability More stable Less stable 
Reversion to virulent 
form[391] 
No (safer) possible 
Administered to 
immunodeficient 
individuals[395] 
yes no 
Immune responses[378] Mostly humoral Humoral and cellular 
 (similar to natural infection) 
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is a mercury-based preservative (ethylmercury) that has been used for decades in multi-
dose vials of vaccines. Despite the good safety profile thimerosal has been removed from 
the majority of vaccines due to concerns related with the possible effects of pediatric 
exposure to mercury[397]. An adjuvant is a substance that is added to a vaccine in order 
to increase the adaptive immune response to a specific antigen[398]. Some vaccines 
containing attenuated or inactivated virus are able to stimulate an efficient immune 
response without the presence of the adjuvant. Examples of adjuvants used in licensed 
vaccines are described in Table II [399-403].  
Table II- Characteristics of adjuvants used in licensed vaccines 
Adjuvant Composition Immune effects Vaccines 
Aluminum aluminium salts mixed with antigens 
Increases local 
inflammation, antigen 
update by APCs and 
antibody production 
Diphteria, tetanus, pertussis, 
inactivated poliomyelitis vaccine, 
hepatitis A and B, HPV, 
meningococcal and pneumococcal 
Virosomes 
Vesicles where antigens in aqueous 
volume are enclosed within a standard 
phospholipid cell membrane bilayer 
Increases uptake by 
APCs and interaction 
with B cells leading to 
T-cell activation. 
Hepatitis and influenza 
AS04 
3-deacyl-monophosphoryl lipid A) derived 
from lipopolysaccharide from Salmonella 
Minnesota, Aluminum salts) 
           Stimulates the TLR4 
and increases Th1 
responses 
Hepatitis B, HPV 
MF59 Squalene 
Increases APC 
recruitment and 
activation. Promotes 
antigen uptake and 
migration of cells to 
lymph nodes. 
Influenza-seasonal and pandemic 
AS03 Vitamin E (α-Tocopherol); Surfactant 
polysorbate80; Squalene 
Cytokines enhancement 
and recruitment of 
innate cells 
Influenza-pandemic 
ISA51 Mineral oil DRAKEOL 6VR     Surfactant 
mannide-mono-oleate 
Strongly immunogenic 
therapeutic vaccine to non-small 
cell lung cancer (NSCLC) 
GLA-AF 
Glucopyranosyl Lipid Adjuvant (GLA) 
and synthetic surfactant DPPC 
(dipalmitoylphosphatidylcholine) 
Stimulates TLR4 Pandemic influenza 
APC- antigen presenting cells; TLRs-Toll-like receptors; HPV- Human Papilloma virus;  
 
3.3.2 Recombinant vaccines 
 
Genetic engineering technology has been used to produce several candidate antigens for 
vaccines [386]. These recombinant vaccines are based on the capacity of one or multiple 
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defined antigens to induce immunity against the pathogen when administered with 
adjuvants or when expressed by plasmids or bacterial and viral vectors. The development 
of efficient vaccines requires the combination of several strategies including different 
delivery systems and adjuvants in order to present the antigen in a way it can elicit  an 
efficient immune response against these antigens [391].  
There are several expression systems for antigenic protein components, such as bacteria, 
yeast, mammalian and insect cells where DNA encoding the antigen determinant can be 
inserted and further expressed [404-406]. Features as the level of expression obtained 
using each specific expression vector and promoter, the selection marker of choice and 
the presence or absence of post-translational modification by the recombinant vector must 
be taken into account in the choice of the system for antigen expression. Due to easy 
handling and high level of expression, bacterial expression systems are widely used. 
Mammalian or insect cells are also used but mainly for antigens in which post-
translational modifications (e.g. glycosylation) are needed [391, 404].   
Vaccine vectors can significantly influence the magnitude and breadth of vaccine-induced 
immune responses. In addition, the type of delivery vector in combination with the route 
of vaccine administration can determine the persistence of vaccine-specific immune 
responses in systemic and mucosal compartments [407]. Apart from the immune potential 
to induce specific, strong and persistent responses, other factors as pre-existing immunity 
must be taken into account.  Pre-existing anti-vector immunity can prevent transduction 
and expression of vaccine genes leading to a reduced immunity. In addition, it can alter 
the natural course of infection leading to catastrophic consequences such as enhanced 
HIV acquisition and accelerated disease progression as was observed in an adenovirus-
based HIV vaccine trial (Step study) [408]. Thus, the development of strategies that 
maximize vaccine immunogenicity and safety is an urgent priority especially for 
HIV/AIDS vaccine (reviewed in [407, 409]). Currently, recombinant vaccine strategies 
include recombinant protein vaccines (protein subunit), live recombinant bacterial or viral 
vector vaccines, DNA vaccines or the combination of all these in prime-boost strategies.  
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3.3.2.1 Recombinant protein vaccines 
 
Recombinant protein vaccines, include highly purified recombinant proteins or subunits 
of pathogens [410, 411]. Currently, hepatitis B vaccine is an example of  recombinant 
protein vaccine and is produced by expressing the hepatitis B surface antigen in yeast 
cells which assembles into virus-like particles (VLP) being extremely 
immunogenic[412]. Advantages of the yeast expression system includes the secretion of 
the antigen into the culture supernatant facilitating its purification.  As eukaryotes, they 
are able to perform post-translational modification of proteins (e.g. glycosylation)[405]. 
Two human papilloma virus (HPV) vaccines (Gardasil® and Cervarix® ) are also based 
on recombinant VLP technology expressing L1, the major protein capsid of the HPV 
virus, in yeast and insect cells, respectively[413]. Administration of L1-based VLPs allow 
the immune system to produce antibody titers 100 fold greater than those occurring in 
natural infection. Also, passive transfer studies using L1-VPL vaccinated animal serum 
into naïve animals confers protection against infection (reviewed in [414]. 
 
3.3.2.2 Live recombinant bacterial or viral vector vaccines  
 
Live recombinant vectors are capable of delivering heterologous antigens by the 
introduction of antigen encoding genes. In addition, the capacity of infection and the 
immunological properties of the live vector can elicit an immune response against the 
heterologous proteins[407].  Live-attenuated bacterial vaccines are an attractive system 
for heterologous antigen presentation as they can elicit humoral and/or cellular responses, 
can be administered orally eliciting mucosal immunity, are antibiotic sensitive allowing 
antibiotic treatment if necessary and, finally, are of low cost. Examples of bacteria used 
as vectors include Mycobacterium bovis BCG , Listeria monocytogenes , Salmonellae spp 
and Shigellae spp[415]. Among these bacterial vectors, M. bovis BCG and S. typhi are the 
most common vectors used eliciting both humoral and cellular responses[391, 415-417]. 
Recombinant BCG expressing HIV antigens elicit specific antibodies, production of IFN-
γ, T- helper cells and CTLs (reviewed in[407]).  
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Recombinant viral vectors are available for vaccine development and include Vaccinia 
(Poxvirus), modified Vaccinia virus Ankara (MVA), NYVAC (derived from the 
Copenhagen Vaccinia strain), adenovirus (Ad), adeno-associated virus (AAV), 
canarypox (ALVAC), fowlpox (TROVAC), Cytomegalovirus (CMV) and others[391]. 
Viral vectors can be either replicative (e.g. Vaccinia and CMV) or non-
replicative/defective (e.g. Ad, MVA, NYVAC). Due to safety issues, replicative defective 
viruses are the most tested viral vectors in clinical trials and vaccine studies against HIV, 
TB and malaria [418, 419]. However, because replicative viruses are more effective in 
protection against infection as they elicit stronger humoral and cell-mediated immune 
responses, they have also been explored by some groups [387, 420-422].  
Non-replicating recombinant viral vectors (adenoviruses, MVA, NYVAC and 
ALVAC) 
 Adenovirus vaccine vectors 
Adenoviruses are non-enveloped icosahedral viruses containing a linear double strand 
DNA being able to infect  and replicate in different parts of the body, such as the 
respiratory tract and the bladder[391]. The stable non-replicative Ad serotype 5 (Ad5) is 
the most used as a delivery vector. Ad5 has the capacity to receive large segments of 
foreign DNA (8kb) in its genome and can be obtained easily and in high titers. Besides 
the induction of potent adaptive immune responses (e.g. effector memory CD8+ T cell 
responses), adenoviruses also stimulate the innate immunity via inflammatory responses 
involving TLR2, TLR9, NOD-like receptors and the type 1 interferon pathways[423, 
424]. On the other hand, Ad vectors can induce both systemic and mucosal immune 
responses[407]. Replicative competent Ad vectors are also being developed due to several 
features as its longer persistence in the host and the fact that lower doses are needed to 
induce immune responses. However, they have more limited clone capacity (3-4kb) 
compared with non-replicative Ad[421]. 
In the HIV field, Ad5 vectors expressing gag, pol, env and nef have been widely used 
showing promising results in diverse animal models. In NHPs, Ad5 expressing SIV Gag 
and Env proteins conferred protection against viral challenge with SHIV-89.6P [425]. In 
the STEP study, Ad5 was used as a booster immunization following DNA priming, 
inducing potent and strong CD8+T cell responses in vaccinated individuals[408, 426]. 
However, pre-existing antibodies against Ad5 and cellular immunity may have 
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significantly compromised the clinical efficacy of this vaccine. In fact, an increase was 
observed in the rate of HIV infection in individuals with pre-existing immunity against 
Ad5 and this trial was interrupted.  To overcome this problem, new immunization 
strategies with other adenovirus serotypes with lower pre-existing immunity (e.g. Ad26 
and Ad35) and heterologous prime-boost regimens have been developed  [427, 428].  
 Recombinant MVA and NYVAC vaccine vectors 
With the exception of Vaccinia virus, that has been used for almost two centuries 
providing cross-protection against smallpox, no other completely natural organism has 
ever been used in standard vaccination [387]. Besides their excellent safety profile, 
inherent adjuvant properties and easy manufacture, recombinant Vaccinia virus vectors 
have large genomes (~190 kb in length) making it possible to introduce large foreign 
genes and achieve their expression at high levels [429, 430]. In addition, poxvirus vectors 
can induce mucosal immune responses when administered by the mucosa route [431]. 
Unlike other DNA viruses, poxviruses have their own transcription machinery, viral 
DNA-dependent RNA polymerase and post-transcriptional modifying enzymes allowing 
a self-sufficient cytoplasmic replication in the host[432].  
MVA is a highly attenuated strain of Vaccinia virus derived from Vaccinia strain Ankara. 
Attenuation of MVA was obtained through 500 passages in embryo fibroblast cells 
resulting in six major deletions corresponding to the loss of 10% of the whole genome. 
In addition, MVA does not replicate in humans [407, 433].  The potency of MVA to 
induce immune responses is largely due to the absence of genes that are involved in 
immune evasion (i.e. those who interfere with IFN-α, IFN-β, and TNF-α) which allows 
the generation of stronger innate immunity[434]. Recombinant MVA when used as a 
boost following DNA, fowlpox or Ad5 priming,  has been shown to be highly 
immunogenic inducing strong and protective cellular and antibody responses against 
malaria antigens (reviewed in[407]). More recently, a heterologous prime-boost 
vaccination with DNA and MVA expressing HIV-1 mosaic Gag has shown to be highly 
immunogenic in mice inducing Gag CD8+ and CD4+ T cell responses[418].  
Attenuated NYVAC vector is derived from a plaque-cloned isolate of the Copenhagen 
Vaccinia strain by the deletion of 18 genes involved in host range virulence. Like MVA, 
NYVAC cannot replicate in humans due to deletions in C7L and K1L genes[407]. In 
contrast to MVA, NYVAC induces mainly CD4+T cell responses [435]. However, in a 
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recent study in chronically infected patients on ART, NYVAC-based vaccine expressing 
Gag/Pol/Nef/Env from an HIV-1 clade B isolate induced broad and polyfunctional CD4+ 
and CD8+ T cells[436]. When used in prime-boost combinations, NYVAC elicits better 
immune responses. Priming with DNA followed by NYVAC boost elicits broad and 
potent T cell responses in more than 90% of vaccinated individuals[437]. Thus, the 
potential of this vector to stimulate and boost potent immune responses should be taken 
into account when considering therapeutic HIV vaccines. In order to improve the 
immunogenicity of poxvirus vectors several strategies have been developed: heterologous 
prime-boost regimens, use of co-stimulatory molecules, deletion of viral 
immunomodulatory genes present in poxvirus genome, enhancement of virus promoter 
strength and vector replication capacity, optimization of the expression of foreign 
heterologous sequences, and the combined use of adjuvants(reviewed in[430]).  
 Canarypox (ALVAC) vaccine vectors 
ALVAC is a safe attenuated Canarypox virus obtained through the repeated passage in 
chick embryo fibroblasts replicating only in avian species[438]. In human cells, ALVAC 
replication is aborted early in the viral replication cycle prior to DNA synthesis[439]. 
Despite being less immunogenic compared with MVA and NYVAC, ALVAC has no 
potential pre-existing immunity in humans making it an attractive vaccine delivery vector. 
Currently, ALVAC is already licensed in veterinary use including feline leukemia virus 
(FeLV) and feline rabies vaccine (PUREVAX)[440].  Using ALVAC expressing SIV 
Gag/Pol/Env antigens protection against low-dose oral SIVmac251 challenge of neonate 
rhesus macaques was achieved [441]. The only HIV vaccine trial (RV144) that has 
demonstrated some degree of protection against HIV acquisition was based in a regimen 
including a priming with ALVAC-HIV(vCP1521) followed by a boost with (AIDSVAX 
B/E rgp120)[118]. Because the AIDSVAX vaccine (recombinant gp120 protein) alone 
showed no efficacy in earlier trials, the success of RV144 was in part associated with the 
immunostimulatory potential of canarypox virus vector and also to the prime-boost 
strategy. Thus, the combination of live viral vector-priming with protein-boost constitute 
a promising approach that should be optimized for increased efficacy. ALVAC is 
currently  being used in the ongoing HIV vaccine trial HVTN 702 [119].  
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Live replicative viral vectors 
Replicating vectors are able to induce persistent immune responses due to continuous 
antigen stimulation that may inhibit viral infection before the viral reservoir establishment 
and evolution of the initial infecting virus [426]. Although there are many advantages for 
using replicative-competent viral vectors in the vaccine field, there are several challenges 
concerning this issue. These includes the achievement of the adequate immunogen 
expression, engineering of genetically stable vectors, and more importantly, the 
achievement of the right balance between replicative capacity and attenuation ensuring 
both immunogenicity and safety[442]. Ad4 and Ad7, replicative competent adenoviruses 
replicating in mucosal tissues, have been successfully used for the prevention of 
respiratory and enteric illness[443]. In addition, Ad4 expressing HIV-1 clade C gp120, 
gp140 and gp120 elicited envelope-specific T cell in mice and antibody responses in 
rabbits. Moreover, serum from rabbits neutralized tier 1 clade C pseudovirus MW965.26 
and the autologous and heterologous tier 2 pseudoviruses to a lesser extent[444]. In mice, 
replicative competent-vector NYVAC-C-KC induce better cellular and humoral 
immunity compared with non-replicative NYVAC [445]. Other vectors used in HIV 
vaccine development and that have shown strong immunogenicity include rhadinovirus, 
yellow fever virus, rabies virus and Semliki Forrest virus (reviewed in[407]). Also, 
Vaccinia virus has shown good results against HIV, hepatitis B virus and influenza virus 
in several animal models[446, 447]. A recent assay in rabbits  using a prime with 
recombinant Vaccinia virus expressing full Env gp160 and subunit gp120 protein (gp120 
monomer) from HIV-1 clade B was able to induce  cross-reactive binding antibodies 
against V1/V2 fusion proteins, ADCC activity  and neutralizing responses against 
heterologous tier 2 HIV-1 pseudoviruses (mostly from clade B) although with limited 
breadth and low titers (1:20-1:100) titers [422]. Also, oral immunization with 
recombinant Vaccinia virus (priming) expressing full-length HIV-1 SF162 Env or  SIV 
Gag-Pol proteins followed by intramuscular protein boost with SF162 gp120 protein 
provided protection against intrarectal challenge with SHIV-SF162-P4 in macaques[448]. 
In addition, mice primed with Vaccinia virus expressing a truncated gp125 and  boosted 
with recombinant polypeptides comprising the C2, V3, and C3 envelope regions 
developed a strong and broad neutralizing response against HIV-2 isolates[2]. Currently, 
several clinical trials using replicating viruses expressing HIV-1 proteins are underway. 
For instance, an oral replicating adenovirus (Ad26) vector expressing HIV-1 Env 
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(NCT02366013)[427]  and a VSV vector (Vesicular stomatitis virus) expressing HIV-1 
Gag (NCT01438606)[428] have recently completed phase 1 of clinical trials.  
 
3.3.2.3 Recombinant DNA vaccine vectors 
 
DNA vaccines consist in the direct injection of a naked DNA plasmid into the host with 
the capacity to induce an immune response and protection. Usually, the plasmid contains 
one origin of replication of E.coli, a strong promoter, multiple cloning sites and a selection 
marker (e.g. antibiotic) so that the antigen can be expressed directly by the host cells 
similar to a response to a natural infection. Advantages of DNA vaccines include stability, 
safety and easy production[407]. In addition, DNA plasmid vaccines can induce both T 
and B cell immune responses. Moreover, they can be used repetitively as a boost without 
immune interferences as is the case of pre-existing immunity[449].  DNA vaccines have 
been widely used to express antigens from influenza, HIV, malaria, TB and others [437, 
450, 451]. However, they have been shown to be poorly immunogenic inducing sub-
optimal immune responses. Improvements in DNA delivery have been performed in order 
to improve DNA vaccine immunogenicity. Such improvements include intramuscular, 
skin or intradermal electroporation and gene gun and biojector devices. In addition, the 
use of cytokines adjuvants (e.g. IL-2, IL-12, IL-15) have contributed to improve the 
immunogenicity of these vaccines[449]. Importantly, delivery of DNA vaccines by 
electroporation induced long-lived immune responses (cellular and humoral) without 
further heterologous boosting [452]. Despite the improvements in recent DNA vaccines, 
it is well established that they show much better immunogenicity when used as priming 
components in conjunction with viral vectors in heterologous prime boost regimens[419, 
451-455]. 
 
3.3.2.4 Prime-boost strategies 
 
Currently, vaccination with several doses (prime-boost regimen) is known to be the most 
effective way to achieve a potent and strong immune response. Prime-boost regimens can 
be autologous, when prime and boost vaccines consist of the same formulation or 
heterologous when immunization regime involves different formulations used 
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sequentially in more than one administration[391]. Several evidences demonstrate that 
heterologous prime-boost immunization can be more effective than autologous 
immunization, especially against intracellular pathogens[456]. In this case, the strategy 
involves the administration of the same antigens but formulated in different ways (e.g. 
purified proteins, live recombinant viral or bacterial vectors or DNA vaccines). The main 
objective of this approach is to combine both humoral and cellular immunity in an attempt 
to enhance the immune response against a specific antigen. Several studies have 
consistently demonstrated the potential of heterologous prime-boost strategies. For 
instance, prime-boost regimens comprising Ad and MVA have recently been shown to 
induce both cellular and humoral responses against SIV and malaria antigens [427, 457, 
458]. Barouch et al have demonstrated protection from both acquisition and disease 
progression by the induction of systemic and mucosal immune responses when using 
Adenovirus/poxvirus and adenovirus/adenovirus-vector-based vaccines expressing 
SIV(SME543) Gag, Pol and Env antigens[457]. Moreover, another study including three 
doses of plasmid DNA followed by Ad5 delivery of immunogens comprising SIV-Gag, 
SIV-Env mosaic immunogens or SIVmac239 Env led to the induction of cellular and 
antibody responses (bNAbs and ADCC) that were associated with protection against 
intra-rectal challenge of SIVsmE660[459]. 
Distinct mechanisms can be attributed to the success of prime-boost regimens. First, the 
use of different immunization strategies reduces anti-vector immunity. Second, and most 
important, the induction of high-avidity T cell responses[460]. In fact, during priming 
immunization, T cells against the most immunodominant epitopes of the antigen are 
induced. Then, heterologous boosting, which shares the relevant antigen with the priming, 
will induce immune responses that focus on the expansion of the immunodominant T 
cells that were previously induced by the priming. This is particular true when live 
recombinant vectors such as MVA and Ad5 are used because they are especially efficient 
in boosting pre-existing memory immune responses [391].  
 
3.3.3 HIV-1 completed efficacy trials  
 
Almost four decades have passed since the discovery of HIV-1 and there is still no vaccine 
available. The development of an HIV-1 vaccine faces several obstacles: 1) the 
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extraordinary genetic diversity of the virus and the high mutational rate, 2) the early 
destruction of CD4+ T cells, 3) the early establishment of latent viral reservoirs, 4) the 
short timeframe of opportunity for the host immune system to eradicate the initial viral 
infection, 5) the unclear immune correlates of protection, 6) safety concerns regarding the 
use of attenuated viruses in humans, and finally 7) the limited exposure of neutralizing 
epitopes in the outer surface of the virus and also the difficulty in exposing these epitopes 
in vaccine candidates [461-463]. On the other hand, the fact that there has been only one 
reported case of effective eradication of the virus (i.e. the Berlin patient) makes the 
development of an HIV-1 vaccine an even greater challenge[464]. Despite the urgent need 
for a vaccine, only six HIV-1 vaccine candidates have completed efficacy trials (Table 
III).  
Table III- Completed HIV-1 vaccine efficacy trials in humans. 
ADCVI- antibody-dependent cell-mediated virus inhibition; ADCC-antibody-dependent cellular cytotoxicity 
 
The first trials VAX003 and VAX004 used Env subunit gp120 proteins derived from 
subtypes B and E adjuvanted in alum that were administered intramuscularly at months 
0,1, 6, 12, 18, 24 and 30 with a final follow-up at month 36.  Despite the induction of 
binding antibodies, no NAbs were induced and no significant protection efficacy was 
achieved [465-468]. Taking into account the crucial role of CD8+ T cells in controlling 
 
Trial 
 
Vaccine immunogens 
 
Immune responses observed 
 
Main Results / 
observations 
 
VAX003 
 
AIDSVAX B/E gp120 in alum 
Non-neutralizing responses 
No NAbs were induced 
 
No efficacy 
 
VAX004 
AIDSVAX B/B gp120 in alum 
Non-neutralizing antibody responses 
ADCVI 
No NAbs were induced 
No efficacy 
 
HVTN 502/ 
Step trial 
 
Ad5 clade B expressing gag/pol/nef 
HIV-1 specific CD4+ and CD8+ T cell 
responses 
No efficacy 
Increased infection 
risk in Ad5 
seropositive 
individuals 
 
HVTN 503 
(Phambili 
trial) 
 
Ad5 clade B expressing gag/pol/nef 
HIV-1 specific CD4+ and CD8+ T cell 
responses 
 
HIV-1 specific CD4+ 
and CD8+ T cell 
responses 
 
 
RV144 
ALVAC-HIV (recombinant canarypox 
vector)/vCP1521 expressing env/gag/pro + 
AIDSVAX B/E rgp120 boost 
non-neutralizing antibodies to variable 
loops (V1V2), high levels of ADCC 
and HIV-1 Env specific IgG3 
responses;low titers of NAbs against 
tier 1 viruses 
31.2% efficacy at 42 
months 
60% efficacy at 12 
months 
 
HVTN 505 
DNA Gag, Pol, and Nef (clade  B) and 
Env (clades A, B and C) + rAd5 subtype B 
gag/pol/env (clades A,, B and  C) 
Cellular and immune responses 
T- cell responses to HIV-1 potential T-
cell epitopes;CD4+ HIV gag responses 
No efficacy 
HVTN 702   
(phase 2b/3) 
 
 
ALVAC-HIV (vCP2438) expressing  env 
/gag/pro  + Bivalent Subtype C gp120 
 
first results expected in 2020 Not applicable 
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HIV replication a new study was designed to promote cellular immune responses. The 
Step study (HVTN 502) used an Ad5 viral vector expressing HIV-1 gag, pol and nef from 
clade B administered at day 1, week 4 and week 26. However, despite the induction of 
specific cellular responses in the first stages of the trial (HIV-1 specific CD4+ and CD8+ 
T cell responses) no efficacy and/or virological control was observed. In addition, 
increased rates of infection were observed in individuals who were Ad5 seropositive as 
described above [408, 469]. A possible explanation for this may be the fact that the 
simultaneous presence of antibodies anti-Ad5 and the virus could have led to the 
activation of T cells which in turn favored HIV replication and decreased the response 
capacity of these cells. The Phambili trial (HVTN 503) used the same strategy as the Step 
trial and the same results were obtained. The HVTN 505 trial tested a multi-clade DNA 
prime (clades A, B and C) and a recombinant Ad5 boost in order to generate both cellular 
and humoral responses but with no success. Finally, RV144 trial conducted in Thailand 
from 2003 to 2006 was the only immunization strategy that demonstrated some degree of 
protection [118, 468]. This trial was based on clade B and CRF01_AE sequences that 
matched the prevailing HIV-1 strains in Thailand and consisted of four priming injections 
of an attenuated recombinant canarypox vector vaccine (ALVAC/vCP1521) expressing 
env, gag and protease genes with combination of two booster injections of a recombinant 
glycoprotein 120 subunit vaccine (AIDSVAX B/E)[118, 468]. Immune responses 
observed in RV144 associated with a reduced risk of HIV-1 infection included non-
neutralizing antibodies to V1/V2, high levels of ADCC and HIV-1 Env specific IgG3 
responses[118, 468, 470].  Although all RV144 recipients produced binding antibodies to 
gp120 they developed low titers of neutralizing antibodies that were mainly against tier 1 
isolates which may explain the modest efficacy of this trial [131]. Based on the immune 
correlated of protection observed in RV144, there are several new HIV-1 vaccine trials 
ongoing. HVTN 702, the most recent phase 2b/3 trial, involves a new version of the 
immunogens and strategy used in RV144 but with some modifications [471]. Vaccine 
regimen consists of two immunizations of ALVAC-HIV (vCP2438) plus three 
immunizations with Bivalent Subtype C gp120. This trial started at November 2016 and 
will evaluate the preventive vaccine efficacy, safety and tolerability in 5400 HIV-
seronegative South African adults with the first results expected in 2020 [472].    
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3.3.4 Vaccination strategies to induce bNAbs 
 
Because broadly neutralizing antibodies are considered the best correlate of antibody 
protection against HIV infection, the development of immunogens that induce bNAbs is 
currently the main priority for the HIV-1 vaccine field   [131, 319, 320, 422, 473-475]. 
So far, generation of immunogens that can elicit bNAbs is one of the unachieved goals in 
HIV-1 vaccine development and until now no vaccine candidate has been able to induce 
consistent  bNAbs against heterologous tier 2 virus from different clades [422, 453, 476-
479]. There are several strategies to elicit or deliver bNAbs by immunization which 
include immunogen design in order to mimic bNAb epitopes, immunogens that bind 
germline precursors of bNAbs (B-cell lineage vaccines), replicating viral vectors 
expressing Env antigens, DNA-based vaccinations, gene transfer of bNAbs (vectored 
immunoprophylaxis) and passive administration of bNAbs [375, 407, 480, 481].  
Immunogen design to mimic Env epitopes include gp120 monomer-lineages, non-native 
gp140 proteins, gp120 core proteins, gp120 OD (outer domain) define proteins, epitope-
specific scaffolds, epitope-based peptides and native-like Env trimers [482]. gp120 
monomers are thought to induce limited bNAb responses against HIV-1compared with 
trimers due to specific features like the exposure of non-neutralizing epitopes and the lack 
of NAb epitopes that are only present in the quaternary structure or in the presence of 
gp41[483, 484].This hypothesis is based on the idea that although the presence of a bNAb 
epitope on an Env immunogen does not necessary means that bNAbs will be raised 
against it, the absence of an epitope or its presence in a conformational innapropriate form 
will probably reduce the chances of an efficient bNAb induction[484]. However, several 
evidences have demonstrated that HIV-1 envelope trimers and monomers induce 
comparable immune responses with oligomers showing only marginal improvements 
over monomers [342, 485, 486].  Env-based immunogens, including gp120 monomers 
and gp140 trimers or oligomers, have been widely used in animal models (and in RV144 
human trial) inducing similar levels of neutralizing responses [152, 422, 487-490].  
A successful HIV-1 vaccine should take into account the native trimer, the interaction of 
bNAbs with the trimer and the evolution of bNAbs and the Env trimer in natural 
infection[372]. For that propose, a new generation native-like Env trimeric proteins such 
as the soluble cleaved BG505 SOSIP.664 gp140 have been developed. This trimer is 
relatively stable, similar to the native virus spikes and expresses multiple epitopes for 
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bNAbs. However, despite the attempts to improve their stability, significant challenges 
remain. Although trimers can be relatively stable in solution they adopt different 
conformational states including those who are less relevant to induce bNAbs. Moreover, 
trimers expose irrelevant immunodominant regions that may distract the immune 
response from the conserved neutralization epitopes [491]. The majority of studies using 
HIV-1 trimers alone have failed in inducing consistent broad and potent neutralizing 
responses against heterologous tier 2 HIV-1 viruses. [478-480, 492]. An exception came 
very recently when four cows immunized with a single trimer immunogen (BG505 
SOSIP) developed an extraordinary broad and potent serum antibody response against 
117 cross-clade isolates [1]. However, with the exception of this study, Env monomers 
and trimers have been shown to be much more effective at inducing broad and potent 
neutralizing responses when administered in combination with other immunogens in 
prime-boost strategies. The majority of HIV vaccine regimens aiming to induce bNAbs 
consists in prime-boost regimens that use combinations of different immunogens, namely, 
recombinant virus expressing HIV envelope [2, 422, 493], and/or  plasmid DNA 
constructs[454], and/or  various HIV purified proteins (e.g. gp120 monomers and trimers)  
[342, 422, 453, 478, 479, 494]. As mentioned before, recent studies have shown that is 
possible to induce NAbs against tier 2 viruses although sporadically, with limited breadth 
and at low levels [422, 453, 476-479]. Table III includes a compilation of some of the 
prime-boost HIV vaccine-regimens performed in small animal models aiming to induce 
NAbs.  
In conclusion, despite the role of antibodies in HIV protection is not completely clear it 
is widely accepted that anti-Env antibodies should be a critical element in a preventive 
vaccine for HIV-1. Therefore, it is expected that the achievements provided by all of the 
previous and ongoing vaccine regimens aimed to induce tier 2 neutralizing responses, 
either in humans or non-human animal models, will lead to an optimization and 
improvement of the ongoing strategies providing crucial insights for the future 
development of a neutralizing antibody vaccine. 
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Table III- Compilation of several prime-boost HIV vaccine-regimens performed in small animal models 
aiming to induce NAbs. 
 
ADCC- Antibody-dependent cell-mediated cytotoxicity; NAb- Neutralizing antibody; rVV- Recombinant Vaccinia virus 
 
 
 
 
 
Authors Immunogens Immunization schedule Main Results 
Quinnan et 
al., 
2006[495] 
 
gp140R2 (soluble, 
oligomeric form of HIV-
1 Env) 
gp120R2 (surface 
component of HIV-1 
Env) 
4 immunizations of 30µg of each 
protein per group 
Days 1, 21, 42, 196 
gp140R2 immunogen induced 
antibodies that achieved 50% 
neutralization of 48/48 and 80% 
neutralization of 43/46 primary strains 
of diverse subtypes;gp120R2 induced 
antibodies that neutralized 9/48 of the 
same strains 
Klasse et 
al., 
2016[479] 
 
 
SOSIP.664 trimers based 
( clade A,B, C and D) 
Various trimers delivered simultaneous 
(clade A+B) at days 1, 28, 140, 168 or 
sequentially at days 252, 336, 420, 511 
30 µg/dose for all groups except one 
that received 90 µg/dose 
-Autologous, tier-2 NAbs 
-Heterologous tier-2 NAb responses 
albeit inconsistently and with limited 
overall breadth. 
Moore et 
al., 
2015[478] 
 
BG505 SOSIP.664 gp140 
BG505 gp120 
YU2gp140-Fd 
B41SOSIP.664gp140 
B41SOSIP.664-
D7324gp140 
 
Days 1, 30, 140, 280; 30 µg/dose 
Days 1, 30, 168; 40 µg/dose 
Days 1, 30, 140; 30 µg/dose 
-BG505SOSIP.664 induced NAbs 
potently against the sequence-matched 
tier-2 virus 
-Tier 1 cross-reactive NAbs 
-B41SOSIP.664 induced a strong 
autologous tier-2 NAb response 
Sanders et 
al., 
2015[476] 
AMC008 SOSIP.664 
trimers 
22 µg of trimers at days 1, 30 and 140; 
NAb response assessment at week 22. 
-Autologous Tier-1B or Tier-2 NAbs  
Low levels of V3-directed Tier-1A 
NAbs. 
 
Kong et al., 
2016[453] 
Prime/boost 
immunization strategy 
gp120 DNA and various 
V1V2-scaffold proteins. 
 
DNA prime at days 1, 15 (or 56), 30 
and 2 protein boosts at days 70 and 98 
(or 126) 
 
-Cross clade anti-V1V2 antibodies 
remain detectable ≥1 year after  the 
last immunization dose 
 
Shiu-Lok 
Hu et al., 
2016[422] 
Poxvirus prime-gp120 
boost strategy 
recombinant Vaccinia 
virus expressing full Env 
gp160 and subunit gp120 
protein 
Priming at days 1 and 56 with 108 PFU 
of rVV and boosting at days 245 and 
336 with the cognate gp120 
-Induction of cross-reactive NAbs  
>50% of tier 2 global HIV-1 isolates     
V1/V2 directed antibodies -ADCC. 
 
Whalen et 
al., 
2013[454] 
DNA-prime protein-boost 
regimen with the gp120 
subunit of HIV-1 JR-CSF 
envelope (Env) 
Priming with 400 µg plasmid DNA 
construct JR-CSFgp120 DNA and 
boosting with JR-CSFgp120 purified 
protein; 
 
Strong autologous neutralization of the 
primary isolate JR-CSF 
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Aims and work plan 
 
Preventing altogether new HIV-1 infections will require the development of an effective 
vaccine. To this end, new immunogens that elicit the production of broadly neutralizing 
antibodies are needed. To date, prime- boost approach used in RV144 trial is still the only 
immunization strategy that has demonstrated some level of protection against HIV-1 
[118, 468]. However, with the exception of the recent results in cows, no vaccine 
candidate has been able to induce potent bNAbs against heterologous tier 2 virus from 
different clades [1, 478, 479]. 
 
Recently, work done in our lab has demonstrated that mice primed with Vaccinia virus 
expressing a truncated gp125 and  boosted with recombinant polypeptides comprising the 
C2, V3, and C3 envelope regions developed a strong and broad neutralizing response 
against HIV-2 isolates[2]. The main aim of this thesis was to determine if a similar 
vaccine strategy would elicit the production of bNAbs against HIV-1 leading to a new 
type of HIV-1 vaccine. 
Several approaches have been adopted to produce the best HIV-1 envelope vaccine 
candidate including the production of consensus envelopes and chimeric envelopes [118, 
418, 422, 448, 496-501]. For our vaccine immunogens it was decided to use envelope 
glycoproteins from isolates of all clades representative of an “old” and stable epidemic 
such as the one ongoing in Angola. Our hypothesis was that ancestral R5 viruses would 
be better at eliciting bNAbs against highly heterologous viruses as they correspond to an 
ancestor of all circulating HIV strains thus encompassing key epitopes and 
conformational determinants that are conserved within the contemporaneous strains. In 
addition, the use of R5 isolates is adequate for vaccination because almost all transmitted 
isolates use CCR5 and a successful vaccine should elicit antibodies that neutralize the 
isolates that are most likely transmitted.   
Specific objectives of this thesis were: 1) characterize HIV-1 samples derived from HIV-
1 isolates from Angola (1993) as well as their env genes as a paradigm of the ancestral 
viruses we intended to use in our vaccine; 2) express envelope genes from Angolan and 
Portuguese isolates in Vaccinia virus 3) produce cognate gp120 and recombinant 
polypeptides encompassing the V3 region and flanking C2 and C3 sequences 4) 
immunize BALB/c mice and rabbits with these envelope constructs using different prime-
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boost regimens; 5) characterize the binding and neutralizing antibody responses in these 
animals; 6) characterize the Tfh and Tfr cell responses in immunized mice. 
Angola had a crucial role in the early dissemination of the HIV-1 epidemic; still, at the 
time there was no genomic data from HIV-1 infected patients from Angola. Currently, 
there are only three full-length genomes of subtype J and four of subtype H available in 
the Los Alamos sequence database. We therefore decided to sequence the full-length 
genomes from three Angolan patients (obtained in 1993) in order to better understand the 
origin of HIV-1 subtypes and recombinant forms (chapter 2). Maximum likelihood 
phylogenetic tree inference and analyses of potential recombination patterns were 
performed to evaluate the sequence classifications and origins.  
 
In chapter 3, a total of seven HIV-1 strains obtained from HIV-1 infected individuals from 
Portugal and Angola were included in the study in order to account for the extensive 
genetic diversity of HIV-1. For all samples, the full-length envelope genes were 
amplified, sequenced and subtyped by phylogenetic analysis.  Co-receptor usage of HIV-
1 isolates was determined in vitro in TZM-bl cells (CD4+, CCR5+, and CXCR4+) and with 
the geno-2-pheno software. To produce the truncated gp120 (gp120t), a stop codon was 
inserted at the end of the reverse primer resulting in the amplification of the gp120 region 
lacking 78 bases at the carboxyl terminus of the C5 region. The use of a truncated protein 
instead of a full protein has been previously associated with better immunogenicity and 
more broad and potent neutralizing responses against HIV-2 [2].  
Recombinant Vaccinia viruses expressing the truncated surface gp120 glycoprotein from 
R5 isolates of HIV-1 subtypes B, C, CRF02_AG and J were successfully produced and 
selected to be used as vaccine immunogens. The antigenicity of truncated gp120 proteins 
was analyzed by Western Blot and Enzyme-Linked Immunosorbent Assay (ELISA) 
assays using sera from HIV-1 infected individuals and HuMAbs directed against gp120. 
We additionally produced, purified and characterized recombinant polypeptides 
comprising the C2, V3 and C3 envelope regions of all HIV-1 subtypes. Antigenic 
reactivity of the purified polypeptides was analyzed by Western blot with plasma from 
HIV-1 infected patients from Angola and quantified in an ELISA assay.  
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The combined immunogenicity of the new recombinant Vaccinia viruses and envelope 
proteins was determined in BALB/c mice (chapter 3) and New Zealand white rabbits 
(chapter 4).  
First, a pilot study was performed in BALB/c mice using the immunization strategy that 
was proven effective in HIV-2 vaccination [2]. In this study, animals were immunized 
with immunogens derived from HIV-1 clades C, CRF02_AG and J. In order to check for 
potent cross-reactive binding antibodies against autologous and heterologous gp120, 
serum antibody responses from all timepoints were analyzed using an ELISA assay. 
Moreover, in order to detect neutralizing antibodies in mice, we performed neutralization 
assays against a panel of 16 HIV-1 viruses including 11 tier 2 HIV-1 [502], 3 HIV-1 
primary isolates (2 subtypes J and 1 CRF02_AG in Env) and 2 tier 1 HIV-1. Neutralizing 
activity of mice serum was tested using a single-round viral infectivity assay using a 
luciferase reporter gene assay in TZM-bl cells.  
In order to test new immunization strategies and immunogens, a second study was 
performed in BALB/c mice in a different facility.  In this study we tested three different 
prime-boost strategies with immunogens derived from HIV-1 clades B, C and 
CRF02_AG. Binding and neutralizing responses were assessed as described previously.  
 Finally, a third vaccination assay (chapter 4) was performed in New Zealand White 
rabbits. The aim of this work was to investigate if the new prototype vaccine also induced 
heterologous neutralizing antibodies in a larger animal that is commonly used in HIV 
vaccine development studies [479, 494, 503]. Binding antibody responses against 
autologous and heterologous gp120 and gp140 proteins were determined in an ELISA 
assay using rabbit sera from different timepoints. Neutralization activity (Ab titer) was 
determined against a panel of 18 HIV-1 viruses, including tier 1 and tier 2 viruses.  
Tfh cells, a recently characterized subset of helper T cells, have been described to be 
essential for antibody class switch and affinity maturation, an important process during 
the production of NAbs [218, 235-238].  Furthermore, Tfr cells, seem to moderate the 
role of Tfh cells in driving antibody production by B cells [258-260].  In order to 
investigate and better understand the role of Tfh and Tfr cells involved in NAbs induction 
we took advantage of spleens from a subset of immunized mice and analyzed the levels 
of Tfh (CD4+ CXCR5+ PD-1+) and Tfrs (CD4+ FOXP3+ CXCR5hi PD-1hi CD25low T-cell 
population) cells by flow cytometry.  Moreover, correlations between Tfh and Tfr 
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numbers and binding and neutralizing response were studied in order to evaluate if this 
vaccine strategy was able to target the right cellular subsets behind the induction of an 
effective NAb response.  
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Abstract 
Angola has an extremely diverse HIV-1 epidemic fueled in part by the frequent 
interchange of people with the Democratic Republic of Congo (RDC) and Republic of 
Congo (RC). Characterization of HIV-1 strains circulating in Angola should help to better 
understand the origin of HIV-1 subtypes and recombinant forms and their transmission 
dynamics. In this study we characterize the first near full-length HIV-1 genomic 
sequences from HIV-1 infected individuals from Angola. 
Samples were obtained in 1993 from three HIV-1 infected patients living in Cabinda, 
Angola. Near full-length genomic sequences were obtained from virus isolates. 
Maximum likelihood phylogenetic tree inference and analyses of potential recombination 
patterns were performed to evaluate the sequence classifications and origins. 
Phylogenetic and recombination analyses revealed that one virus was a pure subtype J, 
another mostly subtype J with a small uncertain region, and the final virus was classified 
as an H/U/CRF02_AG recombinant. Consistent with their epidemiological data, the 
subtype J sequences were more closely related to each other than to other J sequences 
previously published. Based on the env gene, taxa from Angola occur throughout the 
global subtype J phylogeny.  
HIV-1 subtypes J and H are present in Angola at low levels since at least 1993. Low 
transmission efficiency and/or high recombination potential may explain their limited 
epidemic success in Angola and worldwide. The high diversity of rare subtypes in Angola 
suggests that Angola was part of the early establishment of the HIV-1 pandemic. 
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According to the World Health organization (WHO) there are currently about 35 million 
people living with HIV/AIDS worldwide and it is estimated that approximately 39 million 
people have died of AIDS since 1981 [504]. HIV can be divided into two types: HIV-1, 
which is responsible for the worldwide AIDS pandemic, and HIV-2, which is less 
prevalent and virulent [55]. Based on extreme genetic diversity, HIV-1 variants can be 
classified into four major groups: M (main), O (outlier), N (non-M, non-O), and more 
recently P [505]. The M group, which is responsible for the pandemic, includes nine 
different subtypes (A-D, F-H, J and K), more than 70 circulating recombinant forms 
(CRFs), and many unique recombinant forms (URFs) [506]. Groups O, N and P have 
infected a relatively small number of patients worldwide [35].  
 
In sub-Saharan Africa almost all subtypes, CRFs, and URFs circulate; the highest genetic 
diversity has been observed in West Central Africa where the HIV-1 pandemic is believed 
to have originated [35, 49, 507]. On a global perspective, the most prevalent HIV-1 
subtypes are C (50%), A (12%), B (11%), followed by CRF02_AG (8%), G (5%), 
CRF01_AE (5%) and D (2%). The remaining subtypes and recombinant strains represent 
less than 1% of HIV-1 infections [35, 507, 508]. Currently there are only three full-length 
genomes of subtype J and four of subtype H available in the Los Alamos HIV sequence 
database [506]. Full-length subtype J genomes are from Sweden and Cameroon 
(GenBank accession numbers AF082394, AF082395, GU237072) whereas subtype H 
genomes are from Belgium, United Kingdom and Central African Republic (AF190127, 
AF190128, FJ711703, AF005496). In addition, subtype J appears as fragments in several 
CRFs and shorter sequences [506]. 
 
Angola is a South-western African country surrounded by Namibia, Zambia, Democratic 
Republic of Congo (DRC), and Republic of Congo (RC). According to the UNAIDS 
report, HIV/AIDS prevalence among adults in Angola was 2.4% in 2014 [509]. Despite 
this low prevalence, all subtypes except B and many CRFs and URFs have been detected 
in Angola, in particular in the Provinces of Luanda and Cabinda where most studies have 
been done. This high diversity is a direct consequence of the long-standing presence of 
HIV-1 in the country and the frequent interchange of people with the DRC and RC [67, 
68, 510-512]. In this study we describe the first near full-length HIV-1 genomic sequences 
from HIV-1 infected individuals from Cabinda, a province of Angola which is an exclave 
surrounded by DRC in the south and east, and by the RC in the north. 
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Blood samples from HIV-1 infected individuals were collected in 1993 from Hospital 
Distrital de Cabinda, Cabinda, Angola. Samples were collected anonymously. The study 
was approved by the ethics committees of the participating institutions. Virus isolates 
were obtained using the co-cultivation method as described previously [513]. All three 
isolates used the CCR5 co-receptor [514]. Viral genomic RNA was extracted from cell 
culture supernatant and RT-PCR was performed using Titan One Tube RT-PCR System 
(Roche Diagnostic Systems). All amplifications were performed using the Expand Long 
Template PCR system (Roche Diagnostic Systems) according to the manufacturer’s 
instructions. New primers were designed to amplify the full-length genomes 
(Supplementary material, Table 1). Amplified DNA fragments were purified using 
JETQUICK Gel Extraction Spin Kit (Genomed) and sequenced. The nucleotide sequence 
data was deposited in GenBank with accession numbers KU310618-20. Genomic 
sequences were aligned with a set of reference sequences representative of all HIV-1 
group M subtypes obtained from the Los Alamos HIV Sequence Database[515]using 
Clustal X 2.1 (http://www.clustal.org/clustal2/) and the alignment was manually edited 
with GeneDoc (http://iubio.bio.indiana.edu/soft/molbio/ ibmpc/genedoc-readme.html). 
Maximum likelihood (ML) trees were inferred with program PhyML using the Seaview 
software (http://pbil.univ-lyon1.fr/software/seaview.html) using the best-fit substitution 
model identified by Modeltest v3.7 using the Akaike information criterion. To find the 
ML tree an iterative heuristic method combining nearest neighbor interchange and subtree 
pruning and regrafting tree rearrangement methods was used. The reliability of the 
obtained tree was estimated with the approximate likelihood-ratio test (aLRT). Potential 
recombination patterns of our new near full-length sequences were analyzed by 
bootscanning using SimPlot with a sliding window of 500 bp advanced in 100 bp 
increments (http://sray.med.som.jhmi.edu/SCRoftware/simplot/). For each window 100 
bootstrap replicates were generated. Potential recombination breakpoints between 
subtypes were considered when the percentage of permuted trees for a given subtype was 
above 70%. We also used RIP, jpHMM and the branching index (BI) to confirm the 
bootscanning results [516-519].  
An overall genome-wide tree analysis of 93AOHDC250 and 93AOHDC253 showed that 
they clustered with subtype J reference sequences and were more closely related to each 
other than to the other J isolates, which is consistent with their epidemiological data 
(Figure 1).  Note that this tree is not a true phylogeny as it cannot depict the evolutionary 
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history of all recombinant sequences; we used it here merely to investigate the overall 
sequence-based similarity for our classification purpose. 
Bootscanning analysis showed no evidence of recombination in isolate 93AOHDC253 
(Figure 2A). Isolate 93AOHDC250 displayed an untypable region between positions 
1450 and 2050 corresponding to the end of gag gene, the protease (PR) region, and the 
first 192 nucleotides of reverse transcriptase (RT), which was further confirmed by 
phylogenetic analysis (Figure 2B). BI results confirmed that 93AOHDC253 was a pure 
subtype J and that 93AOHDC250 had a genomic region with no known subtype in this 
gag/pol region (Figure 5).  
 
Comparing our new J sequences to existing J sequences in the Los Alamos HIV database 
revealed that subtype J is quite diverse (Figure 3). In the region where most J sequence 
fragments exist (HXB2 positions 7041-7358), 93AOHDC250 and 93AOHDC253 cluster 
together with a previous sequence from Angola, 93AOHDC247 [67]. Interestingly, 
Angolan J sequences occur throughout the phylogeny of this env region, suggesting that 
the J epidemic in Angola is either the origin of subtype J or that there has been a lot of 
influx of subtype J from other geographic regions. The great diversity of subtype J has 
been previously noted in analyses of J-containing CRF11 and CRF13 genomes [520, 
521]. 
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Figure 1 – Overall tree classification of HIV-1 near full-length genomes of isolates 93AOHDC250, 
93AOHDC251 and 93AOHDC253. ML trees were constructed with our sequences (highlighted by 
colored dots) and 136 reference sequences representative of all HIV-1 group M subtypes. Cladistics support 
is indicated by aLRT values. The scale is in units of substitutions per site. 
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The overall tree analysis showed that 93AOHDC251 clustered with subtype H reference 
sequences (Figure 1). Bootscanning analysis indicated an unclassifiable (U) region 
between positions 4936 and 5167 (corresponding to vpr gene), and a region between 
positions 8151 and 8888 (corresponding to the nef gene and 3´LTR) appeared to cluster 
between subtypes A1 and G (Figure 2C). BI analyses again confirmed these results, and 
suggested that the nef/LTR region was below the subtype-defining threshold for subtype 
G (Figure 5). Upon closer inspection using RIP, comparing this region to subtypes A1, G 
and CRF02, it became clear that this region was in fact derived from CRF02; 
93AOHDC251 was closer to CRF02 than either A1 or G in all parts of this region, which 
included a CRF02 A/G breakpoint (Figure 4). Together, these analyses led to a 
classification of this genome sequence as the first H/U/CRF02_AG recombinant.  
 
In this report we describe the first three HIV-1 genomic sequences from Angola, a country 
that with the DRC and RC had a crucial role in the early dissemination of the HIV-1 
epidemic [49, 67]. Sequences were derived from isolates obtained in 1993 from patients 
living in Cabinda, a province in the North that borders both DRC and RC.  
 
One isolate was a pure subtype J, another a J with an at this point unclear segment, and 
one was an H-based recombinant. The unclear region in 93AOHDC250 may be a 
divergent J segment or a segment of an as yet undiscovered subtype. As mentioned above, 
subtype J has previously been described as very diverse and may hide further sub-
subtypes or recombinants of sub-subtype nature [520].  
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Figure 2 – Genomic segment analysis of near full-length genomes. Panels show bootscanning and tree 
analyses of isolates 93AOHDC253 (A), 93AOHDC250 (B) and 93AOHDC251 (C). Tree analysis was done 
for regions suggested by bootscanning to belong to different subtypes. A schematic genome map of the 
subtype composition of the isolates was produced based on the results obtained by bootscanning.  
Chapter 2 - Full-length genomes of HIV-1 from Angola 
72 
 
 
Figure 3 – Subtype J env fragment comparison. At the time this report was written 185 subtype J 
sequence fragments were available in the LANL HIV database. Their HXB2 coordinates covered various 
parts of the HIV-1 genome (A). Previous to our new sequences, only 3 full subtype J genomes have been 
described (long horizontal lines at bottom of graph). The most sequenced region was a part of env (HXB2 
coordinates 7041 to 7358), indicated by the vertical lines in the graph. A ML phylogeny of this region 
revealed that subtype J is very diverse (B). Our new sequences are highlighted by black dots.  
 
Despite being in circulation in Cabinda since 1993, as of February 2015 only 27 J and 73 
H sequences from Angola had been deposited in the Los Alamos HIV Sequence Database 
(3.1 and 8.3% of respective subtype sequences from Angola). Globally, pure subtypes J 
and H are also very rare which suggests low biological fitness, low transmissibility, high 
recombination potential, and unsuccessful introductions into high-risk populations. 
However, the isolates described herein replicate to normal levels in different cell types 
suggesting that their biological fitness is no different from other subtypes [514]. 
Interestingly, we have found that our J and H isolates are much more sensitive (about nine 
times) to the CCR5-antagonist TAK-779 when compared with isolates from other 
subtypes that are more prevalent in Angola and Portugal [514]. This suggests poor 
binding to the main HIV co-receptor (CCR5) which may indicate transmissibility 
problems of these subtypes. On the other hand, J and H subtypes have been found in many 
recombinants such as CRF04_cpx, CRF06_cpx, CRF11_cpx, CRF13_cpx, CRF18_cpx, 
CRF27_cpx, and CRF49_cpx[515]. 
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Thus, the rarity of pure subtype J and H, together with the large HIV-1 diversity in Angola 
and neighboring countries, which suggests they have been around for long times, suggests 
that these subtypes are less fit to transmit or establish infection by themselves. Similar to 
how latent virus may survive within a host through recombination with non-latent 
immune escaping plasma virus, subtype J and H virus may do better if they recombine 
with more fit subtypes [522]. 
HIV-1 subtypes J and H are present in Angola at low levels since at least 1993. The high 
diversity among Angolan subtype J env sequences and the fact that the rare subtype H has 
recombined in Angola together suggest that Angola is either the origin of subtype J or, 
more complicated, that there has been a lot of influx of subtype J from other geographic 
regions. Low transmission efficiency and/or high recombination potential may explain 
their limited epidemic success in Angola and worldwide.  
 
 
 
Figure 4 – RIP analysis of segment III of 93AOHDC251. A sliding window analysis (window size 200 
nt, step 1 nt; significance threshold 0.90) comparing 93AOHDC251 to consensus subtype sequences A1 
and G, and CRF02 prototype sequence IBNG showed that this region was closer to CRF02 in both the A1 
and G parts. The CRF02 A1/G breakpoint is indicated by a bashed vertical line. The top bar indicates 
statistical significance, and the lower bar best match.  
 
 
Chapter 2 - Full-length genomes of HIV-1 from Angola 
74 
 
 
  
  
 
Figure 5 - Branching index (BI) analysis of 93AOHDC253 and 93AOHDC250.   
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Supplementary Material 
 
Table S1- Primers used for polymerase chain reaction amplification of HIV-1 near full-length 
genomes 
Name HXB2 Position Region Sequence (5´-3´) 
JA153  683-707   p17   CTCTCGACGCAGGACTCGGCTTGCT 
P17-894F 894-913  p17  ATGGGCAAGCAGGGAGCTGG 
P17-913R 913-894  p17  CCAGCTCCCTGCTTGCCCAT 
P24-1300F 1300-1324  p24  ATACCCATGTTT(A/T)CAGCATTATCAG 
JA155 (R) 1324-1300  p24  CTGATAATGCTGAAAACATGGGTAT 
P24-1818F 1818-1838  p24  AGAAGAAATGATGACAGCATG 
P24-1838R 1838-1818  p24  CATGCTGTCATCATTTCTTCT 
IBPR1.1 2008-2030  gag NC  AAAAGGGCTGTTGGAAATGTGG 
IBPR2.2 2733-2712  RT  GCAAATACTGGAGT(A/G)TT(G/A)TATG 
IBPR3.1 2119-2140  gag P1-P6  AGGCCAGGGAATTT(T/C)C(T/C)TCAGA 
IB2621PR4 2591-2621  PR  AATGCTTTTATTTT(C/T)TCTTCTGTCAATGGC 
IBRT1 2487-2505  RT  CCTACACCTGTCAACATAA 
IBRT2 3649-3630  RT  TGTTTTACATCATTAGTGTG 
IBRT3 2542-2560  RT  TAAATTTTCCAATTAGTCC 
IBRT4 3579-3560  RT  TAAATTTGATATGTCCATTG 
RT3482FI 3482-3509  RT  AGAACCAGTACATGGRGTATATTATGA 
IB3626RT2 3626-3593  RT  TCCGTTAA(C/T)TGT(C/T)TTACATCATTAGTGTG(A/G)GCA 
RT3864F 3864-3881  RT  CAACAAATCA(A/G)AAGACTG 
P15-3881R 3881-3864  p15  CAGTCTT(T/C)TGATTTGTTG 
P15-4176F 4176-4194  p15  GGAGGAAATGAACAAGTAG 
P15-4194R 4194-4176  p15  CTACTTGTTCATTTCCTCC 
P31-4658F 4658-4675  p31  CAATCCCCAAAGTCAAGG 
P31-4675R 4675-4658  p31  CCTTGACTTTGGGGATTG 
Vif5041F 5041-5059  vif  ATGGAAAACAGATGGCAGG 
Vif5059R 5059-5041  vif  CCTGCCATCTGTTTTCCAT 
Vif5461F 5461-5476  vif  AAGGTAGGATC(T/C)(T/C)TAC 
Vif5476R 5476-5461  vif  GTA(A/G)(A/G)GATCCTACCTT 
PBENV1 5968-5986  rev  CTATGGCAGGAAGAAGCGG 
Rev5986R 5986-5968  rev  CCGCTTCTTCCTGCCATAG 
Env6223RI 6223-6203  rev  CCACTGTCTTCTGCTCTTTC 
PBENV2 6203-6223  rev  GAAAGAGCAGAAGAYAGTGGC 
Env8637FI 8637-8657  gp41  CAGGAACTAAAGAATAGTGC 
PBENV4 8797a8817  nef  TTTTGACCACTTGCCHCCCAT 
PBENV3 9036-9016  nef  AGTCATTGGTCTTARAGGTAC 
Nef9532RI 9532-9511   3´LTR   GCGAAAAGCRGCTGCTTATAT 
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Abstract 
 
Development of immunogens inducing broadly neutralizing antibodies is currently the 
main priority for the HIV-1 vaccine field. Recently, we have demonstrated that bNAbs 
against HIV-2 can be elicited in mice using a Vaccinia vector-prime C2V3C3-boost 
vaccination strategy. Here we tested if a similar vaccination strategy could be effective 
for HIV-1. We produced a set of immunogens consisting of Vaccinia virus vectors 
expressing a truncated form of gp120 derived from four primary isolates belonging to 
subtypes B, C, CRF02_AG and J from Portugal and Angola, and the cognate truncated 
monomeric gp120 glycoproteins and C2V3C3 recombinant polypeptides. BALB/c mice 
were immunized with different combinations of these immunogens. Mice developed 
potent cross-reactive binding antibodies against autologous and heterologous gp120 
antigens. Unlike previous vaccination studies in HIV-2, the C2V3C3 polypeptides were 
found to be poor vaccine antigens. Remarkably, a cross-reactive neutralizing response 
(>50%) was observed against three primary isolates and six heterologous tier 2 HIV-1 
pseudoviruses from different clades in mice immunized with CRF02_AG based 
immunogens. In addition, gp120AG immunogen bound strongly to mAb 447-42D (anti-
GPGR) both in ELISA and Western Blot suggesting that V3 could be an important target 
of bNAbs induced by our best vaccine regimen. Follicular helper T (Tfh) cells provide 
crucial help to germinal center B cells for proper antibody production, and a specialized 
subset of regulatory T cells, follicular regulatory T (Tfr) cells (CD4+PD-1+CXCR5+ 
CD25+ Foxp3+) modulate this process. There was a positive correlation between Tfh cell 
number and binding antibody activity against all gp120 immunogens [(r(gp120C)=0.764; 
r(gp120AG)=0.770; r(gp120J)=0.768, p=0.0001)] and a negative correlation (r=-0.6606, 
p= 0.0438) between the frequency of Tfr cells and neutralization potency. Hence our 
vaccination strategy is able to drive follicular T cells to provide adequate help for 
germinal center B cells to produce broadly neutralizing antibodies. Ongoing studies will 
determine whether this strategy leads to similar results in rabbits. 
 
Keywords: HIV-1 infection, neutralizing antibodies, BALB/c mice, HIV vaccines, B 
cells 
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Introduction  
 
Since the discovery of HIV-1, more than 70 million people have been infected and about 
35 million have died with HIV-1 related disease. At the end of 2015, there were 
approximately 36.7 million people living with HIV[523]. Effective antiretroviral drugs 
can control the virus, prevent disease progression and prevent HIV-1 transmission [524]. 
However, in 2015 <50% of HIV infected adults and children were accessing treatment 
and 2.1 million people became newly infected with HIV[117]. Developing a safe, 
effective and affordable vaccine to prevent HIV infection is the best hope for controlling 
or ending the HIV epidemic. 
The search for a preventive vaccine faces enormous challenges, namely i) the absence of 
well-defined  immune correlates of protection against HIV in humans, ii) the lack of 
adequate animal models that can be used to predict human responses to vaccines , iii) the 
failure in the induction of bNAbs by different antigens, and most importantly, iv) the 
extraordinary sequence diversity of HIV-1 and its capacity to constantly mutate, evolve 
and escape from the host immune response[52, 373, 471, 473, 478, 525, 526].  There are 
at least nine HIV-1 genetic subtypes as well as multiple recombinant forms worldwide. 
On a global perspective five HIV-1 strains dominate the global epidemic: C (50%), A 
(12%), B (11%) followed by CRF02_AG (8%), G (5%) and CRF01_AE (5%). Other 
subtypes, like J and H, represent less than 1% of infections [35, 66, 507, 508, 527]. Most 
vaccine research is based on subtype B. However, there is no guarantee that a subtype B 
vaccine could protect against other HIV-1 subtypes that are  much more prevalent, as 
subtype C which is dominant in India and Southern African countries [35, 528]. An ideal 
vaccine immunogen should be able to contend with the remarkably high diversity of HIV-
1 and induce an immune response able to cross-react with contemporaneous heterologous 
viruses. Although correlates of protection from HIV-1 infection are not completely 
defined, there are several studies that support the crucial role of neutralizing antibodies  
in preventing HIV-1 infection [320, 324, 373, 473, 475, 529-532]. In some individuals, 
broad neutralizing antibodies emerge after  few years of infection and these antibodies 
are able to block a diverse range of viruses including tier 2 viruses, that dominate human 
transmissions, or even tier 3 viruses with a higher resistance profile [473, 474]. Thus, a 
major goal of HIV-1 vaccine development is to identify immunogens that are capable to 
induce these broadly neutralizing antibodies against primary isolates of the virus [478].  
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Proof-of-concept passive immunization studies in nonhuman primates have demonstrated 
that administration of bNAbs can protect from infection [319, 320, 324, 532-535]. These 
antibodies are directed to several epitopes located in HIV-1 envelope glycoprotein (Env) 
and are capable of binding to the virus and prevent infection [536]. Neutralizing epitopes 
on HIV-1 includes the CD4 binding site, V1/V2 loops, V3 loop, gp120/gp41 interface 
region and the fusion peptide and MPER (Membrane-proximal external region) in gp41 
[298, 325-332, 337]. In contrast with the CD4 binding site which is highly conserved, V1, 
V2 and V3 are variable regions [347]. V3 is the most conserved region of the three 
variable regions and it harbors a highly conserved motif, GPGR/Q (residues 312-315 in 
the HXB2). V3 is a highly immunogenic region and anti-V3 antibodies such as the broad 
and potent bNAb 447-52D have been found to neutralize up to 50% of the viruses in 
various multiclade panels [325, 326, 329, 330, 347, 348].  
Despite the urgent need for a vaccine, only six HIV-1 vaccine candidates have completed 
efficacy trials.  To date, the prime-boost regimen used in RV144 trial is still the only 
immunization strategy that has demonstrated some level of protection against HIV-1 
infection [118, 468]. This trial was based on clade B and CRF01_AE sequences and 
consisted of four priming injections of a recombinant canarypox vector vaccine 
(ALVAC/vCP1521) expressing env, gag and protease genes in combination with two 
booster injections of a recombinant glycoprotein 120 subunit vaccine (AIDSVAX B/E). 
Immune responses observed in RV144 associated with a reduced risk of HIV-1 infection 
included non-neutralizing antibodies to V1/V2, high levels of antibody-dependent 
cellular cytotoxicity (ADCC) and HIV-1 specific IgG3 responses[118, 468, 470]. 
Importantly, all RV144 recipients developed low titers of neutralizing antibodies that 
were mainly against tier 1 isolates which may justify the modest efficacy of this trial 
[131]. Despite these limitations, RV144 trial was very helpful to inform new vaccination 
strategies. HVTN 702 [119, 471], the only phase 2b/3 HIV vaccine trial ongoing involves 
a new version of the immunogens and strategy used in RV144 but with some 
modifications: HIV-1 subtype, number of immunizations and type of adjuvant. Vaccine 
regimen  consists of two immunizations of ALVAC-HIV (vCP2438) plus three 
immunizations with  Bivalent Subtype C gp120[472]. Because bNAbs have been 
considered the best correlate of antibody protection against HIV infection, the 
development of immunogens that induce broadly neutralizing antibodies is currently the 
main priority for the HIV-1 vaccine field   [131, 319, 320, 422, 473-475]. So far, no 
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vaccine candidate in humans has been able to induce bNAbs against heterologous tier 2 
viruses from different clades [478, 479]. The majority of HIV vaccine regimens consists 
of prime-boost regimens that use different combinations of immunogens, namely, 
recombinant virus expressing HIV envelope[2, 422, 493], or/and  plasmid DNA 
constructs[454], or/and various HIV purified proteins (e.g. native-like trimers) [342, 422, 
453, 478, 479, 494]. Recent studies have shown that it is possible to induce NAbs against 
tier 2 viruses although sporadically, with limited breadth and at low levels [478, 479]. A 
recent study using a poxvirus prime-gp120 boost strategy based on clade B Envs 
demonstrated the induction of cross-reactive binding antibodies against V1/V2 fusion 
proteins and neutralizing responses against heterologous tier 2 isolates, mostly from clade 
B [422]. In line with this, we previously demonstrated that bNAbs against HIV-2 can be 
elicited in mice using a Vaccinia vector-prime C2-V3-C3-boost vaccination strategy [2].  
The effective production of NAbs is highly dependent on an effective T cell response. 
Broadly neutralizing antibodies exhibit high somatic mutation frequencies suggesting that 
bNAbs generation is likely to be highly dependent on the activity of CD4+ follicular 
helper T cells (Tfh), and may be constrained by host tolerance controls such as follicular 
regulatory T cells (Tfr). Tfh have been described to be essential for antibody class switch 
and affinity maturation, an important process during the production of NAbs [235, 240]. 
These cells are defined by the expression of high levels of surface markers program death-
1 (PD-1) and chemokine CXCR5, especially within germinal centers (GCs)[244]. The 
interplay between HIV infection and Tfh is complex and still remains to be fully defined. 
However, studies report a positive correlation between the frequency of Tfh subsets and 
effective humoral responses against HIV, as measured by the development of 
bNAbs[240], suggesting Tfh as a potential target for vaccine strategies aiming to induce 
neutralizing antibodies.  On the other hand, some studies have shown a negative 
correlation between regulatory CD4+  T cells (CD25+ Foxp3+ CD4+) and bNAbs in HIV-
1 infected individuals[537]. Recently, Tfr cells were identified as a unique subset of CD4 
T cells that controls and regulates GC responses. Similar to Tfh, Tfrs express high levels 
of CXCR5 and PD-1, expressing also Foxp3 which contributes for its regulatory functions 
[259-261]. These cells are important modulators of the GC response as they inhibit GC 
expansion and regulate Tfh and B cell numbers. Studies reported that the avidity of Env-
specific (gp120) antibodies in SIV-infected rhesus macaques correlated with a lower 
frequency of Tfrs[263]. Also neutralizing antibodies to HIV were negatively correlated 
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to Foxp3+ Env-specific follicular T cells in SHIV-infected rhesus macaques [256] . As 
Tfrs frequency has been found to negatively correlate with bNAb generation [256, 263] 
it is important to consider this subset when developing new vaccine strategies against 
HIV.  
In the present study, we aimed to investigate if the vaccine concept used previously 
against HIV-2[2] could be effective in the induction of bNAbs against HIV-1 in mice. 
For this purpose, we produced for priming immunization a new set of recombinant 
Vaccinia virus vectors expressing a truncated form of gp120 from several non-B clades 
of HIV-1 primary isolates from Angola and Portugal and for boosting the cognate 
C2V3C3 polypeptides and truncated gp120 protein. We have also analyze Tfh and Tfr 
cell subsets in immunized animals. We were able to induce cross-reactive binding 
antibodies in mice against all gp120 proteins tested and neutralizing responses against 
HIV-1 heterologous tier 2 isolates from different clades. Tfh cells were positively 
correlated with binding antibodies levels and Tfr cells were negatively correlated with 
neutralizing antibody responses. 
 
Material and Methods 
Ethics statement 
BALB/cByJ mice were maintained under specific pathogen free (SPF) conditions at the 
Instituto de Higiene e Medicina Tropical and  Instituto de Medicina Molecular, where all 
animal work was performed in accordance with Directive 2010/63/EU. All experimental 
procedures were approved by the institutional Animal Welfare Body. Experimental 
animals were females between 8–10 weeks. 
 
Cells, plasmids, viruses, and antibodies 
Rat2 (TK-) cells were purchased from American Type Culture Collection (Rockville, 
MD).  HeLa cells (ATCC® CCL­2™) were obtained from American type Culture 
Collection.  TZM-bl cells were provided by the AIDS Research and Reference Reagent 
Program, National Institutes of Health.  HeLa, Rat2 and TZM-bl cells were cultured in 
complete growth medium that consists of Dulbecco´s minimal essential medium 
(DMEM) supplemented with 10% fetal bovine serum (FBS), 100 U/ml of penicillin-
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streptomycin (Gibco/Invitrogen, USA), 1mM of sodium pyruvate (Gibco/Invitrogen, 
USA), 1mM of L-glutamine (Gibco/Invitrogen, USA) and 1mM of non-essential amino 
acids (Gibco/Invitrogen, USA). All cell cultures were maintained at 37ºC in 5% CO2. The 
following items were obtained from the NIH AIDS Reagent Program: Western Reserve 
Strain of Vaccinia virus (VVWR), a Panel of Global tier 2 HIV-1 Env Clones (cat#12670) 
designed to assess neutralization responses and  HuMAbs 447-52D (anti-V3), VRC01 
(anti-CD4bs), 3BNC117 (anti-CD4bs), HJ16 (anti-CD4bs), PG16 (anti-V2), 2G12 (anti-
N-linked glycans in C2, C3, V4, C4), b12 (anti-CD4bs), and 2F5 (anti-MPER).  
 
Cloning of envelope genes from primary isolates  
 
Envelope genes expressed in this study (Table S1) were obtained by PCR amplification 
from five primary isolates derived from HIV-1 infected individuals from Portugal (n=2) 
and Angola (n=3) and from plasma samples from HIV-1 infected patients (n=2) from 
Portugal and Angola.  Viral genomic RNA was extracted from plasma and/or cell culture 
supernatant and reverse transcription (RT) was performed using Titan One Tube RT-PCR 
System (Roche Diagnostic Systems). Full-length env genes were amplified by nested 
PCR as described previously [538], purified using JETQUICK Gel Extraction Spin Kit 
(Genomed) and sequenced (Table S2 and S3). For subtyping, the nucleotide sequences 
were aligned with reference sequences using ClustalX4 
((http://www.clustal.org/clustal2/) and manually edited with GeneDoc 
(http://iubio.bio.indiana.edu/soft/molbio/ibmpc/genedoc-readme.html). Find model tool 
(https://www.hiv.lanl.gov/content/sequence/findmodel/findmodel.html) was used to 
estimate the best nucleotide substitution model and PhyML v3.1 program in SeaView 
version 4.6.2. was used to compute maximum likelihood phylogenetic trees[539].  
CCR5 and /or CXCR4 usage of primary isolates was determined in TZM-bl cells (CD4+, 
CCR5+, CXCR4+)  in the presence of excessive amounts of the CCR5 antagonist TAK-
779 (10µM) and/or of the CXCR4 antagonist AMD3100 (1.2µM) as previously 
described[514]. For two HIV-1 samples coreceptor usage was determined based on the 
sequence of V3 using the geno2pheno algorithm[540]. 
For each subtype, a group of newly selected primers based on env sequences were 
designed in order to amplify the gp120 region lacking 78 bases at the carboxyl terminus 
of the C5 region. Forward and reverse primers included a restriction site for SalI (5´- 
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GTCGAC-3´) and Reverse primers included a stop codon (CTA) before the restriction 
site. PCR primer numbers and positions are described in Table S2 (Supplemental 
material). All amplifications were performed using the Expand Long Template PCR 
system (Roche Diagnostic Systems) according to the manufacturer’s instructions. gp120 
truncated fragments (named gp120t) were amplified and cloned into the SalI site of the 
Vaccinia virus insertion vector pMJ601. In this vector, protein expression is driven by the 
strong late Vaccinia virus promoter present in pMJ601[541]. 
 
Production of recombinant Vaccinia viruses and expression of Env glycoproteins  
 
Recombinant Vaccinia viruses expressing the glycoprotein gp120t were obtained as 
described[2].Briefly, HeLa cells were transfected with recombinant pMJ601 plasmids 
and simultaneously infected with Vaccinia virus strain VVWR and recombinant Vaccinia 
viruses resistant to 5-bromodeoxyuridine and expressing β-galactosidase were selected in 
Rat2 cells and then propagated in HeLa cells. The recombinant viruses were titrated in 
Rat2 cells using the method of Reed and Muench[542]. 
The method of Rose et al[543] was used to produce gp120t . Briefly, HeLa cells were 
infected with 5 PFU of recombinant Vaccinia virus per cell and incubated for 3 hours. 
Medium containing the infecting virus was replaced with DMEM supplemented with 
2.5% FBS at 3h post infection. After 24 hours of infection medium containing gp120t 
was collected, clarified by centrifugation at 3000xg for 10 minutes and filtered with a 
0.2µM pore size filter to remove Vaccinia virus.  Cells were washed with cold PBS 
(Phosphate buffered saline) and lysed using RIPA+DOC buffer (0.15M NaCl, 0.05M 
Tris-HCl, 1% Triton X-100, 1% DOC, 0.1% SDS). Lysates were centrifuged at 35.000 
rpm for 60 min at 4°C and the supernatant containing the proteins was collected. 
Antigenic reactivity of gp120 obtained from cell lysates and cell-free supernatants was 
quantified by an ELISA assay and by Western-Blot as described below.  
 
Analysis of HIV-1gp120t proteins 
Proteins obtained from the cell lysate and from the cell-free supernatant were analyzed 
on 7.5% SDS-PAGE followed by Coomassie Brilliant Blue staining. For Western blot 
analysis, proteins were prepared in Laemmli sample buffer (125mM Tris, pH 6.8, 2% 
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SDS and 20% glycerol) with β- mercaptoethanol and denaturated by heating for 5 min at 
96ºC, loaded within the acrylamide gel and then  transferred from the gel to nitrocellulose 
membranes  0.45µM (BioRad). After protein transfer, the membranes were treated with 
blocking buffer (1X TBSt with 4% w/v nonfat dry milk) and incubated with serum from 
HIV-1 and HIV-2 infected individuals diluted (1:200) in primary antibody buffer (1X 
TBSt with 4% w/v nonfat dry milk and 5% goat serum) and/or HuMAbs 447-52D (anti-
V3), VRC01 (anti-CD4bs), 3BNC117 (anti-CD4bs), HJ16 (anti-CD4bs), PG16 (anti-V2), 
2G12 (anti-N-linked glycans in C2, C3, V4, C4), b12 (anti-CD4bs), and 2F5 (anti-MPER) 
at 1µg/ml.  Next, the membrane was washed with TBSt 0.25% and incubated with Anti-
human IgG- alkaline phosphatase antibody produced in goat (Sigma) and/or Anti-Human 
IgG-Peroxidase antibody produced in goat (Sigma). Colorimetric detection of proteins 
was performed by AP conjugate Substrate Kit (BioRad) and chemiluminescent detection 
was performed with Pierce™ ECL Western Blotting Substrate (ThermoFisher Scientific). 
Quantification of glycoproteins was done using Kodak image analysis software. 
Binding specificity of the immunogens (gp120) was analyzed by an ELISA assay against 
the eight HuMAbs described above at a final concentration of 10µg/ml. For this purpose, 
Immuno MaxiSorp 96-well microplates (Nunc) were coated with the gp120t supernatant 
(~2.3 to 4µg per well) in 0.05M bicarbonate buffer. Envelope gp120 glycoprotein 
expressed by vPE16, SF162 gp140 (2µg/ml) and M.CON.S D11 gp120 (2µg/ml) were 
used as protein positive controls. Of note, vPE16 is a recombinant Vaccinia virus obtained 
from the plasmid pPE16 (isolate HTLV-IIIB, clone BH8) that expresses gp120 and gp41 
glycoproteins. HIV-1 plasma samples at a final dilution of 1:200 were used as positive 
antibody control and 2F5 antibody (anti-gp41) was used as a negative control. The clinical 
cut-off value of the assay was calculated as the mean OD value of 2F5 reactivity plus 2 
times the SD. Cut-off value of sera from HIV-1 plasma samples and SF162gp140 (which 
reacts with 2F5) was calculated as the mean OD value of HIV-seronegative samples plus 
2 times the SD. 
 
Production, expression and analysis of C2V3C3 polypeptides  
 
A DNA fragment of 534 nucleotides comprising the C2, V3 and C3 coding regions from 
all isolates (6858-7392 in HXB2) was amplified using primers described in Table S2 and 
cloned into the bacterial expression vector pTrcHis (Invitrogen). Expression of C2V3C3 
polypeptides in Escherichia coli strain TOP10 were induced with isopropyl-β-D-
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thiogalactopyranoside (IPTG) according to the manufacturer´s instructions and protein 
purification was performed using Dynabeads® His-tag Isolation & Pulldown (Life 
Technologies). Bradford assay (Bio-Rad) was performed to determine protein 
concentration. Purified recombinant polypeptides were analyzed by SDS-12% PAGE and 
the antigenic structure of the purified polypeptides was analyzed by an ELISA assay with 
plasma samples from HIV-1 infected patients from Angola (n=28). Briefly, Immuno 
MaxiSorp 96-well microplates (Nunc) were coated with recombinant polypeptides from 
HIV-1 subtypes C, CRF02_AG, J, G and H (2.5µg/ml) diluted in 0.05M bicarbonate 
buffer (pH 9.4) by overnight incubation at 4°C and blocked with 2% gelatin (Bio-Rad).  
Plasma from HIV-1 infected patients (starting at 1:100) was added to the microplates and, 
after 2h of incubation at room temperature, anti-Human IgG (Fc specific)−Alkaline 
Phosphatase antibody produced in goat (Sigma) was added as a secondary antibody. 
Colorimetric reaction was developed with SIGMAFAST™ p-Nitrophenyl phosphate 
(pNPP) Tablets and read at 405 and 492 nm against a reference wavelength of 620 nm on 
a microplater reader. The clinical cut-off value of the assay, calculated as the mean OD 
value of HIV-seronegative samples plus 2 times the SD, was determined using samples 
from healthy HIV-seronegative subjects. Binding antibody titer was calculated as the 
highest plasma dilution giving a positive reaction (OD / cut-off> 1).  
 
BALB/c mice immunizations 
 
Recombinant Vaccinia viruses expressing gp120t (VVgp120), soluble gp120t (Sgp120) 
and recombinant polypeptides C2V3C3 described above were used as vaccine 
immunogens in two separate immunization experiments. In the first experiment, herein 
considered a pilot study, we used the immunization strategy that was proven efficient in 
HIV-2 vaccination but with some minor modifications [2].  A total of 20 six week 
BALB/mice (BALB/c ByJ (H-2d, BALB/c)) divided in six groups (Groups 1-6, mice 1-
20) were first immunized intraperitoneally (IP) with 2x107 PFU of recombinant Vaccinia 
viruses from clades C, CRF02_AG and J in 100 µl of PBS  (Table 1). Mice were boosted 
three times (IP route) at days 15 and 30 with 10µg of C2V3C3 from the cognate subtype 
and at day 45 with gp120 supernatant also from the cognate subtype. Groups 1 and 2 were 
control groups. Group 1 didn´t received any immunogen and group 2 was immunized 
with VVWR. Three to four mice were used in each group with the exception of group 1 
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that included only 2 mice. Of note, although groups 3 and 4 received exactly the same 
immunogens, C2V3C3 administered to group 4 was purified with urea instead of 
imidazole.  
 
Table 1. BALB/c mice immunization scheme in the pilot study 
Groups ID 
HIV-1 env 
clade 
Priming Boost I (IFA) Boost II (IFA) Boost III (CFA) 
Day 1 Day 15 Day 30 Day 45 
1 M1-M2 X X X X X 
2 M3-M5 VWR (control) VVWR X X X 
3 M6-M8 C VVgp120C C2C3Ca C2C3Ca Sgp120C 
4 M9-M11 C VVgp120C C2C3Cb C2C3Cb Sgp120C 
5 M12-M16 CRF02_AG VVgp120AG C2C3AG C2C3AG Sgp120AG 
6 M17-M20 J VVgp120J C2C3J C2C3J Sgp120J 
 
A total of 20 female BALB/mice (BALB/c ByJ (H-2d, BALB/c)) divided in six groups were first immunized intraperitonealy (IP) with 2x107 
PFU of recombinant Vaccinia viruses expressing gp120t from clades C, CRF02_AG and J and boosted with 10µg of C2V3C3 and 7-12.9 
µg of gp120 supernatant from the cognate subtype. Each animal was immunized at days 1, 15, 30 and 45. Mice sera was collected fifteen 
days after immunization. All mice were sacrificed at day 60. Groups 1 and 2 were control groups; ID- Animal Identification; M- Mice; CFA- 
Complete Freunds Adjuvant; IFA- Incomplete Freund´s Adjuvant; a C2C3 eluted in imidazole; b C2C3 eluted in urea 
 
 
 
In the second experiment, called the main study, 30 female BALB/c ByJ (H-2d, BALB/c) 
between 8-10 week old were included. Animals were divided in eleven groups (1-5B) 
according to the immunogen clade and immunization strategy (Table 2). 
Animals from groups 3, 4 and 5 were primed (IP route) with 2x107 PFU of recombinant 
Vaccinia virus expressing gp120t in 100µl of PBS and boosted two times with 10µg of 
recombinant polypeptides C2V3C3 and one time with 100 µl of soluble gp120t. Animals 
from groups 3A, 4A and 5A were primed with 2x107 PFU of recombinant Vaccinia virus 
expressing gp120t in 100µl of PBS and boosted three times with 100 µl of soluble gp120t. 
Finally animals from groups 3B, 4B and 5B were primed with 100 µl of soluble gp120t 
and boosted two times with 10µg of recombinant polypeptides C2V3C3 and one time 
with 100 µl of soluble gp120t.  The amount of protein included in the 100 µl was 9.1µg 
of gp120B, 12.9 µg of gp120C and 7 µg of gp120AG.  
Groups 3, 3A and 3B were immunized with immunogens derived from HIV-1 clade C, 
groups 4, 4A and 4B with immunogens derived from clade CRF02_AG and groups 5, 5A 
and 5B with immunogens derived from clade B (Table 2). Groups 1 and 2 were control 
groups. Group 1 didn´t received any immunogen and group 2 was immunized with VVWR. 
Complete Freund’s adjuvant (CFA) (Sigma) was used for priming in groups 3B, 4B and 
5B whereas Incomplete Freund’s adjuvant (IFA) (Sigma) was used for all the boosts. In 
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both studies, the schedule of immunization consisted of one priming and three boosts at 
days 15, 30 and 45. Mice sera were collected immediately before each immunization to 
access for binding antibodies and 15 days after the last immunization. Mice were 
sacrificed on day 60. 
 
Table 2. BALB/c mice immunization scheme in the main study 
Groups ID HIV-1 env clade Priming 
Priming 
adjuvant 
Boost I (IFA) Boost II (IFA) Boost III (IFA) 
Day 15 Day 30 Day 45 
1 M1-M2 X X X X X X 
2 M3-M4 VWR (control) VVvwr X SVVWR SVVWR SVVWR 
3 M5-M8 C VVgp120C X C2C3C C2C3C Sgp120C 
3A M9-M11 C VVgp120C X Sgp120C Sgp120C Sgp120C 
3B M12-M13 C Sgp120C  CFA C2C3C C2C3C Sgp120C 
4 M14-M17 CRF02_AG VVgp120AG X C2C3AG C2C3AG Sgp120AG 
4A M18-M20 CRF02_AG VVgp120AG X Sgp120AG Sgp120AG Sgp120AG 
4B M21-M22 CRF02_AG Sgp120AG  CFA C2C3AG C2C3AG Sgp120AG 
5 M23M26 B VVgp120B X C2C3C C2C3C Sgp120B 
5A M27-M28 B VVgp120B X Sgp120B Sgp120B Sgp120B 
5B M29-M30 B Sgp120B  CFA C2C3C C2C3C Sgp120B 
A total of 30 female BALB/cByJ divided in 11 groups were  immunized intraperitonealy with different combinations of  immunogens:2x107 
PFU of recombinant Vaccinia virus expressing gp120t from HIV-1 subtypes B, C and CRF02_AG in 100µl of PBS; 10µg of recombinant 
polypeptides C2V3C3 C and C2C3AG and 7-12.9 µg of gp120t. Each animal was immunized at days 1, 15, 30 and 45. Mice sera was 
collected fifteen days after immunization. All mice were sacrificed at day 60. Groups 1 and 2 were control groups; ID- Animal Identification; 
M- Mice; CFA- Complete Freunds Adjuvant; IFA- Incomplete Freunds Adjuvant 
 
 
Envelope-specific antibody binding in mice sera 
In order to analyze serum antibody responses, Immuno MaxiSorp 96-well microplates 
(Nunc) were coated with gp120 supernatant (clades B, C, AG and J) and recombinant 
polypeptides C2V3C3 (clades C, AG and J) as described above. After overnight 
incubation at 4°C microplates were blocked with 2% gelatin (Bio-Rad).  Mouse anti-
serum from days 0, 15, 30, 45 and 60 was heat inactivated for 1 hour at 56ºC added to the 
microplates (1:200 final dilution in a total volume of 100µl) and incubated for 2 hours at 
room temperature. Anti-Mouse IgG-Alkaline Phosphatase antibody produced in goat 
(Sigma) at 1:2000 dilution was added to the microplates as a secondary antibody. 
Colorimetric reaction was developed as previously described. Negative controls were 
preimmune serum and serum from mice immunized with VVWR. Positive control was 
serum from HIV-1 infected individuals. In this case, the secondary antibody was Anti-
human IgG- Alkaline Phosphatase antibody produced in goat (Sigma). Sera with an 
optical density (OD) above the preimmune controls were considered positive.  
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Neutralization assays 
A panel of sixteen HIV-1 viruses including eleven tier 2 HIV-1 from a reference panel 
[502], three HIV-1 primary isolates (two subtypes J and one CRF02_AG in Env) and two 
tier 1 HIV-1 viruses (NL4.3 and SG3.1) were used in neutralizing assays in order to 
evaluate the neutralizing antibody response in mice (Table S4). Primary isolates were 
obtained from HIV-1 infected patients by co-cultivation with peripheral blood 
mononuclear cells (PBMCs) from seronegative subjects. Env-pseudotyped viruses were 
produced by transfection of Env-expressing plasmids in 293T cells using pSG3.1Δenv as 
backbone and titrated in TZM-bl cells as described [502, 544].  Neutralizing activity of 
mice serum was tested using a single-round viral infectivity assay using a luciferase 
reporter gene assay in TZM-bl cells, as described previously [2, 300].  Briefly, the cells 
(10.000 cells in 100µl of DMEM supplemented with 10% heat-inactivated fetal bovine 
serum) were added to each well of 96-well flat-bottom culture plates (Nunc) and allowed 
to adhere overnight. Next, 100 µl of each virus (200 TCID50/well) were incubated for 1h 
at 37ºC with heat-inactivated mice sera (56ºC, 1 hour)  in a total volume of 200 µl of 
growth medium (DMEM supplemented with 10% heat-inactivated fetal bovine serum) 
containing DEAE-Dextran (19.7 µg/ml) and added to the cells. Final serum dilution used 
in the assays was 1:40. After 48h, culture medium was removed from each well and plates 
were analyzed for luciferase activity on a luminometer (TECAN) using Pierce™ Firefly 
Luciferase Glow Assay Kit (ThermoFisher scientific). Wells with medium were used as 
background control and virus-only control were included as infection control. The effect 
of pre-immunized serum on infection was used as baseline neutralization. To monitor the 
amount of neutralization activity that was not HIV specific, each serum sample was tested 
against a pseudovirus carrying the vesicular stomatitis virus (VSV).  
Sera from HIV-1 infected individuals and HuMAbs PG9 and VRC-CH31 in a final 
concentration ranging between 0.05-0.5µg/ml were used as positive controls of the assay 
[502]. Percent neutralization was determined by calculating the difference in average 
RLU (Relative light units) between test wells containing post-immune sera and test wells 
containing pre-immune sera after the normalization of the results using the average RLU 
of cell controls[545].  Results were considered valid if the average RLU of virus control 
wells was ≥10 times the average RLU of cell control wells. Neutralization assays were 
performed with sera obtained fifteen days after the last immunization (day 60). 
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Characterization of Tfh and Tfr cells from mice spleen  
To better understand the correlation between Tfh/Tfr subsets and NAb production spleen 
cells were harvested from the animals and red blood cells were lysed. Cells were washed 
in PBS with 0.01% NaN3, 2% FBS. Cells were stained for flow cytometry analysis with 
fluorochrome-labeled monoclonal antibodies anti-CD4-APC, anti-CD8-APC-Cy7, anti-
anti-CD25-FITC, anti-Foxp3-Pacific Blue, anti-PD-1-PE-Cy7 and anti-CXCR5-PercP 
(BioLegend®, San Diego) following the standard procedures for surface and intracellular 
stainings. Tfh cells were identified as CD4+ PD-1+ CXCR5+ cells and Tfrs as CD4+ PD-
1+ CXCR5+ CD25+ Foxp3+ cells[262, 263].   
 
Statistical analysis 
Statistical analysis was performed with GraphPad Prism 5.0. Medians of C2V3C3 
binding responses were estimated with interquartile range (IQR).  Kruskal-Wallis test and 
Dunn´s multiple comparison test was used to compare median binding antibody responses 
against recombinant polypeptides C2V3C3 from different subtypes. Non parametric 
Mann Whitney test was used to compare antibody binding titers. Spearman's rank 
correlation coefficient (r) was used to analyze the association between IgG binding 
responses of mice sera and neutralization percentage and the association between Tfh and 
Tfr counts and binding antibodies levels and neutralization activity. Statistical 
significance between two groups was determined using the two tailed non-parametric 
Mann-Whitney U test. Linear regression was calculated to determine the correlations 
between parameters. P values <0.05 were considered significant.  
 
Results 
Generation of recombinant Vaccinia Viruses expressing HIV-1 gp120t from 
different subtypes 
 
Phylogenetic analysis showed that the envelope gene sequences belonged to subtypes B, 
C, CRF02_AG, G, H and J thereby representing the most frequent subtypes worldwide 
(Figure 1). In addition, all HIV-1 isolates used the CCR5 co-receptor.  
Recombinant Vaccinia viruses expressing the truncated surface glycoprotein gp120 from 
subtypes B, C, CRF02_AG, H and J were obtained with infectious titers in the range of 
Chapter 3 – A prime-boost strategy induces bNAbs in mice 
 
92 
 
107-109 PFU/ml. To investigate the expression of truncated gp120 proteins, HeLa-CCL2 
cells were infected with recombinant Vaccinia (5 PFU/cell) and cell lysates and cell-free 
supernatants were obtained and analyzed. Western-blot analysis with plasma from HIV-
1-infected patients demonstrated the presence of gp120t both in cell lysate and in cell 
supernatant (~120kDa) albeit at different levels (Figure 2A-B). The amount of gp120t 
recovered from cell supernatant ranged from 63 to 129 µg/ml. No gp160 or gp41 was 
observed as expected. The presence of a highly reactive second band above the 120kDa 
band in Western Blot analysis is consistent with different patterns of glycosylation. 
 
gp120t binds to V3 and CD4bs-specific neutralizing monoclonal antibodies 
 
To gain further insights into their antigenic structure, the binding reactivity of gp120 
immunogens used in the main immunization assay (Sgp120B, Sgp120C and Sgp120AG) 
was tested in an ELISA assay against sera from HIV-1 infected patients and Human 
bNAbs targeting the CD4bs, V3 and N-linked glycans in C2, C3, V4 and C4 regions. 
C2V3C3 immunogens were not included in this analysis because we assumed that they 
were not responsible for the neutralization observed. Antibodies from HIV-1 infected 
patients and HuMAb 447-52D bound to all glycoproteins (Table 3).  
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Figure 1- Phylogenetic analysis of HIV-1 env genes used as vaccine immunogens. The maximum 
likelihood phylogenetic trees were constructed with alignments of reference sequences representative of all 
HIV-1 group M subtypes and the env gene sequences from Angolan and Portuguese patients. Env sequences 
used to produce vaccine immunogens are represented with colored dots. Sequence RBF168 GU111555 
belonging to HIV-1 group P was used as outgroup. Only bootstrap values above 70% are shown. 
 
 
For gp120AG, which was the protein expressed to higher levels, this result was further 
confirmed by Western-blot analysis (Figure 2C).The epitope of 447-52D  is the crown 
sequence GPGR of the V3 loop [546]. HJ16 (CD4bs-specific) bound to all glycoproteins 
in the ELISA assay, but not in WB analysis (Table 3). 
These results demonstrate that the novel glycoproteins present adequately the continuous 
V3 loop neutralizing epitope and suggest that it fails to form the neutralizing epitopes of 
a conformational nature. 
 
C 
B 
CRF02 AG 
G 
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Figure 2- Western blot analysis of gp120t expressed by recombinant Vaccinia virus VVgp120B, 
VVgp120C, VVgp120AG and VVgp120J.  Cell lysate (A) and cell supernatant (B) were incubated with 
HIV positive sera. Cell supernatant from clade AG (Sgp120AG) was incubated with V3 HuMAb 447-52D 
(C). vPE16, a recombinant Vaccinia virus expressing the HIV-1 envelope, rVV/ALI, a recombinant 
Vaccinia virus expressing the HIV-2ALI envelope and M.CON.S-D11 a gp120 subunit Env  from the group 
M consensus sequence, were used as HIV positive controls.  Mock-uninfected cells; VWR- cells infected 
with the WR strain of Vaccinia virus used (negative controls).  
 
 
gp120AG has a GPGR motif in V3 crown region and a high probability of glycan 
occupancy on position N332 
 
Analysis of the amino acid sequence of all our immunogens revealed that all isolates 
(immunogens) differ at sequence level and number of amino acids (Figure S2). For 
instance, V2 (126C-196C, HXB2), V3 loop (296C-331C, HXB2), V4 hypervariable 
region (385C-418C, HXB2) and C4Dbs beta sheet 23/24 (451G-471G, HXB2) were the 
most divergent regions regarding sequence and number of amino acids, whereas CD4 
binding loop (345S-374H, HXB2), loop D (275V-283T) and gp120/gp41 interface (56S-
82Q) were the most conserved regions. Interestingly, we found that gp120AG had a 
GPGR motif in a conserved epitope in V3 crown region (GPGQ/R) in contrast with 
GPGQ motif presented in the majority of the tested viruses, including tier 1 and 2 viruses 
from clades A, C, CRFO7, G and J. The data also revealed that gp120AG had a high 
B 
C 
A 
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probability of glycan occupancy (Pg=0.79) in position 332 (HXB2) as demonstrated by 
the presence of the motif NVS in this position (Figure S2)[547].  
 
Table 3. Binding activity of selected human monoclonal bNAbs against the new monomeric gp120 
glycoproteins and reference gp120 and gp140 glycoproteins 
 
 
Green values correspond to positive results as defined by OD/cut-off ≥ 1; The clinical cut-off value of the assay was calculated as the 
mean OD value of 2F5 reactivity plus 2 times the SD. For the positive control of the assay (HIV+) as well as SF162gp140 (which 
reacts with 2F5) the cut-off value was calculated as the mean OD value of HIV-seronegative samples plus 2 times the SD. HuMAbs 
were used at a final  concentration of 10µg/ml; 
 
 
Immunogenicity of the C2V3C3 polypeptides         
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          
Recombinant polypeptides comprising the C2V3C3 envelope region were obtained for 
subtypes C, CRF02_AG, G, H and J with concentrations ranging between 80-120 µg/ml. 
Antigenic reactivity of the purified polypeptides was analyzed by Western blot (Figure 
3)  with plasma from HIV-1 infected patients from Angola and quantified in an ELISA 
assay.  
 
 
 
 
Figure 3- Western-Blot analysis (12%) of HIV-1 C2V3C3 recombinant polypeptides from clades C, J, H, 
G and CRF02_AG expressed in Escherichia coli strain TOP10. All recombinant polypeptides were 
incubated with serum from HIV-1 infected individuals.  
 
3BNC117 CD4bs 3.82 11.47 0.81 1.05 0.86
HJ16 CD4bs 0.31 11.47 1.08 1.71 1.10
PG16 V2 0.20 2.37 0.91 1.24 0.86
2G12 N-linked glycans 3.82 11.47 0.68 0.97 0.91
b12 CD4bs 3.82 11.47 0.76 0.97 0.63
VRC01 CD4bs 2.96 31.62 0.94 0.91 0.87
447-52D V3 2.96 31.62 2.32 2.62 2.81
HIV+ sera unknown 3.82 7.53 3.18 1.67 2.59
Sgp120AG          HuMAbs  Epitope SF162gp140 M.CO N.S D11gp120 Sgp120B Sgp120C
~22kDa 
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The majority of plasma samples (n=28) reacted with the recombinant polypeptides 
indicating that the polypeptides present a conformation that was recognized by anti-HIV-
1 antibodies. Median binding antibody titers (log10) ranged from 2.151 to 2.903 (Figure 
4B). Higher titer of binding antibodies was observed for subtype C (C2V3C3C) and the 
lower for subtype G (C2V3C3G) (p<0.05) which can be related with the predominance 
of subtype C in Angola [527, 528]. 
 
A                                                                                       B 
 
Figure 4- Antibody reactivity (A) and antibody binding titer (B) of 28 plasma samples against 
recombinant polypeptides C2V3C3 from different subtypes. A- Dot-plot graphic showing the median 
binding antibody reactivity (OD/Cutoff) and interquartile range of 28 plasma samples against five different 
recombinant polypeptides from clades C, CRF02_AG, J, G and H. B- Dot-plot graphic showing the median 
binding antibody titers and interquartile range of 28 plasma samples against the different recombinant 
polypeptides. Kruskal-Wallis test and Dunn´s multiple comparison test was used to compare the median 
values. p values < 0.05 were considered statistically significant. The black line in each group represents the 
median value. *p=≤0.05, **p≤0.01, ***p≤0.001.  
 
Envelope glycoproteins elicit cross-reactive gp120 binding antibodies 
and neutralizing antibodies in mice  
 
To investigate the combined immunogenicity of our HIV-1 immunogens, BALB/c mice 
were inoculated with several combinations of recombinant VV expressing gp120t 
(VVgp120), soluble gp120t (Sgp120t) and recombinant polypeptides C2V3C3 from 
different clades (Table 1 and Table 2). 
 Binding antibody responses were analyzed in mice sera drawn at five different timepoints 
(T0-T4) using an ELISA assay with Sgp120t and recombinant polypeptides C2V3C3 as 
capture antigens. For all immunized groups, binding antibody responses were higher than 
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those from control groups. In the pilot study, the majority of immunized mice developed 
binding antibodies against C2V3C3 only after the third immunization and at low levels 
(Figure S1). Moreover, strong antibody responses against this polypeptide were only 
observed in mice immunized with clade C immunogens (Figure S1). In contrast, all 
immunized mice developed antibodies that reacted with autologous and heterologous 
Sgp120t soon after the priming with no significant differences between subtypes. 
Neutralizing antibodies against tier 2 viruses from different clades were produced in at 
least one animal per group (Table 4, Figure 5A). At  1:40 dilution, animals immunized 
with clade C, were able to neutralize >50%  two heterologous tier 2 pseudoviruses from 
clades A and C and one primary isolate from  clade J. In addition, one animal immunized 
with clade J neutralized at more than 50% only one heterologous tier 2 pseudovirus from 
clade C.  Remarkably, one animal immunized with AG immunogens (M13, Group 5) 
elicited neutralizing antibodies against four tier 2 pseudoviruses and 2 primary isolates 
from different clades (Table 4). Overall, the percentage of neutralized tier 2 viruses per 
group was 23% (3/13) for group 3 (immunized with clade C), 46% (6/13) for group 5 
(immunized with clade AG) and 8% (1/13) for group 6 (immunized with clade J).   
To confirm and extend these results we performed a second immunization experiment in 
a different facility and with some modifications. For this study, 11 groups of 30 female  
BALB/cByJ 8-10 weeks old were included. All groups (except control groups) were 
immunized with different combinations of our immunogens, namely recombinant 
Vaccinia virus expressing gp120t from clades B, C and CRF02_AG, C2V3C3 
polypeptides and soluble gp120t (Table 2). All immunized mice generated IgG antibodies 
against autologous and heterologous Sgp120t but only some of them produced antibodies 
against C2V3C3 (Figure 6).  In all groups, mice produced cross-reactive antibodies 
against autologous and heterologous Sgp120t soon after the priming. Like in the pilot 
study priming followed by three boosts was strictly necessary to achieve a potent binding 
antibody response against gp120t (subtypes B, C and AG). Overall, mice primed with 
gp120t produced the strongest IgG response against gp120t from different clades 
comparing with groups primed solely with Recombinant Vaccinia virus (groups 3B, 4B 
and 5B- Figure 6).  
Similar to the pilot study we observed that mice immunized with clade C immunogens 
developed the strongest response against C2V3C3 polypeptides although only after the 
third immunization indicating that C2V3C3 antibodies arise slowly. 
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A- Pilot study                                                              B- Main study 
 
 
Figure 5- Heatmap graphic representation of sera neutralization potency and virus sensitivity from 
immunized mice from the  pilot  study (A) and main study (B) against 12 tier 2 pseudoviruses, 3 
primary isolates (93AOHDC250, 93AOHDC253, 01PTHDECJN) and two tier 1 viruses (SG3.1 and 
NL4.3). The color key histogram summarizes the percentage of neutralization. More potent sera is 
represented by red. To monitor the amount of neutralization activity that is not HIV-1 specific each serum 
(final dilution 1:40) was tested against a pseudovirus carrying the VSV (only for main study); light yellow 
indicates <30% neutralization; orange indicates neutralization values between 30-48%; red indicates >49% 
of neutralization.  Missing neutralization data are indicated by white cells (NA) in the heatmap 
 
Moreover, in all groups, mice immunized with C2V3C3 polypeptides developed a 
moderate binding IgG response against C2V3C3 polypeptides from different clades. 
Interestingly, mice immunized with VV expressing gp120 and boosted three times with 
cognate gp120t did not produced antibodies against C2V3C3 indicating that epitopes 
present in the C2V3C3 polypeptides  were not presented in gp120 immunogens (Groups 
3A, 4A and 5A-Figure 6).  Overall, there were no significant differences between 
immunogen responses, i.e., groups that were immunized with an immunogen from a 
specific subtype didn´t produce more binding antibodies to the autologous immunogen 
compared with the heterologous one. Regarding antibody neutralization, at 1:40 dilution 
Chapter 3 – A prime-boost strategy induces bNAbs in mice 
99 
 
at least one animal per main group (immunized with subtypes C, AG, and B) neutralized 
at least one tier 2 virus at more than 50%, including viruses from different clades (Table 
5; Figure 5B). However, there were significant differences between subtype immunogen 
concerning neutralization efficacy. Mice primed with VV expressing gp120t AG and 
boosted with the cognate gp120t (Group 4A) produced a cross-reactive neutralizing 
response (>49%) against two HIV-1 primary isolates, one heterologous (clade J) and one 
autologous (clade AG), and two heterologous tier 2 pseudoviruses (clades B and 
CRF07_BC).  As expected, mice sera from this group potently neutralized the autologous 
virus (01PTCJN) (70% neutralization) (Table 5).  Mice immunized with gp120 from 
clade B plus C2V3C3 from clade C (Groups 5, 5A and 5B) had the weakest neutralizing 
response with only one group (M23-M26, Group 5) neutralizing one virus at more than 
50% (Table 5). Sera from Group 3 (immunized with clade C immunogen), neutralized 
one tier 2 virus (Clade B) and one primary isolate from clade AG while sera from group 
4 (clade AG) neutralized only one tier 2 virus from clade B (>53%) (Table 5; Figure 5B). 
Both groups 3 and 4 were primed with VV expressing gp120t and boosted with C2V3C3 
polypeptides and gp120t. The weakest neutralizing responses were observed in animals 
primed solely with gp120t (groups 3B, 4B and 5B) instead of recombinant VV. Curiously, 
these groups achieved the higher IgG binding response against all gp120t indicating that 
the majority of antibodies generated were of non- neutralizing type (Figure 6). Tier 2 
clade B virus PX2278 was the most neutralized virus followed by primary isolate 
01PTHDECJN (Table 5, Figure 5B). In fact, PX2278 was neutralized at more than 50% 
by all mice from groups immunized with clade AG immunogens (groups 4, 4A and 4B) 
which suggests that this immunogen may be useful for the development of a subtype B 
vaccine.  Overall, the total percentage of neutralized tier 2 viruses per group were 21% 
(3/14) for mice immunized with clade C (groups 3, 3A, 3B),  43% (6/14) for groups 
immunized with clade AG (groups 4, 4A and 4B) and 7% for groups immunized with 
clade B+C (5, 5A, 5B). Tier 2 viruses BJOX2000 (clade CRF07), PCE1176 (clade C) and 
246F3 (clade AC) were not neutralized by any sera in both studies.  Both experiments 
(pilot and main study) generated coherent and reproducible results demonstrating that 
groups immunized with clade AG immunogens produced the best neutralizing response. 
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Figure 6- Binding IgG response (OD values)  over time against gp120t supernatant (B, C, AG) and 
C2V3C3 polypeptides (C,AG) in BALB/c mice immunized with different combinations of HIV-1 
immunogens (main study): Groups 3, 4 and 5- mice primed with VV expressing gp120t and boosted with 
C2V3C3 polypeptides and gp120; Groups 3A, 4A and 5A- mice primed with VV expressing gp120t and 
boosted with gp120; Groups 3B, 4B and 5B- mice primed with gp120t and boosted with C2V3C3 
polypeptides and gp120 (A)- Mice immunized with clade C immunogens; (B)- Mice immunized with clade 
AG immunogens; (C)- Mice immunized with clades B (gp120) and C (C2V3C3) immunogens. For all mice, 
the schedule of immunization included one priming and three boosts at days 15, 30 and 45. Fifteen days 
after each immunization, sera were collected and assayed for the presence of binding antibodies against 
HIV-1 immunogens.Blue lines represent immunized mice from the respective group; black lines represent 
mice from control group (G1-M1-M2).
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Table 4- Neutralizing activity in sera of mice immunized in the pilot study. 
 
 
Columns subheading indicate virus designation, clade and tier; Percent neutralization was determined in TZM-bl cells measuring the reduction in number of RLU 
relative to wells with the corresponding preimmune sera. Beige highlighting indicate less than 30% of neutralization; salmon highlighting indicate ≥ 31-49%; red 
highlighting indicate equal or more  than 50% of neutralization; ND indicate the groups where neutralization activity was not measured. HIV-1 positive control was 
used at 1:20 final dilution; mice sera was used at 1:40 final dilution.   
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Table 5- Neutralizing activity in sera of mice immunized in the main study.  
 
 
 
Columns subheading indicate virus designation, clade and tier; Percent neutralization was determined in TZM-bl cells measuring the reduction in number of RLU 
relative to wells with the corresponding preimmune sera. Beige highlighting indicate less than 30% of neutralization; salmon highlighting indicate ≥ 31-49%; red 
highlighting indicate equal or more  than 50% of neutralization; ND indicate the groups where neutralization activity was not measured. HIV-1 positive control was 
used at 1:20 final dilution; mice sera was used at 1:40 final dilution; VSV was used as the negative control. 
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Vaccine strategy affects Tfh and Tfr balance  
In order to investigate which CD4+ T cell subsets were involved in NAbs induction we 
determined the number and proportion of Tfh and Tfr cells using flow cytometry.  There 
was a positive correlation between Tfh cell number and binding antibody reactivity 
against all gp120 immunogens [(r(gp120C)=0.764; r(gp120AG)=0.770; 
r(gp120J)=0.768, P=0.0001)] (Figure 7A). However, no correlation was found between 
Tfh levels and neutralization activity. Tfr proportion (%) inversely correlated with 
neutralization potency (r=-0.6606, P=0.0438) and breadth (r=-0.9710, P= 0.028) (Figure 
7B).   
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7 – Tfh and Tfr cell counts significantly correlate with levels of binding antibodies in mice 
primed with Vaccinia viruses expressing gp120t and boosted with C2V3C3 polypeptides and gp120t 
from clades C, AG and J (pilot study).  A- The figure represents the linear regression between serum 
antibody levels (OD/cut off) of immunized mice (day 60) detected by ELISA assays  against the different 
HIV-1 immunogens (C, AG and J) and total Tfh counts (x106) from mice spleens.  B.1-Tfr cells percentage 
measured within CD4 T cell subset inversely correlate to neutralization potency (% of neutralization) 
induced by the same mouse serum (p=0.0438). B.2- Tfr cells percentage measured within CD4 T cell subset 
inversely correlate to the number of viruses neutralized (neutralization breadth by the same mouse serum 
(p=0.028). C- Flow cytometry plots of Tfh (within CD4+FOXP3-) and Tfr (within CD4+CD25+FOXP3+) 
cell percentage representative of control group (G1, M1) and immunized animal with neutralization activity 
(G3, M6).  
Group 1 (naive) Group 3 (clade C) 
CD4+FOXP3- CD4+CD25+FOXP3+ CD4
+CD25+FOXP3+ CD4+FOXP3- 
P= 0.0438; r=-0.6606 P= 0.028; r=-0.9710 
gp120 C 
P= 0.0001; r=-0.764 
gp120 AG 
P= 0.0001; r=-0.770 
gp120 J 
P= 0.0001; r=-0.768 
A 
B 
C 
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Discussion  
We show here that mice primed with VV expressing gp120AG and boosted with the 
cognate gp120AG developed autologous and heterologous neutralizing antibodies against 
different HIV-1 tier 2 clades which is the main goal of a global HIV vaccine.  
Immunogens used in this study were derived from the envelope genes of primary isolates 
originated from Portugal and Angola belonging to clades C (Angola, 2008), J (Angola, 
1993), B (Portugal, 1997) and CRF02_AG (Portugal, 2001). Of note, the “Portuguese” 
CRF02_AG viral isolate was obtained from a child of Angolan origin that was in Portugal 
at the time of the sample collection. 
We hypothesized that envelope glycoproteins from viruses from an old epidemic such as 
the HIV epidemic in Angola would be better at eliciting bNAbs against heterologous 
viruses as they comprise key epitopes and conformational determinants that should be 
conserved within the contemporaneous strains due to functional constraints [46, 66, 67]. 
All envelope glycoproteins were derived from R5 isolates because R5 isolates dominate 
the early stages of HIV disease being preferentially transmitted over X4 isolates. To our 
knowledge, this is the first vaccine study using envelope immunogens from viruses 
coming from an old epidemic and from HIV-1 clades CRF02_AG and J where 
neutralizing antibodies against tier 2 HIV-1 isolates were produced [471].   
Our results demonstrate clear differences in neutralization efficacy related with the 
immunogen clade. Immunogens derived from clade CRF02_AG were able to elicit 
bNAbs against six heterologous HIV-1 tier 2 pseudoviruses and three primary isolates. 
The ability to raise neutralizing antibodies against primary isolates is noted because 
primary isolates are produced in PBMCs and unlike envelope-pseudotyped viruses their 
glycosylation profile is similar to clinically relevant isolates[548, 549].  
Interestingly, mice immunized with gp120 from subtype B, the most common subtype 
used in vaccine trials, raised the weakest neutralizing responses with only one group 
neutralizing one tier 2 virus at more than 50% [408, 466-468]. The fact that an AG-based 
immunogen could induce broadly neutralizing responses against HIV-1 tier 2 viruses 
from different clades (including clade B) supports the urgent need of new vaccine 
immunogen design studies that have non-B subtypes in consideration. 
Unlike previous vaccination studies in HIV-2[2], the C2V3C3 polypeptides did not 
contribute for the neutralizing responses in vaccinated animals indicating that they are 
Chapter 3 – A prime-boost strategy induces bNAbs in mice 
107 
 
unable to effectively present the V3 neutralizing epitopes and confirming that there are 
major differences in the antigenic structure of this variable region between HIV-1 and 
HIV-2[550]. Another interesting finding was the higher IgG binding response against the 
different gp120 (B, C and AG) in groups that were primed with gp120t solely instead of 
recombinant VV (Figure 6- Groups 3B, 4B and 5B). However, this high IgG levels didn´t 
correlate positively with increased neutralization activity. In fact, these three groups 
achieved the weaker neutralizing response. These results are consistent with several 
studies and clinical trials demonstrating that the administration of monomeric gp120 or 
other Env proteins alone is not enough to induce broad and potent neutralizing antibodies 
against HIV infection [2, 408, 467, 468, 478, 487-489, 551].  However, elicitation of 
bNAbs by the same monomeric gp120 protein was achieved in animals primed with 
recombinant VV expressing truncated gp120.  
The observation that only groups primed with Vaccinia virus developed bNAbs 
emphasize the importance in the choice of the prime-boost regimen suggesting a possible 
role for the use of replication-competent virus in HIV-1 vaccine design [2, 422, 448]. 
Poxvirus vectors are among the most used in vaccine development due, in part, to the 
success of the Vaccinia virus vaccine in eradicating smallpox [387, 420]. However, due 
to safety issues they have been replaced by safer non-replicating human poxvirus vectors 
such as MVA, NYVAC and Canarypox (ALVAC) [118, 420, 421].  Although these 
vectors are able to induce humoral and cellular immune responses in the host they fail in 
inducing consistent bNAb responses against tier 2 viruses when used as vaccine 
candidates[118, 419, 455, 552-554].  
Replicative-competent viral vectors, have been described as being more effective in 
conferring protection against infection as they elicit stronger humoral and cell-mediated 
immune responses when compared  with highly attenuated non-replicative viral vectors 
[387, 420, 421, 555]. For instance, Shiu-Lok Hu et al, [422] using a prime-boost approach 
based on a recombinant VV expressing full Env gp160 and subunit gp120 protein, was 
able to induce  in rabbits cross-reactive neutralizing activities against >50% of tier 2 
global HIV-1 Env-pseudotyped viruses. The use of a live recombinant Vaccinia virus 
vector in our immunization strategy may have been determinant for the generation of a 
strong Tfh mediated cellular response which in turn enabled an effective NAb production. 
The positive association between Tfh cells response and gp120-specific binding antibody 
response provide additional support for Tfh cells as important players in the induction of 
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an HIV-specific antibody response, regardless of the lack of correlation with 
neutralization[240, 254-256]. Furthermore, Tfrs which are in fact involved not only in the 
inhibition of Tfh function, but also in B cell maturation and antibody production 
processes, were inversely correlated to our neutralization parameters, including potency 
and breadth (percentage of neutralization and number of viruses neutralized), when 
analyzed individually for each mice serum [259, 260, 262]. Therefore, the efficiency of 
this new vaccine strategy including the induction of neutralizing antibodies may rely on 
the triggering of these specific subsets of the T cell response. Overall, our results provide 
additional support for the use of replicating competent recombinant Vaccinia viruses as a 
component of an HIV vaccine as they can induce the cell-mediated immune responses 
that are important for antibody production and HIV-specific neutralizing antibodies.  
In order to better understand why CRF02_AG immunogens induce more potent and broad 
neutralizing responses compared with the immunogens from other clades we analyzed 
the amino acid sequence of all our immunogens (Figure S2). The observation that 
gp120AG had a GPGR motif in a conserved epitope in V3 crown region (GPGQ/R) and 
the majority of the tested viruses had the GPGQ motif was interesting since GPGR is 
uncommon outside subtype B. For subtype B the consensus sequence for the V3 crown 
motif is GPGR, while for non-B subtypes is often GPGQ [330, 556-559]. Of note, 447-
42D was the only monoclonal antibody that recognized our immunogen both in ELISA 
and Western Blot analysis. 447-52D binds to and neutralizes preferentially virus with 
GPGR motif in the V3 crown with limited capacity against those with the GPGQ motif 
[329, 330, 556]. Another interesting observation related with this was that the PX2278 
tier 2 HIV-1 from clade B, which has a GPGR motif, was neutralized by all AG 
immunized groups (4, 4A and 4B). Overall, these results suggest that unlike the other 
envelope constructs gp120AG induces the production of potent neutralizing antibodies 
directed against the V3 crown. Importantly, the g120AG immunogens were able to induce 
bNAbs against B and non-B Env-pseudoviruses and HIV-1 primary isolates that did not 
present the GPGR motif indicating that NAbs targeting other epitopes were also elicited. 
Broadly neutralizing antibody HJ16 [325] (obtained from a clade C infected patient), 
bound to all gp120 immunogens in ELISA assay (albeit at lower levels) suggesting some 
exposition of CD4 binding site epitopes. On the other hand, the lack of binding to other 
NAbs targeting conformational epitopes is consistent with the monomeric nature of our 
immunogens. In sum,  the demonstration that antibodies induced by the novel vaccine 
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immunogens neutralized tier 2 HIV-1 isolates from different clades despite targeting 
essentially the V3 crown provides further support for the V3 crown as a crucial vaccine 
target [325, 326, 330].  
Although our results support the possibility that the main target of the NAbs produced by 
our immunogens is the V3 crown, other epitopes, may also have been involved in 
neutralization. Position N332 in gp120 is known to be a vulnerable site for neutralization 
by some bNAbs [547, 560, 561]. Several studies have demonstrated that the second 
position (X) in NXS/NXT motifs can indicate whether or not a glycan will be attached 
[547, 562, 563]. The observation that gp120AG had a high probability of glycan 
occupancy (Pg= 0.79, motif NVS) together with the fact that PX228, the tier 2 HIV-1 
pseudovirus neutralized by all AG immunized mice, also have a high probability of 
glycan occupancy (Pg= 0.86, motif NIS) suggests that AG immunogens could also have 
induced glycan-dependent bNAbs directed to this region in immunized mice. However, 
further studies will be necessary to clarify the epitope specificities of NAbs induced by 
the new immunogens. 
In conclusion, our results confirm that a prime-boost immunization strategy with 
recombinant Vaccinia virus expressing the monomeric envelope gp120t (priming) and 
the cognate gp120t (boost) can induce in mice a heterologous HIV-1 tier 2 neutralizing 
response, albeit with limited breadth and potency. Remarkably, however, CRF02_AG-
based immunogens were able to induce a potent envelope binding antibody response and 
a broad neutralizing response against B and non-B subtypes. Antibody responses were 
associated with adequate Tfh and Tfr responses indicating that our vaccine strategy is 
targeting the cellular subsets required for the induction of an effective NAb response.  
Thus, our findings provide support for testing these new HIV-1 immunogens and vaccine 
strategy in other animal models. Finally, our study provides proof-of-concept for a new 
type of HIV-1 vaccine based in non-B subtypes that uses a replication-competent virus 
for priming. Ongoing studies will determine whether this strategy leads to similar results 
in rabbits. 
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Supplementary Material 
 
Table S1. Characterization of HIV-1 primary isolates included in the study 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Sample Year Origin Co-receptor usage Env subtype 
93AOHDC250 1993 Angola CCR5 J 
93AOHDC251 1993 Angola CCR5 H 
93AOHDC253 1993 Angola CCR5 J 
01PTHDECJN 2001 Angola (obtained in Portugal) CCR5 CRF02_AG 
08AO34HDP 2008 Angola CCR5 C 
97PTINSA43 1997 Portugal CCR5 B 
00PTEBB 2000 Portugal CCR5 G 
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Table S2- Primers used for polymerase chain reaction amplification of HIV-1 Env, C2V3C3 and 
truncated gp120  
1 Underlined letters indicate the restriction site for SalI; the stop codon CTA is indicated in bold letters 
 
 
 
 
 
 
 
 
 
 
Amplified 
fragment 
Name Orientation Sequence (5´- 3´)1 Clade HXB2 
position 
Full-length Env PBENV1 Forward CTATGGCAGGAAGAAGCGG All 5968-5986 
PBENV2 Forward CCACTGTCTTCTGCTCTTTC 
 
All 6203-6223 
 
PBENV3 Reverse AGTCATTGGTCTTARAGGTAC All 9036-9016 
PBENV4 Reverse TTTTGACCACTTGCCHCCCAT All 8797A8817 
Truncated gp120 RC1gp120SalI Forward TTGTGTGTCGACGAAAGAGC
AGAAGAYAGTGGC 
All 6203-6223 
 
RC2gp120BCSalI Reverse TTCTGTGTCGACCTAATATTT
ATATAATTCACTTCTC 
B,C 7661-7682 
RC2gp120GAGS
alI 
Reverse TTCTGTGTCGACCTAATACT
TATATAATTCACTTCTC 
G,CRF02
_AG 
7661-7682 
RC2gp120JSalI Reverse TTCTGTGTCGACCTAATATTT
ATATAACTCACTCCTC 
J 7661-7682 
RC2gp120HSalI Reverse TTCTGTGTCGACCTAATATTT
ATATAGCTCACTTCTC 
H 7661-7682 
C2-V3-C3 HIV1EPIT11 Forward TGTGGATCCCCAATTCCYAT
ACATTATTG 
All 6858-6878 
HIV1EPIT12 Reverse TGAAAGCTTTCATCAGAAAA
ATTCYCCTCYAC 
All 7374-7392 
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Table S3. Primers used for sequencing of HIV-1 env gene segments 
 
 
 
 
 
 
 
 
 
 
 
Primer Orientation Sequence (5´- 3´) HXB2 position 
PBSEQ1 Forward AGCYTAAAGCCATGTGT 6567 – 6583 
PBSEQ2 Reverse ACACATGGCTTTARGCT  6567 – 6583 
PBSEQ3 Forward CAGTACAATGTACACA 6955 – 6970 
PBSEQ4 Reverse TGTGTACATTGTACTG 6955 – 6970 
PBSEQ5 Forward CATAGTTTTAATTGTRGAGG  7344 – 7363 
PBSEQ6 Reverse CCTCYACAATTAAAACTATG 7344 – 7363 
PBSEQ13 Forward GGACAATTGGAGAAGTGAA 7652 – 7670 
PBSEQ7 Forward GAGAGAAAAAAGAGCAGT 7745 – 7762 
PBSEQ8 Reverse ACTGCTCTTTTTTCTCTC 7745 – 7762 
PBSEQ9 Forward ATCTGCACCACTAATGT 8031 – 8047 
PBSEQ10 Reverse ACATTAGTGGTGCAGAT 8031 – 8047 
PBSEQ11 Forward CCTGTGCCTCTTCAGCTACC 8510 – 8529 
PBSEQ12 Reverse GGTAGCTGAAGAGGCACAGG 8510 – 8529 
Chapter 3 – A prime-boost strategy induces bNAbs in mice 
113 
 
 
 
 
Table S4. Global panel of tier 2 HIV-1 Env-pseudoviruses and HIV-1 primary isolates used in 
neutralization assays.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Env- pseudoviruses 
(n=11) 
HIV-1 Clade Origin Year 
pTRO11 env B Italy 1995 
p25710 env C India 1999 
p398F1 env A Tanzania 2001 
pX2278 env B Spain 2007 
pBJOX2000 env CRF07_BC China 2007 
pX1632 env G Spain 2004 
pCE1176 env C Malawi 2004 
p246F3 env AC recomb Tanzania 2001 
pCH119 env CRF07_BC China 2004 
pCE0217 env C Malawi 2007 
pCNE55 env CRF01_AE China 2007 
Primary isolates (n=3) Subtype Origin Year 
01PTCJN 
CRF02_AG Angola (obtained in 
Portugal) 
2001 
93AOHDC250 J Angola 1993 
93AOHDC253 J Angola 1993 
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Figure S1 
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Figure S1 - Binding IgG response (OD values)  overtime against gp120t supernatant (C, AG, J) and 
C2V3C3 polypeptides (C,AG, J) in BALB/c mice in the pilot study: Groups 3 and 4-mice primed with 
VV expressing gp120t and boosted with C2V3C3 polypeptides and gp120 from clade C; Group 5- mice 
primed VV expressing gp120t and boosted with C2V3C3 polypeptides and gp120 from clade AG; Group 
6- mice primed with VV expressing gp120t and boosted with C2V3C3 polypeptides and gp120 from clade 
J. For all mice, the schedule of immunization included one priming and three boosts at days 15, 30 and 45. 
Fifteen days after each immunization, sera were collected and assayed for the presence of binding 
antibodies against HIV-1 immunogens.Blue lines represent immunized mice from the respective group; 
black lines represent mice from control group (G1-M1-M2). 
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Figure S2 
                                                               gp120/gp41 interface (PGT151)                                                            
                      *        20         *        40         *        60         *        80         *       100         *            
HXB2       : MRVK---EKYQHLWRWGWRWGTMLLGMLMICSATEKLWVTVYYGVPVWKEATTTLFCASDAKAYDTEVHNVWATHACVPTDPNPQEVVLVNVTENFNMWKNDMVEQMHEDIISLW : 112 
AY669728_  : ....GIRKN....----..G..L...IIV....V.......................................................G....K......N.....Q....... : 111 
93A0HDC250 : .K.METQTSWKS.----....L.IF..F...K...Q...............K..........S.S..G..I...............I..E.......I.E.............V. : 111 
08AO34HDP  : ...MGIMRNC.QW----.I..ILGFW......VVGN...............K............EK....................M..G.........E....D.......... : 111 
01PTHDECJN : .K.RGIQKNCPL.----.G...IIFWIMI..KT-.D............RD.E..................................IR.E.......I...N......G...... : 110 
97PTINSA43 : .K..GIWKNC...----......FIWL...G..A.PR............DT...................................I..E...........N.A........... : 111 
                             
                                                           V2 (CH01, PG9)   N160K                N7 glycan (197)                                                        
               120         *       140         *       160         *       180         *       200         *       220         *       
HXB2       : DQSLKPCVKLTPLCVSLKCTDL--KNDTNTNSSSGRMIMEKGEIKNCSFNISTSIRGKVQKEYAFFYKLDIIPID-------NDTTSYKLTSCNTSVITQACPKVSFEPIPIHYC : 218 
AY669728_  : ...............T.N.K.V---.A...TNG.EGT-..R..........T....DE......L.....VV...-------.NN...R.I..D..........I.......... : 215 
93A0HDC250 : .E.......I.....T.N...ARLQTNNS.T...PE.-------.......T.E..D.RK....L..RQ.V.Q.NNGIDKGTSNYSD.V.IN......K........Q....... : 219 
08AO34HDP  : ...............T.N.NSIS-N.I.DS.DTVTSN--G.D.M......VT.ELKD.KK....L..R...VSLNKNSS---ENSSE.R.IN..S.TV.......N.D....... : 220 
01PTHDECJN : ........Q......T.D.H.YS-..E..NTGMGED.---........Y..T.EL.D.K..V.SL..RP.VVKLNEA-----.NSST.R.IN....A........T......... : 216 
97PTINSA43 : ...............T.N...FG-NTT.KNT..NWET-.....M.......T....D.M.....L.....VV..EENKNNSSGNYSN.RMI..............T......... : 224 
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                                                             CD4bs (Loop D)    N280D           V3 loop  GPGR/Q motif   N332                                                                                     
                    240         *       260         *       280         *       300         *       320         *       340            
HXB2       : APAGFAILKCNNKTFNGTGPCTNVSTVQCTHGIRPVVSTQLLLNGSLAEEEVVIRSVNFTDNAKTIIVQLNTSVEINCTRPNNNTRKRIRIQRGPGRAF-VTIGKIGNMRQAHCN : 332 
AY669728_  : ...........D.....K...K..................................D...N.........KE...............S.H.--......YT.GEI..DI...... : 328 
93A0HDC250 : ...........D.K.....S.............K............I....II...K.ISN..........HT...E.I.LA.....S...--...QVLFA.GEI..DI...Y.. : 332 
08AO34HDP  : ....Y................H...........K.................I...TKDLNVTQN....H.KEH...L..........SV..--...Q..YA.NAI..DI...... : 333 
01PTHDECJN : ...........D.G.S.A.T.R.I.........K..A.............GI....E.I.N.........KEP.K...........RG.H.--....T.YAAGEI...I...... : 329 
97PTINSA43 : ...........DNK.....................................I....E.....T.....H..E.I.......S...KRS.S.--......WT.GEVT.DI...... : 337 
 
 
                           CD4bs (VRC01-CD4 binding loop)                    V4 region                  CD4bs(VRC01-beta20/21)                                                                                                             
                 *       360         *       380         *       400         *       420         *       440         *       460       
HXB2       : ISRAKWNNTLKQIASKLREQFGNNKTIIFKQSSGGDPEIVTHSFNCGGEFFYCNSTQLFNSTW-FNST-----WSTEGSNNTEGS------DTITLPCRIKQIINMWQKVGKAMY : 435 
AY669728_  : .......D.....VI......E-....V.NH.........M......................-N.--------N.........-------N................E...... : 426 
93A0HDC250 : .N.TS..S..HKVIG..K.H.K-....S.EPA....Q.....T...........TSE...LSRL..GSGEETSNK.H----------------..........VR...R..Q.I. : 430 
08AO34HDP  : .TEG...K..YEV.K..K.Y.P-.R..K.NS.....L.........A.......TSL..E----R.V.ESNVTN.NS-T.S.TANNASISDKN......L.........A.R... : 442 
01PTHDECJN : V.KTD..R..Q.V.IQ.K.H.T.ATR...NK.....L..T..............TSN....S.-E...M--TSNI.SE..-----------.....Q...........R..Q... : 430 
97PTINSA43 : ..G.Q.....IH.VK..K.KL.-....V.N..........M.....R................P....L--LSN..--W.S.K.I-----N..............L..E...... : 442 
 
 
                          
Chapter 3 – A prime-boost strategy induces bNAbs in mice 
 
118 
 
              G458Y CD4bs (VRC01- beta23/24)        end of gp120t          gp120/gp41 interface (PGT151)                                                                                                        
                      *       480         *       500         *       520         *       540         *       560         *            
HXB2       : APPISGQIRCSSNITGLLLTRDGGNSN--NESEIFRPGGGDMRDNWRSELYKYKVVKIEPLGVAPTKAKRRVVQREKRAVGIGALFLGFLGAAGSTMGAASMTLTVQARQLLSGI : 548 
AY669728_  : ....R...................INE--.GT..........K.........................................V........................L..... : 539 
93A0HDC250 : ....A.N.T.T.............P..--GTN.T...T..................E...V.I..........E.......M..V................I.....V....... : 543 
08AO34HDP  : ....E.N.I.R........V...TVN.----T.T...I....K.............E.K...I...G......E..........V................L...A....V.... : 553 
01PTHDECJN : ....P.V...E.............T..---G..T...E............................R......E..........V................I............. : 542 
97PTINSA43 : ....R...N...K....I.........NS.GT.T......N.K..............L....I.....Q..........A.L--M................V.......L..... : 555 
                                       
                                                        N611A   gp120/gp41 interface (PGT151)                                                                                                         
               580         *       600         *       620         *       640         *       660         *       680         *       
HXB2       : VQQQNNLLRAIEAQQHLLQLTVWGIKQLQARILAVERYLKDQQLLGIWGCSGKLICTTAVPWNASWSNKSLEQIWNHTTWMEWDREINNYTSLIHSLIEESQNQQEKNEQELLEL : 663 
AY669728_  : ...............RM..............V.......G...............................DR...NM.....E...D....E.YT................... : 654 
93A0HDC250 : ....S...K.........K............V..........................T....S......Y.E..DNM..L..EK......GI.YN....A..T......D..A. : 658 
08AO34HDP  : ....S........................T.VV.I............................S......Q.D...NM...Q.....S...YT.YQ.L...HI......KD..A. : 668 
01PTHDECJN : ....S.............K............V..L.A.....................T....S.....TYDS..GNM..LQ..K..S...YT.YD...K..........D..A. : 657 
97PTINSA43 : ....K...N......................V..........................N....D.......DT..HNM.....E...D...D..YT.L.K............... : 670 
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               W672A  MPER (4E10/2F5)                                                                                                                        
                    700         *       720         *       740         *       760         *       780         *       800            
HXB2       : DKWASLWNWFNITNWLWYIKLFIMIVGGLVGLRIVFAVLSIVNRVRQGYSPLSFQTHLPTPRGPDRPEGIEEEGGERDRDRSIRLVNGSLALIWDDLRSLCLFSYHRLRDLLLIV : 778 
AY669728_  : ..........D..K......I........I......T...................L..A......................G.....F.....V..................T. : 769 
93A0HDC250 : ..........D.S.......I........I....I....A.............L..LI.A.TEV...G....G...QG.T......S.F...A.................FI..A : 773 
08AO34HDP  : .S.N...S....S.......I........I....I....A.I..............LT.N......LGR.......Q.....V...S.F.P.V..........C.RQ...CI... : 783 
01PTHDECJN : ..........D..S.....RI..I.....I.........T.I..............LTHHQ.E.....R...G...Q.....V...S.F.T.V.................FA..A : 772 
97PTINSA43 : ..........D.SK......I........I...........A..............RF.VR...............Q........AG.F.EI..V..........RL........ : 785 
                                                                                                         
                 *       820         *       840         *       860         *       880         *       
HXB2       : TRIVELLGRR-------GWEALKYWWNLLQYWSQELKNSAVSLLNATAIAVAEGTDRVIEVVQGACRAIRHIPRRIRQGLERILL : 856 
AY669728_  : ..........-------...V....................................I..AL.RTY...L...T........A.. : 847 
93A0HDC250 : A.T..T....-------...I...LG..AV..R.......I....T...V.......I..IA.RVF...I.........F..A.. : 851 
08AO34HDP  : A.A......SSLRGLQR.......LKS.V...GL...K..IN..D.I..........I...I.R......N...T.L..F.AP.. : 868 
01PTHDECJN : V.T.....HSSLKGLRL.......LK...S..G.......IN..DT......NW...I..IG.RTG...CN...........S.. : 857 
97PTINSA43 : ..T..F....-------.........................................L.IL.R.F...L...T........A.. : 863 
 
Figure S2- Amino acid sequence alignment of four envelope sequences included in the present study and location of neutralizing epitopes.  
Amino acid sequences of the envelope glycoproteins of isolates 93AOHDC250 (clade J), 08AO34HDP (clade C), 01PTHDECJN (clade CRF02_AG) and 97PTINSA43 (clade 
B) used to produce the immunogens of the study. Epitopes of representative broadly neutralizing human monoclonal antibodies were extracted from several publications [153, 
154, 365, 564-569].The location of the neutralizing epitopes is indicated in relation to the reference HIV-1 strains HXB2 (KO3455) and JR-FL (AY669728) also included in 
the alignment. Location and name of the neutralizing epitopes and corresponding NAbs are shown in red. Aminoacids corresponding to an epitope are shown in boldface letters. 
Specific mutations and/or motifs and respective sequence are shown in yellow. N7 glycan (position 197 in HXB2) is shown in purple.  
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Abstract  
A vaccine to prevent HIV infection is the best hope for controlling or ending the HIV-1 
epidemic. Despite years of research there is still no vaccine for HIV-1. Broadly 
neutralizing antibodies are considered the best correlate of protection against HIV 
infection but their induction by vaccination remains a difficult task. Poxvirus-based 
heterologous prime-boost immunization regimens have been widely used in HIV vaccine 
trials as they provide a strong T and B cell immune response, occasionally inducing the 
production of neutralizing antibodies. We previously demonstrated that bNAbs against 
HIV-2 could be elicited in mice using a Vaccinia vector-prime C2-V3-C3-polypeptide 
boost vaccination strategy [2]. More recently, using novel clade CRF02_AG gp120 
glycoproteins and a recombinant Vaccinia virus prime-gp120 boost immunization 
regimen we were able to induce heterologous tier 2 HIV-1 cross-clade neutralizing 
antibodies in mice. Here, New Zealand White Rabbits were immunized with the same 
CRF02_AG derived immunogens in order to examine if NAb responses against tier 2 
viruses of all clades could also be elicited. All immunized rabbits generated antibodies 
binding to autologous and heterologous gp120 and gp140 proteins and one rabbit 
generated antibodies that neutralized at more than 50% 13/16 tier 2 global HIV-1 
pseudoviruses tested. These results confirm our previous results in mice and support the 
use of CRF02_AG based immunogens as a component of a new preventive HIV-1 
vaccine.  
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Introduction 
HIV infection is still a major global public health issue. Since the beginning of HIV 
epidemic about 70 million people have become infected and about 35 million people have 
died of AIDS. At the end of 2015 about 2.1 million people became newly infected 
resulting in a total of 36.7 million cases of HIV infected individuals until that year [570]. 
Therefore, prevention of new HIV-1 infections will depend on the development of an 
effective and safe vaccine. However, despite years of research in this field, there is still 
no vaccine available for HIV. This incapacity in producing an effective vaccine is related 
with the lack of adequate animal models that can be used to reliably predict human 
responses to vaccines, the extraordinary genetic diversity and high mutational rate of HIV 
and the limited exposure of neutralizing epitopes in the outer surface of the virus as well 
as the incomplete knowledge of all the vulnerable sites of HIV [35, 52-54, 461, 462]. On 
the other hand, no vaccine antigen produced until now has been able to induce a protective 
effect against HIV in vaccinated animals and/or humans. 
The most promising vaccine trial that was able to induce some degree of protection (31%) 
was the RV144 conducted in Thailand from 2003 to 2006 [118, 468]. This trial was based 
on clade B and CRF01_AE sequences and consisted of four priming injections of a 
attenuated recombinant canarypox vector vaccine (ALVAC/vCP1521) expressing env, 
gag and protease genes plus two booster injections of a recombinant glycoprotein 120 
subunit vaccine (AIDSVAX B/E)[118, 468]. Interestingly, as shown in previous trials 
none of the immunogens alone induced protective responses [465-468]. Immune 
responses observed in this trial correlated with protection from HIV-1 infection included 
antibodies to variable loops (V1 and V2), high levels of antibody-dependent cellular 
cytotoxicity (ADCC) [118, 468, 470].  Low titers of neutralizing antibodies were also 
observed but only against tier 1 isolates which may justify the modest degree of the 
protection observed in this trial [131].  
Broadly neutralizing antibodies are considered the best correlate of antibody protection 
against HIV infection. Passive administration of bNAbs has been shown to protect 
humanized mice and macaques against high-dose challenge with HIV or SHIVs viruses 
[316-324]. In addition, bNAbs have been shown to have an active role in therapy 
contributing to the decline of plasma viremia to undetectable levels in HIV-1 infected 
humanized mice and SHIV-infected macaques, especially when combined with other 
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bNAbs and/or ART [571-574]. Recently, Nussenzweig and colleagues have demonstrated 
that the passive administration of HuMAb 3BNC117 was safe and effective in  reducing 
viral load in HIV-1 infected individuals[575]. Thus, bNAbs can be used to prevent HIV-
1 infection but also disease progression.  
bNAbs are directed to several epitopes located in HIV-1 envelope glycoprotein and are 
capable of binding to the virus preventing infection [536]. Therefore, bNAbs should be a 
crucial element in a preventive or therapeutic HIV vaccine as they are able to neutralize 
primary isolates from different clades [131, 316, 318-320, 322, 324, 422, 473-475]. 
Recent studies in rabbits have shown that it is possible to induce bNAbs against 
heterologous tier 2 viruses although sporadically, with limited breadth and at low levels 
[478, 479]. However, the induction of efficient and consistent bNAb responses against 
heterologous tier 2 virus from different clades has been a difficult task for the majority of 
vaccine candidates.  Remarkably, the recent immunization of four cows with the trimer  
BG505 SOSIP resulted in the rapid elicitation of broad and potent serum antibody 
responses in all immunized animals [1]. In addition, one monoclonal antibody with an 
ultra-long CDR H3 of 60 amino acids isolated from one cow neutralized 72% (n=117) of 
HIV-1 cross-clade isolates. The induction of these potent and broad NAbs to HIV may 
provide important clues regarding the quality and nature of the new generation of 
immunogens currently used in vaccine trials.    
Due to its surface exposure and immunogenicity, gp120 has been a major target for HIV 
vaccine development. However, with the exception of the recent experiments in cows [1], 
monomeric and trimeric preparations of gp120 have repeatedly failed to induce broad and 
potent neutralizing responses against tier 2 viruses when administered alone [342, 478, 
487-490, 492, 576]. The recent success of the trimer BG505 SOSIP immunization in cows 
is related with unique features of their immune system which allowed the rapid elicitation 
of potent and broad neutralizing responses. In fact, cows produce antibodies with 
exceptionally long CDR H3 at a much higher frequency and faster (months versus several 
years in humans) than HIV-1 infected individuals who produce bNAbs [1, 351, 374, 577, 
578].  
Heterologous prime-boost regimens based in a combination of different immunogens 
have been widely used in the majority of HIV vaccine regimens aiming to induce bNAbs 
as they provide a stronger overall immune response [422, 453, 454, 479, 494, 579]. One 
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of the most common approaches is the use of attenuated live viral vector vaccines 
(replicating and non-replicating) in combination with various HIV envelope proteins as 
exemplified by the RV144 trial described above [118]. Viral vector vaccines are able to 
elicit a wide range of immune responses including antibodies, CD4+ T cells and CD8+ T 
cells [207, 418, 421, 553, 579-581]. Moreover, replicative-competent viral vectors (e.g. 
Vaccinia virus strain Western Reserve and Cytomegalovirus)  can act like adjuvants 
activating the immune system as they are able to actively invade and replicate in host 
cells  leading to an increase and continuous exposure of the antigen [207, 387, 420, 421, 
582]. In addition, replicating vaccines can elicit life-long protective immunity[421]. 
However, due to safety issues, non-replicative attenuated vaccine vectors as ALVAC, 
NYVAC and MVA are preferentially used in pre-clinical HIV/SIV vaccine studies being 
also able to induce cellular and humoral immune responses although in a less extent 
compared with replicating vectors[391, 418, 553, 581, 583]. For instance, Williamson 
and colleagues using a heterologous prime-boost vaccination with DNA and MVA 
expressing HIV-1 mosaic Gag were able to elicit Gag CD8+ and CD4+ T cell responses 
in mice. However, no antibodies were induced [418].   
Within prime-boost immunization regimens with live viral vaccines, Vaccinia viruses are 
among the most exploited for vaccine development. This is because they have large 
genomes allowing the insertion of more than 10kb of foreign DNA and consequently high 
levels of gene expression [387, 420]. Other advantages of Vaccinia viruses include its 
easy manufacturing, the capacity to infect efficiently a wide range of different cell types 
both in vivo and in vitro  and the possibility to be handled in BSL-2 facilities [584, 585].  
We previously demonstrated that bNAbs against HIV-2 could be elicited in mice using a 
Vaccinia vector-prime C2-V3-C3-polypeptide boost vaccination strategy [2]. More 
recently, using novel clade CRF02_AG gp120 glycoproteins and a recombinant Vaccinia 
virus prime-gp120 boost immunization regimen we were able to induce heterologous tier 
2 HIV-1 cross-clade neutralizing antibodies in mice (chapter 3) [586]. Specifically, mice 
primed with Vaccinia virus expressing gp120 from clade CRF02_AG and boosted three 
times with the cognate gp120 protein developed autologous and heterologous neutralizing 
antibodies (>50%)  against  four tier 2 HIV-1 isolates from different clades.   
Rabbits are an animal model frequently used in HIV vaccine development assays 
constituting a preferential host for testing immunogens aimed at inducing broadly 
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neutralizing responses [479, 494, 503]. Rabbit antibodies have high affinity, specificity 
and can recognize unique epitopes[587]. In fact, monoclonal antibodies derived from 
rabbits have the potential to cross-react with human, non-human primate and mouse 
antigens [588]. More importantly, the CDR H3 length distribution in rabbit antibodies is 
more similar to humans than to mouse antibodies which is a very important feature  since 
human  bNAbs have unusual long CDR H3 loops necessary to penetrate the Env glycan 
shield [351, 374, 589].  Also, like human antibodies, rabbit antibodies are able to 
recognize a large variety of epitopes that may not be immunogenic in mice [589]. Finally, 
the possibility of obtaining large amounts of sera compared with mice make rabbits an 
attractive animal model for vaccination studies. 
The aims of the present study were to confirm and extend our previous results in mice in 
order to examine if NAb responses against tier 2 viruses representative of all HIV-1 clades 
could also be elicited in rabbits.  
New Zealand White rabbits were primed with a live recombinant VV expressing a 
truncated form of gp120 from clade CRF02_AG and boosted with the cognate truncated 
gp120 protein. Using this immunization strategy we were able to induce the production 
of antibodies binding potently to the autologous and heterologous gp120 glycoproteins 
and antibodies that potently neutralized tier 2 HIV-1 envelope-pseudoviruses from 
multiple clades. As far as we know, no other vaccine study has been able to induce this 
type of response using clade AG based immunogens and so the present study represents 
a major contribution for HIV vaccine immunization field aiming to induce bNAbs. 
 
Material and methods  
Cells, viruses and antibodies 
Rat-2 (TK-) cells were purchased from American Type Culture Collection (Rockville, 
MD).  HeLa cells (ATCC® CCL­2™) were obtained from American type Culture 
Collection.  TZM-bl cells were provided by the AIDS Research and Reference Reagent 
Program, National Institutes of Health.  HeLa and TZM-bl cells were cultured in complete 
growth medium that consists of Dulbecco´s minimal essential medium (DMEM) 
supplemented with 10% fetal bovine serum (FBS), 100 U/ml of penicillin-streptomycin 
(Gibco/Invitrogen, USA), 1mM of sodium pyruvate (Gibco/Invitrogen, USA), 1mM of 
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L-glutamine (Gibco/Invitrogen, USA) and 1mM of non-essential amino acids 
(Gibco/Invitrogen, USA). All cell cultures were maintained at 37ºC in 5%CO2. Plasmid 
pMJ601was a gift from Bernard Moss[541]. The following items were obtained from the 
NIH AIDS Reagent Program:  a Panel of Global tier 2 HIV-1 Env Clones (cat#12670) 
designed to assess neutralization responses, the Western Reserve Strain of Vaccinia virus 
(VWR), recombinant proteins M.CON.SD11gp120 and SF162 gp140 Trimer and 
HuMAbs PG6, HJ16 and VRC01. 
 
Production of recombinant Vaccinia viruses and expression of env glycoproteins  
 
Recombinant Vaccinia viruses expressing the glycoprotein gp120t from clade 
CRF02_AG were obtained by transfection of recombinant plasmids as described 
previously (chapter 3). The method of Rose et al[543] was used to produce gp120t . 
Briefly, HeLa cells were infected with 5 PFU of recombinant Vaccinia virus per cell and 
incubated for 3 hours. Medium containing the infecting virus was replaced with serum-
free DMEM at 3h post infection. After 24 hours of infection medium containing gp120t 
was collected, clarified by centrifugation at 3000xg for 10 minutes and filtered with a 
0.2µM pore size filter to remove Vaccinia virus.  In order to collect cell lysates we 
performed the same assay in parallel and  after 48h, cells were washed with cold PBS and 
lysed using RIPA+DOC buffer (0.15M NaCl, 0.05M Tris-HCl, 1% Triton X-100, 1% 
DOC, 0.1% SDS).  Lysates were centrifuged at 35.000 rpm for 60 min at 4°C and the 
supernatant containing the proteins was collected. Antigenic reactivity of gp120 obtained 
from cell lysates and cell- free supernatants was analyzed by Western-Blot using sera 
from HIV-1 infected individuals. For Western blot analysis, proteins were prepared in 
Laemmli sample buffer (125mM Tris, pH 6.8, 2% SDS and 20% glycerol) with β- 
mercaptoethanol and denaturated by heating for 5 min at 96ºC, loaded within the 
acrylamide gel and then  transferred from the gel to nitrocellulose membranes  0.45µM 
(BioRad). After protein transfer, the membranes were treated with blocking buffer (1X 
TBSt with 4% w/v nonfat dry milk) and incubated with serum from HIV-1 and HIV-2 
infected individuals diluted (1:200) in primary antibody buffer (1X TBSt with 4% w/v 
nonfat dry milk and 5% goat serum). Next, the membrane was washed with TBSt 0.25% 
and incubated with Anti-Human IgG Peroxidase antibody produced in goat (Sigma). 
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Chemiluminescent detection was performed with Pierce™ ECL Western Blotting 
Substrate (ThermoFisher Scientific).  
 
Immunization  
Eight female New Zealand White rabbits were purchased and maintained at the Faculdade 
de Medicina Veterinária, Lisboa (FMV), from October 2016 to March 2017. All animal 
care and handling were approved by Ethics and Animal Welfare Committee (CEBEA- 
Comissão de Ética e Bem-Estar Animal da FMV). Rabbits were divided in three groups:  
Group 1 (placebo) was immunized with 500 µl  of PBS, Group 2 (control) was primed 
with 500 µl of  2x107  PFU of Vaccinia virus strain WR (VVWR) and boosted three times 
with 500 µl of VVWR  supernatant (SVVWR) and group 3 was primed with 500 µl of  2x10
7  
PFU of recombinant VV expressing gp120t from HIV-1 CRF02_AG clade 
(VVgp120AG) and boosted three or four times with 500 µl of VVgp120AG supernatant 
(Sgp120AG) corresponding to 35 µg of the cognate gp120 protein (Table 1). For all groups 
boosts were performed at days 35, 63 and 121 (boost I, II and III). Two rabbits of the 
main group (R6 and R8) received an extra boost at day 150 (boost IV). SVVWR and Sgp120AG 
boosts were emulsified in IFA in a 1:1 ratio. All immunizations were administered 
subcutaneously and blood samples were collected from the marginal ear vein. Rabbit sera 
was collected immediately before each immunization plus two times between boost II 
and III to access for binding antibodies. All rabbits were sacrificed on day 154.  
 
Envelope-specific antibody binding reactivity in sera of immunized rabbits 
 
HIV-1 gp120 specific binding antibodies were analyzed during the experiment by ELISA 
using rabbit sera from six time points (T0-T5). Briefly, Immuno MaxiSorp 96-well 
microplates (Nunc) were coated with 2.3 µg of autologous Sgp120AG and heterologous 
recombinant gp120 derived from a consensus HIV-1 group M envelope gene sequence 
(M.CON.SD11) at 1 µg/ml. Rabbit sera from the last timepoint (day 154) was also tested 
against the heterologous gp140 trimer (SF162) at 1 µg/ml. All proteins were diluted in 
0.05M bicarbonate buffer. After overnight incubation at 4°C microplates were blocked 
with 2% gelatin (Bio-Rad).  Rabbit anti-serum (1:300 final dilution) from days 1, 35, 63, 
99, 121, and 154 was heat inactivated for 1 hour at 56ºC [590], added to the microplates 
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and incubated for 2 hours at room temperature. Anti-rabbit IgG-Alkaline Phosphatase 
antibody produced in goat (Sigma) was added at 1:2000 dilution to the microplates as a 
secondary antibody. Colorimetric reaction was developed with SIGMAFAST™ p-
Nitrophenyl phosphate (pNPP) tablets and read at 405 and 492 nm against a reference 
wavelength of 620 nm on a microplate reader. In order to confirm the reactivity of 
autologous and heterologous proteins we use positive (serum from HIV-1 infected 
individuals) and negative (serum from healthy donors) controls at 1:200 final dilution.  
Sera from pre-immunized rabbits and from rabbits immunized with VVWR were used as 
negative controls of the assay. Sera with an optical density (OD) above the cutoff (mean 
OD of rabbits immunized with VWR immunogens plus four times the standard deviation) 
were considered positive. Binding antibody titer of rabbit sera from the last timepoint 
against autologous and heterologous gp120 proteins was calculated using the function 
log10 of the highest serum dilution at which a positive reaction (OD / cut-off> 1) was 
obtained.  
Reactivity of gp120 truncated proteins against rabbit sera from the last time point was 
also analyzed by western blot analysis as described above. For this propose rabbit sera 
was used at 1:200 final dilution in primary antibody buffer and anti-rabbit IgG-Alkaline 
Phosphatase antibody produced in goat was used as a secondary antibody at 1:2000. 
Colorimetric detection of proteins was performed by AP conjugate Substrate Kit 
(BioRad).  
 
Neutralization assays 
 
A panel of 17 HIV-1 viruses including 12 tier 2 HIV-1 from different clades [502], four 
HIV-1 primary isolates ( clades CRF02_AG, J and Untypable) and one tier 1 pseudovirus 
were used in the neutralization assays in order to detect neutralizing antibodies in rabbits. 
Primary isolates were obtained from HIV-1 infected patients by co-cultivation method 
with PBMCs from seronegative subjects. Env-pseudotyped viruses were produced by 
transfection of Env-expressing plasmids in 293T cells using PSG3.1Δenv as backbone 
and titrated in TZM-bl cells as described [502, 544].   
Neutralizing activity of rabbit serum was tested using a single-round viral infectivity 
assay using a luciferase reporter gene assay in TZM-bl cells, as described previously [2, 
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300].  Briefly, cells (10 000 cells in 100µl of DMEM supplemented with 10% heat-
inactivated fetal bovine serum) were added to each well of 96-well flat-bottom culture 
plates (Nunc) and allowed to adhere overnight. Next, 100 µl of each virus (200 
TCID50/well) were incubated for 1h at 37ºC with heat-inactivated rabbit sera (56ºC, 1 
hour)  in a total volume of 200 µl of growth medium (DMEM supplemented with 10% 
heat-inactivated fetal bovine serum) containing DEAE-Dextran (19.7 µg/ml) and added 
to the cells. Final serum dilution used in the assays was 1:20.  Neutralizing antibody titers 
were also obtained for rabbit serum with positive neutralization responses (>50%). In that 
case, 100 µl portions of 2-fold serial dilutions beginning at 1:20 were mixed with 100 µl 
of each virus and incubated for 1 hour before added to the cells. After 48h, culture medium 
was removed from each well and plates were analyzed for luciferase activity on a 
luminometer (TECAN) using Pierce™ Firefly Luciferase Glow Assay Kit (ThermoFisher 
scientific). Wells with medium were used as background control and virus-cells wells 
were included as infection control. The effect of pre-immunized serum on infection was 
used as baseline neutralization. To monitor the amount of neutralization activity that was 
not HIV specific, each serum sample was tested against VSV.  Sera from HIV-1 infected 
individuals (1:40) and HuMAbs PG16, HJ16, VRC01 in a final concentration between 
0.001-2µg/ml were used as positive controls of the assay [591]. PG16 was used against 
246F3 (0.08 µg/ml), BJOX2000 (0.04 µg/ml), X1632 (0.04 µg/ml), SG3.1 (2 µg/ml),  
PCNE8 (2 µg/ml), PCE1176 (0.01 µg/ml), PX2278 (0.004µg/ml), 25.710.243 (0.02 
µg/ml) and HIV-1 primary isolates 01PTCJN, 93HDC252, 93HDC253 and 93HDS249 
(1 µg/ml); HJ16 against PCE0217 (0.2 µg/ml), Tro11 (0.16 µg/ml), PCH119 (0.28 
µg/ml); VRC01 against PCNE55 (1.2  µg/ml), 398F1 (0.4 µg/ml). Percent neutralization 
of rabbit sera was determined by calculating the difference in average RLU between test 
wells containing post-immune sera and test wells containing pre-immune sera after the 
normalization of the results using the average RLU of cell controls[545].  Results were 
considered valid if the average RLU of virus control wells was ≥10 times the average 
RLU of cell control wells. Neutralization titer (ID50) was defined as the highest dilution 
for which 50% of neutralization was achieved.  Neutralization percentage of the positive 
controls was determined by calculating the difference in average RLU between test wells 
(cells + sample + virus) and cell control wells (cells only), dividing this result by the 
difference in average RLU between virus control (cell + virus) and cell control wells, 
subtracting from 1 and multiplying by 100[592]. Neutralization assays were performed 
with sera from the last timepoint (day 154).  
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Purification of HIV gp120 envelope 
Purification of gp120 AG from cell culture supernatant was performed based on  Dr. Jim 
Arthos’s protocol (Laboratory of Immunoregulation, NIAID, NIH) [593]. This technique 
allows the concentration of recombinant gp120 from cell culture supernatant using lectin 
affinity chromatography. In this case, agarose bound Galanthus nivalis lectin (GNL) 
(Vector Laboratories) was used which binds to the terminal D-mannose groups of HIV 
envelope glycoprotein gp120. For purification 1000 ml of HeLa cell culture supernatant 
containing gp120 AG in complete DMEM medium without FBS was used. Briefly, a 
Sigma 1.0x10 cm chromatography column was used with 4 ml of GNL slurry, settle and 
washed with 40 ml of PBS at 0.2ml/min. Then, cell culture supernatant was pumped 
through the lectin column at 1 ml/min and the flow-through was collected to determine 
the efficiency of the binding. After washed with ten volumes of cold PBS 5 ml of a 
mannose solution (0.5 M methyl alpha-D-manno-pyranoside, Sigma) was added at 0.25 
ml/min. Eluted proteins were collected with a Frac-100 collector (Pharmacia) in 2 ml 
fractions and absorption at 280nm was measured (Nanodrop UV spectrophotometer). 
Finally contaminating proteins from the eluted fractions were removed through metal-
affinity chromatography using TALON Superflow (GE) charged previously with 200mM 
cobalt chloride (2 ml on a Sigma 1.0x10 cm chromatography column). Flow-through 
fractions containing gp120 were collected and concentrated using Vivaspin 6® >100.000 
MWCO PES according with the manufacturer´s instructions. Proteins obtained were 
analyzed on SDS- 7.5% PAGE followed by BlueSafe protein stain (Nzytech) and 
quantified using Nanodrop.  
 
IgGs purification 
Rabbit’s sera were purified by affinity chromatography using a 5-ml Protein A HiTrap 
column (GE Healthcare) attached to an ÄKTA start protein purification system (GE 
Healthcare). PBS was used as equilibration and washing buffer and 0.5 M acetic acid for 
elution. Eluted fractions were neutralized immediately using 0.5 volumes of 1M Tris-HCl 
(pH 9.0), pooled, and dialyzed against PBS using PD-10 Desalting Columns (GE 
Healthcare). Protein purity was analyzed by SDS-PAGE followed by Coomassie Blue 
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staining. Protein quantification was determined using the classic Bradford reagent (Bio-
Rad). 
Data analysis 
Data analysis and graphs were performed with GraphPad Prism 5.
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Table 1- Rabbit immunization schedule  
 
    T0   T1   T2   T3 T4     T5 
    
Blood 
Colection  
Priming  
Blood 
Collection 
Boost I 
Blood 
Collection 
Boost II 
Blood 
Collection  
Blood 
Collection 
Boost 
III 
Boost 
IV 
Blood 
Collection 
Groups ID Day 1  Day 1 Day 35 Day 35 Day 63 Day 63 Day 99 Day 121 Day 121 Day 150 Day 154 
1 R1 ● - ● - ● - ● ● - - ● 
  R2 ● PBS ● PBS ● PBS ● ● PBS - ● 
2 R3 ● VVWR ● SVVWR ● SVVWR ● ● SVVWR - ● 
  R4 ● VVWR ● SVVWR ● SVVWR ● ● SVVWR - ● 
3 R5 ● VVgp120AG ● Sgp120AG ● Sgp120AG ● ● Sgp120AG - ● 
 R6 ● VVgp120AG ● Sgp120AG ● Sgp120AG ● ● Sgp120AG Sgp120AG ● 
 R7 ● VVgp120AG ● Sgp120AG ● Sgp120AG ● ● Sgp120AG - ● 
  R8 ● VVgp120AG ● Sgp120AG ● Sgp120AG ● ● Sgp120AG Sgp120AG ● 
 
VVWR- wild-type Vaccinia virus strain Western Reserve; SVVWR- supernatant of cells infected with VVWR; VVgp120AG- Vaccinia virus expressing gp120 from HIV-1 clade 
CRF02_AG; Sgp120AG- gp120 supernatant of cells infected with VVgp120AG ; PBS- phosphate-buffered saline; ●- done; ID- animal identification; R- rabbit; T0-T5 refer to 
time of blood collectio
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Results   
 
Immunization 
 
Throughout the procedure all animals were maintained in a good health status in 
ventilated cages in a temperature controlled room. Changes in behavior and physical 
status were monitored regularly. The majority of animals demonstrated some degree of 
stress/anxiety at the time of immunogen administration.  With the exception of one animal 
(R7), all infected and immunized rabbits developed a small lesion in the site of injection 
after priming which constitutes a typical side effect of Vaccinia virus vaccination. Blood 
collection was performed at six time points during the assay (table 1) in order to monitor 
antibody responses against the heterologous and autologous gp120.  
 
All immunized rabbits developed cross-reactive gp120 binding antibodies  
 
In order to monitor the kinetics of antibody production in vaccinated animals binding 
antibody activity to the autologous and heterologous gp120 glycoproteins was analyzed 
with an ELISA assay using rabbit sera collected at the different time points (T0-T5). As 
expected, binding antibody responses of the vaccinated animals (G3) were much higher 
than those from animals in the control groups (G1 and G2) (Figure 1). All immunized 
rabbits from group 3 developed specific antibodies against the autologous gp120AG and 
heterologous gp120 M.CON.SD11 soon after the priming (OD/cutoff >1) with the 
exception of two animals (R7 and R8) that only developed binding antibodies against the 
heterologous protein after the first boost (Figure 1). For group 3, binding antibody 
responses against the autologous gp120AG were always very potent (overflow levels or 
OD>3) even at high sera dilutions.  
In general, vaccinated animals showed an increase in IgG binding response against 
M.CON.SD11 up to boost II (day 99) followed  by a slight decline of antibody response 
at day 121 which matches the period of time where animals didn´t receive any boost 
immunization. In fact, after the last immunizations (boost III for R5-8 and boost IV for 
R6 and R8) all the animals presented a considerable IgG binding response against the 
autologous (Ab titer between 4.408 and 5.311, mean 4.784) and heterologous gp120 
immunogens (Ab titer between 3.204 and 4.408, mean 3.881) suggesting that the last 
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immunization strongly contributed to the establishment of a sustained antibody response 
(Figure 1, table 2). 
 
 
 
 
 
 
 
 
 
Figure 1- Total binding IgG response of immunized rabbit sera against heterologous protein HIV-1 
group M consensus gp120 envelope M. CON-S D11. Animals R5-58 (group 3) represent animals primed 
with VVgp120AG and boosted with Sgp120AG.  Priming was administered at day 1 and boosts I, II and III at 
days 35, 63 and 121, respectively; *Animals R6 and R8 received an extra boost at day 150 (boost IV); All 
animals were sacrificed at day 154 (T5). Cut-off value was calculated as the mean OD of rabbits immunized 
with VWR immunogens (control group 2) plus four times the standard deviation. OD/cut-off≥1 was 
considered positive and is defined by the dashed line. 
 
Rabbit R7 developed a positive binding response through all the experiment albeit at a 
lowest level compared with the animals from the same group. In addition, at the last time 
point (day154) R6 and R8 who received an extra boost at day 150 (boost IV) developed 
the highest IgG binding response which can be due to the extra antigen stimulation 
provided by the fourth boost. Moreover, rabbit sera from the last time point also reacted 
with HIV-1 SF162 gp140 trimer (OD/cut-off= 4.284, 4.284, 1.010 and 3.992 for R5, R6, 
R7 and R8, respectively).  
Rabbit antibodies also reacted strongly with the autologous gp120AG and multiple 
heterologous gp120s in Western blot (Figure 2).  Similar to our previous results (Chapter 
3), we observed a characteristic pattern of two major bands with approximate molecular 
weight marker of ~120 kDa and ~150kDa. The extra band with 150kDA may reflect the 
presence of protein aggregates or alternative glycosylation profiles relative to gp120 [2]. 
This two band pattern was also observed in SDS-PAGE and Western blot analysis with 
rabbit antisera after lectin purification of gp120 (Figure 2). Overall, these results 
demonstrate that the novel CRF02_AG immunogens elicit the production of HIV specific 
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antibodies in rabbits that are able to recognize and bind strongly to different HIV-1 Env 
trimers and monomers.  
 
Table 2- Binding antibody titer of sera from vaccinated rabbits against autologous and heterologous 
gp120 glycoproteins at day 154 
 
 
 
 
 
 
         Rabbit anti-serum from day 154 was used at a 1:300 final dilution; heterologous gp120 (M.CON.SD11)  
           was used at 1µg/ml and the autologous gp120 glycoprotein (Sgp120AG) was used at 2.3 µg/ml;  
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2 Western blot analysis of gp120t expressed by recombinant Vaccinia virus VVgp120B, 
VVgp120C, VVgp120AG and VVgp120J. A-gp120 supernatant (Sgp120AG) incubated with immunized 
rabbit sera and B- non-immunized rabbit sera; C- SDS-PAGE of gp120AG after lectin affinity 
chromatography purification (Pgp120AG); D-Western-blot analysis of Pgp120AG against immunized rabbit sera; 
Precision Plus Protein All Blue Standards (10-250 kDa) was used as a molecular weight marker. 
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Induction of heterologous tier 2 HIV-1 neutralizing antibodies  
 
In order to determine the neutralizing capacities of the antibodies produced in immunized 
rabbits,  sera from day 154 was tested against a panel of 17 HIV-1 viruses including 12 
tier 2 env-pseudotyped viruses  from different clades [502], four HIV-1 primary isolates 
(clades AG, J and untypable) and one tier 1 lab-adapted env-pseudotyped virus (SG3.1). 
At a 1:20 dilution, none of the sera from control animals showed neutralizing activity 
(Table 3). Sera from 2 of 4 animals of group 3 neutralized one or more tier 2 viruses 
whereas the remaining two failed to do so. This neutralization was HIV-specific as 
determined by the lack of neutralization of VSV-pseudotyped viruses. Notably sera from 
one vaccinated animal (R8) was able to neutralize at more than 50% almost the entire 
virus panel (13/16) at 1:20-1:80 titers. In addition, four of the viruses from the panel were 
neutralized at more than 80% by this particular sera (table 3). These results demonstrate 
that the new CRF02_AG based immunogens induce in rabbits a potent and broad 
neutralizing response against HIV-1 primary isolates and tier 2 HIV-1 Env-pseudotyped 
viruses from all clades.  
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Table 3- Neutralization of tier 1 and 2 HIV-1 viruses by rabbit sera  
 
 
Columns subheading indicate virus designation, clade and tier; Group1-non-immunized rabbits; Group2- rabbits primed with VVWR and boosted with SVWR; Group 3- rabbits primed with VVgp120Ag and boosted with Sgp120AG. Percent neutralization 
was determined in TZM-bl cells measuring the reduction in number of RLU relative to wells with the corresponding preimmune sera. Beige highlighting indicate less than 30% of neutralization; salmon highlighting indicate ≥ 31-49%; red highlighting 
indicate equal or more  than 50% of neutralization; HuAb s refer to  PG16, HJ16, VRC01 in a final concentration between 0.02-1µg/ml; HIV+ refers to HIV-1 positive sera at 1:20 final dilution; rabbit sera was used at 1:20 final dilution. VSV was used 
as a negative control.
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Discussion 
 
Here it was demonstrated that one out of four rabbits primed with a live recombinant 
Vaccinia virus expressing gp120 from a  clade CRF02_AG isolate and boosted with the 
cognate gp120 developed potent neutralizing responses against nearly the entire panel of 
tier 2 HIV-1 viruses tested (13/16), although at low titers (1:20-1:80). A similar strategy 
using a replication-competent Vaccinia virus expressing the full Env (gp160) plus two 
gp120 subunit boosts was also able to induce cross-reactive neutralizing activities against 
>50% of  a panel of tier 2 HIV-1 isolates in rabbits [422]. Like in our study, the 
neutralizing response was observed only in some animals and at low titers (1:20-1:100).  
The choice of these immunogens and immunization strategy was based in a previous 
study where  mice developed  neutralizing responses against a number of heterologous 
tier 2 isolates albeit with more limited breadth and potency (chapter 3) [586]. Whereas 
mice developed heterologous neutralizing responses of more than 49% against 4/14 
(29%) tier 2 HIV-1 isolates of clades B, CRF07_BC, J and CRF02_AG (autologous 
virus), rabbit developed bNAbs against 13/16 (81%) tier 2 isolates of clades CRF01_AE, 
CRF07, CRF02_AG, C, AC, G, B, A, J and U (untypable).  
In addition, antibody binding response was seven fold higher in rabbits, with all 
immunized animals maintaining strong responses against the autologous gp120 through 
the whole experiment.  In the previous study, mice immunized with the same immunogen 
combination developed a positive antibody response against Sgp120AG but at significant 
lower levels and with a decline between boost I and II [586]. 
Despite differences in binding antibody titers between the two assays, both studies 
demonstrated that gp120 immunizations strongly boosted antibody reactivity which in 
turn may have contributed to the neutralization observed. Interestingly, Shiu-Lok Hu and 
colleagues [422] have recently demonstrated that repeated immunization with gp120 have 
little effect in neutralization against heterologous tier 2 isolates.  
SF162, a gp140 trimer, was recognized in an ELISA assay by antibodies present in sera 
of all immunized rabbits (Group 3) from the last time point but not by mice sera from the 
corresponding time point in the previous study (chapter 3). This may explain in part the 
more effective neutralizing responses in rabbits as trimers closely resembles the native 
viral spikes.   
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Differences concerning the antibody binding response against autologous gp120 
immunogen and the potency and breadth of neutralizing responses in mice and rabbits 
may be assigned to several issues that includes the immunization schedule, immunogen 
administration and, most important, natural features inherent to the animal model. In fact, 
it is well known that rabbit antibodies have a higher specificity and affinity being able to 
recognize epitopes that are not immunogenic in mice thus justifying the significant 
difference between neutralization breadth observed in both studies [587-589].  
In conclusion, in this study we have shown that in rabbits a prime-boost vaccination 
strategy based on recombinant Vaccinia viruses expressing a novel CRF02_AG gp120 
and the cognate gp120 is able to induce the production of antibodies potently binding to 
monomeric and trimeric autologous and heterologous envelope glycoproteins as well as 
potent and broadly neutralizing antibodies. These results are consistent with previous 
findings in mice and provide strong support for additional vaccination studies in NHPs.  
The results obtained in both studies suggest that the novel CRF02_AG-based 
immunogens and prime-boost immunization strategy may be able to induce the type of 
response intended in a preventive HIV-1 vaccine. 
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About 30 years ago, when HIV-1 was discovered, people strongly believed that a vaccine 
would be developed in a short period of time. Today, after years of intense work in the 
vaccine field there is still no safe and efficient vaccine for HIV. Although the introduction 
of ART has contributed to turn HIV infection into a manageable disease, a vaccine for 
HIV is currently the best hope for the control and eventual cure of HIV infection.  
Genetic diversity of HIV-1 is huge with multiple subtypes and recombinants unevenly 
distributed all over the world and an effective vaccine will need to contend with this 
diversity. Several strategies such as the use of mosaic and consensus envelope 
glycoproteins have been pursued in the past but with no success [118, 418, 422, 448, 496-
501]. Most current vaccine candidates are based on subtypes B and C because of their 
higher global prevalence relative to the other subtypes and recombinants [118, 119, 465-
468, 507, 594-597]. However, it is highly unlikely that a subtype B-or C-based vaccine 
could provide significant protection against other HIV-1 genetic forms.  Thus, candidate 
vaccines based on other non-B HIV-1 strains that are prevalent in developing countries 
with high HIV-1 burden need to be explored.  
The work described in this thesis is a contribution for the development of a new 
generation of HIV vaccines based on live Vaccinia virus vectors and ancestral envelope 
immunogens obtained from primary R5 isolates from the Angolan and Portuguese HIV-
1 epidemics. We based our work on these isolates to test the hypothesis that envelope 
glycoproteins from primary isolates present in highly complex and long-term epidemics 
could contend better with the genetic and antigenic diversity of HIV-1 compared with 
envelope glycoproteins from isolates from more recent and monovalent epidemics. In 
support of this, Hahn BH and colleagues have shown that immunization with ancestral 
envelope genes recognized a greater number of contemporary clade C antigens  compared 
to immunization with a contemporary subtype C env control[598].  
To better characterize  H and J subtypes which were intended to be used in the new 
vaccine, the full-length genomes of three isolates from 1993 from Angola, previously 
identified as clustering with subtypes H and J based on small gene fragments [514, 
538], were sequenced and analyzed phylogenetically (Chapter 2). We had previously 
shown that these isolates replicated well in culture and were highly sensitive to entry 
inhibitors [514, 538].   The evidence that HIV-1 pandemic first emerged in West Central 
Africa and that Angola had a crucial role in the early dissemination of the HIV-1  
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determined the genomic characterization and inclusion of these subtypes in the new HIV-
1 vaccine [67, 68, 510-512].   
Near-full-length envelope gp120 fragments from HIV-1 isolates from Angola and 
Portugal, obtained from 1993 to 2008 and belonging to subtype B and non-B clades (C, 
CRF02_AG and J) were expressed successfully in Vaccinia virus (chapter 3). Selected 
isolates to include in the vaccine used the CCR5 coreceptor because most transmitted 
isolates use this receptor [104, 166, 599].  
Monomeric gp120 was used for our vaccine because 1) it encompasses most of the 
neutralizing domains in the HIV envelope [461, 600, 601] and 2) it was used with some 
success in HIV-2 and HIV-1 vaccines [2, 422, 453, 454, 479, 494, 579, 602].   In addition, 
C2V3C3 boosts were used in order to expand and direct the antibody response generated 
after the priming towards the central C2, V3, and C3 envelope regions.  Moreover, 
C2V3C3 boosts were found to be crucial for the induction of high levels of bNAbs against 
HIV-2[2]. 
Antibodies neutralizing at least one heterologous tier 2 isolate were elicited in mice 
immunized with clades B, C, CRF02_AG, and J but there were significant differences 
between immunogens. Overall, mice immunized with Vaccinia virus expressing the 
envelope gp120t derived from clade CRF02_AG followed by a boost with the cognate 
truncated gp120 developed more potent and broad Env-binding and neutralizing 
antibodies relative to mice receiving immunogens from other clades. Subsequently, 
rabbits vaccinated with the CRF02_AG-based immunogens developed neutralizing 
antibodies against several heterologous tier 2 HIV-1 pseudoviruses and primary isolates 
from different clades. To the best of our knowledge, this was the first vaccine trial using 
an immunogen derived from clade CRF02_AG that was able to induce bNAbs against 
heterologous tier 2 HIV-1 pseudoviruses of all clades and against primary virus isolates.   
Neutralization of primary isolates is very important because they are produced in PBMCs 
and, unlike envelope-pseudotyped viruses, their glycosylation profile is similar to 
clinically relevant isolates [548, 549]. These results suggest that the new CRF02_AG 
derived immunogens may be useful as a new HIV-1 vaccine and should be further tested 
in NHPs. It should be noted however that even with the best immunogens the 
neutralization results were inconsistent as they were only observed in few vaccinated 
animals. Similar inconsistency has been described in recent studies using other 
vaccination approaches [422, 453, 476-479, 492]. Some explanations have been offered 
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to account for this problem such as behavioral features (i.e. stress) inherent to the animal 
that affect vaccine intake and subsequent immune response [422, 598, 603]. In our case, 
we believe that the main problem is likely related with the initial infection by the 
recombinant Vaccinia viruses which we did not control for. In the future we plan to 
closely monitor Vaccinia virus infection before boosting immunizations using a simple 
immunoassay to detect Vaccinia virus-specific antibodies. 
The use of immunogens derived from ancestral primary isolates, i.e. isolates showing 
lower evolutionary distances to the most recent common ancestor (MRCA) defining each 
clade,  may have been important for the induction of broadly binding and neutralizing 
antibody responses. In fact, envelope proteins derived from contemporaneous isolates 
have failed to elicit such broad antibody responses in rabbits; usually the antibodies 
produced only bind to and neutralize tier 1 isolates, the autologous isolate and some 
heterologous tier 2 isolates matched by subtype [422, 444, 448]. The use of a truncated 
gp120 protein instead of a full protein may also have contributed for the success of the 
immunization as it was previously associated with more broad and potent neutralizing 
responses against HIV-2 than the full-length cognate gp120 [2]. Compared to the full-
length envelope glycoproteins, the truncated version of gp120 lacking the C5 region 
allows for higher levels of expression and shedding while exposing adequately the main 
neutralizing domains identified in our study, the V3 region and CD4-binding site. These 
two features are important for the antigenic stimulation of B cells towards the 
development of high affinity broadly neutralizing antibodies [604-609].  
The use of a live Vaccinia vector in the priming immunizations has contributed crucially 
for the induction of bNAbs as demonstrated by the observation that animals primed with 
gp120 solely developed the weakest neutralizing response.  Many other researchers have 
shown previously, in different animal models and in humans that priming with 
monomeric gp120 or vaccination with monomeric gp120 only does not lead to the 
production of bNAbs  [2, 408, 467, 468, 478, 487-489, 551]. With the exception of a 
recent study in cows immunized with the SOSIP-BG505 trimer where broad and potent 
serum antibody responses were rapidly elicited [1],  much better antibody responses have 
been obtained when monomeric or trimeric proteins are used in combination with other 
immunogens [2, 422, 453, 454, 479, 494, 579].     
Advantages of using Vaccinia virus as vaccine vectors include their easy production, the 
capacity to infect  efficiently a wide range of different cell types both in vivo and in vitro, 
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their large genomes allowing the insertion of large segments of foreign DNA and high 
levels of expression of the transgene  [387, 420, 584, 585]. In addition, live Vaccinia virus 
vectors elicit stronger humoral and cell-mediated immune responses when compared with 
highly attenuated non-replicative viral vectors [387, 420, 421, 555]. This is because live 
replicative viral vectors act like adjuvants activating the immune system and continuously 
replicate in host cells leading to high level and  continuous exposure of B and T cells to 
the vaccine antigen [207, 387, 420, 421, 582].  
Despite these advantages, killed or highly attenuated non-replicative viral vectors are 
often preferred as vaccine vectors due to safety issues concerning possible adverse 
reactions with live viral vectors [391, 418, 553, 581, 583]. Most adverse events caused 
by live vectors are minor and occur primarily in immunocompromised patients [610, 
611]. In this context it is perhaps important to note that  adverse reactions to Vaccinia 
virus could potentially be interrupted and reversed with the  administration of a CCR5 
antagonist as Vaccinia uses the CCR5 molecule to enter into the cells [610, 612-614]. 
Recently we and others have shown that the CCR5-antagonist TAK-779 inhibits the 
replication of Vaccinia virus strain WR in vitro and in vivo (in mice) suggesting that this 
drug could be a useful safety net against adverse effects eventually caused by vaccination 
with live Vaccinia vectors (Diniz & Taveira, unpublished)[615]. 
The use of live recombinant Vaccinia virus vector in this immunization strategy may have 
been also determinant for the generation of a strong Tfh mediated cellular response which 
in turn enabled an effective Nab production. Tfh cells are a potential target for HIV 
vaccines aiming to induce bNAbs as they have been positively correlated in humans and 
NHPs with an effective humoral response against HIV [240, 254-256, 616-619]. In our 
mice studies, Tfh cell number correlated positively with binding antibodies against gp120 
immunogens but no correlation was observed between Tfh levels and neutralization 
activity. Similarly, Crotty and colleagues have demonstrated that mice immunized with 
soluble BG505 SOSIP.664 trimers developed high-quality Tfh responses that positively 
correlated with Env-binding IgG antibodies but not with NAbs[620]. Also in our study, 
Tfr cell frequency were found to inversely correlate with neutralization potency and 
breadth in immunized mice. These cells are important modulators of the germinal center 
responses and their frequency have been inversely associated in NHPs with higher quality 
Env-specific antibodies and NAbs [256, 263]. Thus, the efficiency of the new vaccine 
strategy may, at least partially, be based on the triggering of the specific subsets of T 
Chapter 5- General Discussion and Conclusions 
 
149 
 
follicular cells that drive B cell responses to the right path. Overall, our results provide 
additional support for the use of replicating competent Vaccinia viruses as a component 
of an HIV vaccine. 
Using the same prime-boost strategy and the same CRF02_AG based immunogens, one 
rabbit (chapter 4) was found to develop more potent and broad antibody responses 
comparing with mice (chapter 3). Whereas mice developed antibodies neutralizing  29% 
of tier 2 HIV-1 isolates (clades B, CRF07_BC, J and CRF02_AG), the rabbit developed 
antibodies neutralizing 81% of the tier 2 isolates including clades CRF01_AE, CRF07, 
CRF02_AG, C, AC, G, B, A, J and U (untypable). In addition, binding antibody response 
was 7-fold higher in rabbits with all immunized animals maintaining strong responses 
against the autologous gp120 throughout the whole experiment. Finally, antibodies 
present in sera of all immunized rabbits from the last time point but not in mice sera bound 
to SF162, a gp140 trimer, in an ELISA assay.  This may explain in part the more effective 
neutralizing responses in rabbit as trimers closely resemble the native viral spikes.  
Unlike previous vaccination studies in HIV-2 [2], boosting the mice with the C2V3C3-
polypeptide did not contribute for the development of neutralizing responses implying 
that the most potent conformation-dependent neutralizing domains  in the V3 region of 
HIV-1 are not adequately presented by this polypeptide. It is also possible that antibodies 
against this region are slow to develop as suggested by the increased levels of anti-
C2V3C3 antibodies in the last timepoint. Overall, these results confirm that there are 
major differences in the antigenic structure of V3 between HIV-1 and HIV-2 [2, 550]. 
Interestingly, whereas the majority of the viruses tested in the neutralization assays had 
the GPGQ motif in V3 crown region, the gp120 from CRF02_AG clade used in 
vaccination had a GPGR motif. For subtype B the consensus sequence for the V3 crown 
motif is GPGR, while for non-B subtypes it is often GPGQ [330, 556-559]. Tier 2 clade 
B Env-pseudovirus PX2278, which has the canonical GPGR motif, was neutralized by 
all animals immunized with the CRF02_AG derived glycoproteins. Together with the 
strong binding of the anti-GPGR human monoclonal antibody 447-52D to gp120 AG this 
indicates that, unlike the C2V3C3-polypeptides, our CRF02_AG monomeric gp120 
glycoprotein presents adequately this dominant neutralizing epitope in V3 and leads to 
the induction of potent neutralizing antibodies directed against the V3 crown. 447-52D is 
known to bind and neutralize preferentially viruses from clade B but it also neutralizes 
viruses from non-B clades although in a lesser extent [330, 348, 546, 621, 622]. NAbs 
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against heterologous HIV-1 viruses targeting the V3 loop of gp120 have been widely 
described by several authors highlighting the importance of this region [325, 326, 330, 
347, 623].  In a recent study where 66 HuMabs specific to V3, CD4bs and V2 were tested 
against 41 tier 1, 2 and 3 Env-pseudoviruses neutralization and breadth of anti-V3 
HuMabs were found to be significantly higher than those directed to other regions [624]. 
Importantly, only anti-V3 antibodies were able to neutralize tier 2 and 3 viruses.  Overall, 
our results showing that antibodies induced by the novel CRF02_AG gp120-based 
vaccine neutralized tier 2 HIV-1 isolates from different clades despite targeting 
essentially the V3 crown, provide further support for the V3 crown as a crucial vaccine 
target.  
Because g120AG immunogens were also able to induce NAbs against non-B Env-
pseudoviruses and primary isolates that did not present the GPGR motif, NAbs targeting 
other epitopes must have also been elicited.  In fact, HuMAb HJ16 (a CD4 binding site 
bNAb obtained from a clade C infected patient) bound in ELISA to all gp120 
immunogens, although at low levels, suggesting some exposition of CD4 binding site 
epitopes which may have contributed to the neutralization observed [325]. CD4bs is a 
highly conserved site present in the gp120 of all HIV-1 clades needed for the initial virus-
host interaction and therefore it represents one of the most attractive targets for vaccines 
that aim to induce neutralizing responses [422, 625-628].   
The target of the largest and most diverse group of bNAbs that recognize N-linked glycan 
containing epitopes is the region adjacent to the highly conserved N-linked glycosylation 
site at N332 which includes the V3 loop base and nearby glycans [547, 560, 561]. 
Antibodies directed to V3 glycans are major contributors to neutralization breadth and 
potency [154, 335, 352, 354, 629]. The observation that the novel CRF02_AG based 
immunogen had a high probability of glycan occupancy in position N332 together with 
the fact that PX228, the tier 2 HIV-1 pseudovirus neutralized by all gp120 AG immunized 
mice, also had a high probability of glycan occupancy (Pg= 0.86, motif NIS) in this 
position suggests that these immunogens could also have induced glycan-dependent 
bNAbs directed to this region in immunized mice and rabbits. However, further studies 
will be necessary to clarify the epitope specificities of NAbs induced by the novel 
immunogens produced in this study. 
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Conclusions 
The high  diversity  among  Angolan  subtype  J  sequences  suggest that Angola is either 
the origin of  subtype J or that there has been a lot of influx of subtype J from other  
geographic  regions. In addition, the  high  diversity  of  rare  subtypes  in Angola  is 
consistent with  the important role of this region in  the  early  establishment  of  the  HIV-
1 pandemic.  
It was demonstrated that it is possible to induce neutralizing antibodies against 
heterologous tier 2 HIV-1 pseudoviruses and primary isolates in different animal models 
using a prime-boost immunization strategy based in a live replicative viral vector 
expressing the envelope gp120t derived from an ancestral CRF02_AG clade subtype. 
These results provide support for the use of Vaccinia virus as a vaccine vector for HIV-1 
and for the a priori hypothesis that envelope immunogens from ancestral non-B strains 
could induce potent and broad antibody responses against contemporaneous isolates of 
all clades. Finally, the V3 crown was found to be one of the main targets of neutralizing 
antibodies induced by the novel immunogens supporting the V3 region as one of the 
constituents of a successful HIV-1 vaccine. Further studies will be necessary to formally 
identify the other neutralizing targets of our vaccine and to understand why only a fraction 
of the animals produced broadly neutralizing antibodies.  
 
Future perspectives 
Optimization of this particular vaccine, namely the nature of the immunogens and 
immunization regimen, may lead to a considerable improvement in antibody responses, 
namely in breadth and potency. In order to expand and elicit neutralizing responses 
against more conserved epitopes, such as CD4bs and glycan regions, new env constructs 
with deletions in some variable loops may be an important approach as it may ultimately 
turn the conserved regions of gp120 more accessible to neutralizing antibodies. In 
addition, shielding of irrelevant domains could also lead to the exposition of more 
important domains and consequently target the right set of NAbs to the neutralizing 
epitopes. Co-immunization of this new Env constructs in a prime-boost regimen with the 
same recombinant Vaccinia virus vector used in this study could induce higher antibody 
responses. Although this new vaccine concept was able to induce bNAbs against 
heterologous HIV-1 tier 2 pseudoviruses and primary isolates belonging to different 
Chapter 5- General Discussion and Conclusions 
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clades, the inclusion of immunogens from different non-B clades in the same prime-boost 
regimen (i.e. vaccine cocktail) could contribute to increase further the breadth of Nab 
responses. Our medium-term perspective if all goes well is to test the new vaccine (or its 
modifications as described above) in nonhuman primates. 
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